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General introduction 
‘’Sensing and signalling in upper gastrointestinal tract’’ 
The gastrointestinal (GI) tract has a variety of functions related to digestion and 
absorption of nutrients and to the epithelial barrier. In this respect, the GI tract is also a 
sensory organ that responds to a large variety of signals originating from the GI 
lumen. The upper GI tract is the first part of this organ, thereby exposed to exogenous 
and endogenous potential noxious substances. On the one hand, the GI tract 
regulates the processes of detection, digestion and absorption of nutrients. On the 
other hand, the GI tract protects the body from potentially noxious or toxic materials 
entering the systemic compartment via an effective intestinal epithelial barrier. 
Sensing of substances via mucosal receptors and an extensive intestinal neuronal 
network is crucial for homeostasis.  
In this thesis, we primarily focus on the upper GI tract and its ability to sense the 
chemical content of the gut lumen in order to orchestrate responses relevant to 
preserve GI physiology. We specifically focus on 1) the role of the upper GI tract in 
detection, digestion and absorption of nutrients and food components in controlling 
satiety and food intake and 2) the role of Transient Receptor Potential Vanilloid 1 
(TRPV1) and its involvement in the protection of the mucosal integrity in the upper GI 



















1. Role of the upper gastrointestinal tract in controlling 
food intake and satiety 
The upper GI mucosa senses many exogenous substances such as nutrients, 
chemicals, tastants and potentially noxious substances. Gut luminal chemosensing is 
a crucial element in the regulation of food intake and energy balance. Several 
physiological functions are affected by luminal substances: motility and transport, 
secretion, digestion and absorption.1-5 It has been shown that intraluminal nutrients 
are sensed by specific receptors located in the luminal membrane of cells in the GI 
mucosa.6,7 This sensing is primarily regulated by enteroendocrine cells (EECs), 
located in the intestinal epithelium. EECs represent the first level of integration of 
signals derived from the GI lumen. Via an enteric network of neurons these signals 
communicate with various regions in the central nervous  to maintain GI and systemic 
health.8 These cells, as part of the enteroendocrine system, interact with and react to 
dietary components and nutrients. Several studies have shown that activation of 
these receptors results in the release of gut peptide from ECC cells.8 These peptides 
can exert their effect by 1) acting locally on the specific receptors (paracrine route) or 
2) on receptors on the vagal cholinergic afferent nerve endings (neuroendocrine 
route), which on their turn signal the nucleus of the solitary tract and CNS regions or 
3) release into the systemic circulation excreting effects at distant sites (endocrine 
route).  
 
EECs play a key role in GI chemosensing and contain a wide variety of receptors, 
which are expressed on the luminal side of the GI mucosa cells. The majority of these 
receptors are G-protein coupled receptors (GPCRs). One of the receptor families 
expressed by EECs include the taste receptors. There are two major groups of taste 
detecting GPCRs expressed in the GI tract; the taste receptor type 1 (TAS1R) sensing 
umami and sweet, and the taste receptor type 2 (TAS2R) detecting the bitter taste.9,10 
Various studies have shown that these taste receptors can be found throughout the 
entire GI tract.11-14 Recently, much scientific attention has been paid to the effects of 
bitter substances on the GI tract related to food intake and satiety. It was observed 
that infusion into the stomach of bitter substances resulted in inhibition of gastric 
motility.15,16 The bitter taste is evolutionary linked to (presence of) toxic substances, 
and this adverse reaction is assumed to be inborn.17 With regards to inhibition of food 
intake, it was recently observed that infusion of a combination of tastants (sweet, 
bitter and umami) into the duodenum resulted in a significant decrease in food intake, 
accompanied by a reduction in hunger and an increase in satiety feelings.18 The 
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presence and activity of these taste receptors in the GI tract points to relevance of 
sensing luminal substances thereby maintaining intestinal and systemic homeostasis. 
Gastrointestinal signals affecting satiety and satiation  
The upper GI tract plays a major role in the regulation of satiety and food intake. Both 
the stomach and the small intestine are important in this regard but underlying 
mechanisms differ from each other. Important functions of the stomach include the 
storage of an ingested meal, the so-called adaptive relaxation of the proximal 
stomach, the mixing and grinding of nutrients with gastric contents in order to start 
the process of digestion with degradation of nutrients that consequently allow a 
stepwise controlled transport to the duodenum.19 The satiating effect that arises after 
ingestion of a meal mainly results from pressure and volume changes of the stomach 
wall, also known as mechanical stimulation. After ingestion of a meal, stretch and 
tension mechanoreceptors are triggered and vagal and splanchnic nerve endings in 
the stomach wall are activated. These (mechano)receptors relay their information to 
various brain regions and result in satiation and meal termination.20 Several studies in 
humans have repeatedly shown that gastric distension by an inflated balloon resulted 
in decreased hunger scores. Such strong inhibitory signals, when repeatedly or 
chronically administered have the potential to result in weight loss.21-23 Based on 
these results, influencing gastric signals arising after meal ingestion, may be a 
potential target to modulate feelings of satiety/satiation and food intake.  
Gastric contents are transported further into the small intestine and this results in the 
activation of a negative feedback mechanism that reduces food intake and induces 
satiety. Signals arising from the small intestine are more nutrient induced (chemical) 
compared to gastric signalling (mechanical). Welch et al. were the first to perform an 
in vivo human study, in which lipid was infused directly into the duodenum. These 
authors observed a decrease in food intake and a delay in gastric emptying.24 After 
this study, several other human studies were performed, in which macronutrients 
(carbohydrates, proteins and lipids) were infused into various parts of the small 
intestine. Repeatedly, a decrease in food intake and increase in satiety was 
observed25-29, although the magnitude of the effect is dependent on the type of 
stimulus, intestinal site of delivery and the gut area exposed to macronutrients. This 
mechanism is called the ‘’intestinal brake’’ and all parts of the small intestine 
(duodenum, jejunum and ileum) are able to activate this feedback mechanism.  
Chapter 1 
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2. Responses of the upper gastrointestinal tract and the 
role of TRPV1 in protecting against potential noxious 
substances  
The physiological role of the GI tract is to digest and absorb nutrients, but also to 
select and eliminate potential harmful substances. These tasks require an adequate 
and detailed analysis of the luminal contents of the GI tract in order to activate the 
appropriate effector mechanisms.30 The GI tract is innervated by intrinsic sensory 
neurons of the enteric nervous system. These neurons and the related receptors are 
able to sense chemicals and changes in chemical composition in the gut lumen as 
well as being able to initiate protective responses.31 These sensory neurons contain a 
wide variety of receptors. There is growing evidence for involvement of the TRPV1 
receptor, an important nociceptive receptor in the regulation GI mucosal defense.32 
The TRPV1 receptor can be activated by capsaicin, noxious heat (>42ºC), protons 
(pH<6), lipogenase products and is expressed by 50-70% of all sensory neurons.33 
TRPV1 expression has also been observed in non-nervous tissue such as gastric 
epithelial cells.34 Activation of the TRPV1 receptor results in the release of the 
proinflammatory sensory neuropeptides substance P and calcitonin gene related 
peptide (CGRP) leading to neurogenic inflammation and local vasodilation.35 These 
findings demonstrate that TRPV1 receptors are a potential factor in several GI 
symptoms and disorders but are also is a potential target for therapies in GI diseases 
with subsequently altered GI mucosal barrier. 
Aim and outline of the thesis 
The GI tract has the ability to sense luminal contents with subsequent activation of 
several pathways that are involved in maintaining GI and systemic homeostasis. The 
GI tract continuously communicates via the gut-brain axis with the brain and vice 
versa. Identification of the clinically important intestinal nutrient sensors and their 
signalling pathways may help to provide potential new drug targets for the treatment 
of obesity, anorexia, pain and several other GI disorders. In the first part of this thesis, 
we aimed to explore interventions that influence satiety and food intake regulation 
after the presence of nutrients, tastants or a local anesthetic in the GI tract. In the 
second part, we focused on tastants and on the TRPV1-mediated pathway and its 
involvement in the maintenance of the GI mucosal barrier protection 
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Several studies have shown that infusion of nutrients in the small intestine results in 
the activation of the intestinal ‘’brakes’’, a negative feedback mechanism on the 
functions of the more proximal parts of the GI tract and on food intake and satiety. It 
has been well established that infusion of all three macronutrients (protein, lipid, and 
carbohydrates) into all parts of the small intestine (duodenum, jejunum and ileum) can 
activate this intestinal brake. Chapter 2 provides an overview of the current evidence 
of intestinal brake activation with special attention for the existence of a proximal to 
distal gradient in the magnitude of the effects on food intake and satiety.  
 
Studies investigating the intestinal brake were performed by intubation with an 
intestinal catheter in order to infuse the nutrients into the desired part of the small 
intestine. However, this invasive procedure is not feasible in daily practice and 
therefore not an option in weight management strategies. In chapter 3, we describe 
the results of a proof-of-concept study in which we investigated the effects of an 
orally ingested encapsulated nutrient mixture containing proteins and carbohydrates, 
targeting the distal small intestine, on food intake and satiety. In chapter 4, we 
describe the results of a proof-of-concept study on ingestion of encapsulated lipid as 
emulsion-alginate beads, in order to achieve distal delivery of the degradation 
products of lipids, on food intake and satiety.  
 
Distension of the stomach and consequently activating the mechanoreceptors in the 
gastric mucosa results in meal termination. In chapter 5, we investigate whether 
postprandial gastric signalling can be impaired by infusion of the local anesthetic 
lidocaine and if there is evidence for an effect on food intake and satiety. 
  
It was already observed that intraduodenal infusion of a mixture of tastants in humans 
significantly decreased food intake. Currently, there is no evidence from human 
studies for taste receptor activation in the more distal small intestine. Thus, it is not 
known whether the before mentioned proximal to distal gradient in the magnitude of 
intestinal brake activation, as explored in chapter 2, is also operational and active for 
taste receptor activation. In chapter 6, we describe the effect of intra-duodenal 
and/or intra-ileal activation of taste receptors on food intake and satiety. 
 
There is growing evidence for the potential protective properties of the TRPV1 
receptor on the sensory afferent neurons in the mucosa of the GI tract. In chapter 7, 
we investigate the effect of capsaicin infusion into the esophagus on the mucosal 
integrity, as reflected by baseline impedance, and the possible involvement of the 
TRPV1 receptor pathway in this effect. In chapter 8, we investigate an alternative 
Chapter 1 
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method for the evaluation of intercellular space area and compared it with the classic 
method. Chapter 9 serves as a summary of the key findings of the studies presented 
in this thesis and discusses our new findings in relation to previous described studies 
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Gastrointestinal nutrient infusion site and eating 
behavior: Evidence for a proximal to distal 
























The rapidly increasing prevalence of overweight and obesity demands new strategies 
focusing on prevention and treatment of this significant health care problem. In the 
search for newand effective therapeutic modalities for overweight subjects, the 
gastrointestinal (GI) tract is increasingly considered as an attractive target for medical 
and food-based strategies. The entry of nutrients into the small intestine activates so-
called intestinal “brakes”, negative feedback mechanisms that influence not only 
functions of more proximal parts of the GI tract but also satiety and food intake. 
Recent evidence suggests that all three macronutrients (protein, fat, and 
carbohydrates) are able to activate the intestinal brake, although to a different extent 
and by different mechanisms of action. This review provides a detailed overview of 
the current evidence for intestinal brake activation of the three macronutrients and 
their effects on GI function, satiety, and food intake. In addition, these effects appear 
to depend on region and length of infusion in the small intestine. A recommendation 
for a therapeutic approach is provided based on the observed differences between 




Obesity is considered to be a global health problem with a rapidly rising prevalence 
that has more than doubled over the past 30 years.1 Obesity and its associated 
comorbidities result in a rapidly expanding impact on health care utilization and 
costs.2 Weight loss strategies, apart from bariatric surgery, have poor success rates 
and an unfavorable long-term outcome. Bariatric surgery is known to be a highly 
effective strategy in the treatment of obesity, but it is still seen as a drastic measure 
and only indicated in a small group of morbidly obese subjects. For example Roux-
en-Y gastric bypass (RYGB), a combined procedure with a restrictive and a 
malabsorptive component, results in increased exposure of the distal small intestine 
to nutrients. The response of the gastrointestinal (GI) tract to this increased exposure 
of nutrients appears to play a major role in the success of bariatric surgery. In order to 
find new, effective, and less invasive approaches for overweight subjects, 
investigators are now focusing more on the GI tract as a target for medical and food-
based weight loss strategies. 
After ingestion of nutrients and their digestive products, several processes are 
activated that initiate digestion and absorption and also affect satiety and food intake. 
First, postprandial distension of the stomach results in the release of satiety signals; 
mechanoreceptors of the stomach interact with the brain by vagal and spinal sensory 
nerves. Thereafter, emptying of nutrients into the small intestine results in chemical 
interaction of the ingested nutrients with various luminal receptors in the gut wall. Part 
of this interaction is the activation of the so-called “intestinal brakes”, negative 
feedback mechanisms that influence not only motility3,4 and secretion5-7 of more 
proximal parts of the GI tract but also satiety and food intake. 
Welch, et al. were the first to perform a human in vivo study in which a fat emulsion 
was directly infused into the ileum to assess the effect of this infusion on eating 
behavior. They observed a reduction in food intake and a delay in gastric emptying 
rate compared with the placebo.8 Up to now, several others have demonstrated the 
inhibitory effects of ileal fat infusion on food intake, but this brake mechanism 
appears not to be restricted to the ileum. The existence of an intestinal brake effect 
on food intake is also present in the more proximal parts of the small intestine (the 
duodenum and jejunum). In a direct comparison between fat infusion into the 
duodenum and into the ileum (0.9 kcal/min), a more potent effect on appetite and 
fullness was observed when the same amount of fat was infused into the ileum.9 This 
observation points to the existence of a proximal to distal gradient in the negative 
feedback of the small intestine on eating behavior. 
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Thus far, the “intestinal brake” has mainly been explored with ileal fat infusion as the 
brake substrate; however, delivery of carbohydrates (CHO) and protein in other parts 
of the small intestine also has the ability to induce an intestinal brake and to suppress 
food intake and feelings of hunger. The potency of the intestinal brake is suggested 
not only to be dependent on the site of intestinal delivery, but also on the length of 
the region that is exposed as well as the duration and type of macronutrient infusion. 
This review will focus on the effects of intestinal brake activation on GI function, 
satiety, and food intake. The literature regarding the intestinal brake has been 
reviewed before.10,11 Our aim is to give special attention to the existence of a possible 
proximal to distal gradient in the magnitude of the intestinal brake effect. In addition, 
effects of the various macronutrients will be compared. 
2. Site-dependent effects on GI function 
2.1 Motility 
The theory of intestinal brake activation originates from the hypothesis that 
steatorrhea was associated with small bowel hypomotility; malabsorbed fat that 
reached the ileum and colon is associated with inhibition of duodenal and jejunal 
motility.12 The presence of nutrients in the small intestine is essential for subsequent 
absorption and digestion, and this control is accomplished via adaptation of GI 
transport, including gastric emptying and intestinal transit. 
2.2 Small intestinal transit time 
Delayed small intestinal transit time is best described in the context of the ileal brake. 
Spiller, et al. infused 10 g fat (90 kcal in 30 min) in the ileum and observed a delay in 
transit time with an inhibition of jejunal pressure waves.13 This is in line with a study 
conducted by the same research group a few years later in which they compared 
free fatty acid infusion into the ileum vs. jejunum. Taken together, these observations 
indicate that infusion of fat into the ileum exerts an inhibitory effect on jejunal motility. 
However, when fat was infused directly into the jejunum, transit time was accelerated 
and the jejunal flow was increased.14 These results suggest that important differences 
exist between jejunal and ileal activation and their effects on small intestinal transit 
time and motility. 
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2.3 Gastric emptying rate 
A delay in gastric emptying, in the absence of mechanical obstruction, is thought to 
result from changes in gastric motor functions: via an increase in phasic and tonic 
pyloric pressure waves15 or via suppression of antral pressure waves15 and a 
reduction in fundic tone.16 Cook, et al. observed an increase in the frequency and 
amplitude of the isolated pyloric pressure waves (IPPW) after infusion of fat into the 
duodenum.17 The delivery of nutrients into the duodenum delays gastric emptying 
and increases phasic and tonic pressure in regions located near the pylorus. Lin, et al. 
infused oleate (fat) in the small intestine of dogs with a proximal jejunal fistula (≈60 cm 
from the pylorus) or with a distal midgut fistula (≈150 cm from the pylorus). They 
observed an inhibition of gastric emptying in a dose-related fashion. Herewith, the 
existence of a similar “brake” mechanism in the duodenum and jejunum was shown.18 
Lin, et al. also demonstrated a full inhibitory response on gastric emptying when 
oleate was infused over a total length of 150 cm in the small intestine. This result 
suggests that increasing the exposure of nutrients to regions of the small intestine 
strengthens the inhibitory response on gastric emptying. 
Only a few studies explored the inhibitory effect of nutrient infusion in different 
regions of the small intestine on GI motility. For instance, gastric emptying of a liquid 
meal was significantly more delayed after ileal fat infusion compared to infusion of 
the same amount of fat in the duodenum.19 Infusion of a mixture of glucose and rice 
starch into the ileum induced changes in upper GI function and delayed gastric 
emptying.20 With respect to protein, the effects on gastric emptying are not uniform. 
In dogs, amino acid infusion of 0.3, 0.6, or 0.9 kJ/min generated a dose-dependent 
delay in gastric emptying.21 Welch, et al. infused a protein hydrolysate (8%) into the 
human ileum and found no inhibitory effect on gastric emptying.22 
Taken together, the findings from these studies indicate that nutrients in the small 
intestine regulate the gastric emptying process15 and the extent of this nutrient-
mediated feedback is not only dependent on the region exposed to nutrients, but 
also on the length of the small intestine exposed to nutrients18 and type of 
macronutrients infused.  
3. Site-dependent effects on food intake and satiety: 
duodenal brake 
Most of the studies evaluating the effects of intestinal nutrient infusion on food intake 
and satiety have been conducted by duodenal delivery (Table 2.1). This is probably 
due to the fact that positioning an intestinal catheter in the duodenum is easier and 
more convenient than positioning the catheter in the jejunum or ileum. Alternatively, 
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to isolate the observed small intestinal effects from oral and particularly intragastric 
effects, it is best to infuse the nutrients as proximal as possible in the gut, that is, 
directly after passing the pylorus, avoiding the effects of gastric emptying. The 
existence of a duodenal brake for CHO originates from the idea that increased 
interactions of glucose with glucose-sensing receptors will also increase the satiating 
effects of CHO.23 This idea was based on two principles; (1) glucose in the small 
intestine was shown to stimulate vagal activity; and (2) infusion of glucose elevated 
plasma insulin in cats.24 From then on, several studies more systematically evaluated 
the effects of CHO infusion into the duodenum on satiety and food intake. Lavin, et al. 
observed a significant reduction in energy intake (17%), suppression of hunger, and 
increase in satiety when glucose was infused into the duodenum compared to 
intravenous infusion of glucose in a placebo-controlled study, while blood glucose 
concentrations did not differ between the two interventions.23 Two years later, the 
same researchers observed comparable results after intraduodenal infusion of 
glucose (3.2 kcal/min): a significant reduction in energy intake of 26% compared to 
control.25 When comparing the studies that infused CHO into the duodenum, 
Macintosh, et al. found a significant effect on food intake, with a threshold of ≥2.86 
kcal/min.26 Furthermore, an inhibitory effect on the desire to eat was already 
observed at a caloric load of 2.0 kcal/min.27 Taken together, these observations 
indicate that activation of the duodenal brake by CHO leads to an increased 
perception of fullness, suppression of hunger, an increase in satiety, and a reduction 
in energy intake (Table 2.1), unaffected by fluctuations in blood glucose 
concentrations. Changes in blood glucose concentrations have a significant impact on 
the gastric emptying rate in healthy adults and thereby interfere with the observed 
effects on food intake and satiety. There is evidence that hypoglycemia accelerates 
gastric emptying and consequently hastens the absorption of CHO from the GI tract. 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Protein is considered to be the most anorectic of the three macronutrients.45,46 
Consequently, several investigators have studied the effects of intraduodenal protein 
infusion on food intake and satiety. Furthermore, it has been established that 
intraduodenal infusion of pea protein results in a greater decrease in energy intake 
when compared with oral ingestion of the same amount of pea protein.28,47 Ryan, et al. 
conducted a study to evaluate the effect of intraduodenal whey protein infusion on 
satiety and energy intake. Assuming that intraduodenal fat and CHO suppress 
appetite and energy intake in a dose-dependent manner, this group aimed to study 
whether a dose-dependent effect of duodenal protein delivery exists on appetite. 
Caloric infusion rates of 0.5, 1.5, and 3.0 kcal/min of protein showed that the effects of 
intraduodenal protein are indeed dose dependent and resulted in suppression of 
food intake (Table 2.1). However, this effect was only found to be significant vs. 
placebo after an infusion of 3 kcal/min (26.3% reduction in food intake).28 
Remarkably, no significant decrease in hunger or appetite scores during and after 
protein infusion was observed (Table 2.1). Intraduodenal nutrients can potently 
suppress food intake, while little to no effect is seen on appetite perceptions. In 
addition, Steinert, et al. observed a more potent appetite-suppressing effect after 
intragastric infusion of glucose than with intraduodenal infusion. These results 
indicate that the stomach has an important contribution in inducing satiety 
mechanisms and that this is possibly mediated by mechanical factors, such as gastric 
distension.48 This effect may be macronutrient dependent, related to the influence of 
the macronutrient on the gastric emptying rate. Another explanation for the lack of 
effect on satiety and hunger scores may be related to the differences in appetite-
suppressive effects within different sources of protein.49 In addition, the absence of 
the satiating effects of intraduodenal protein may have been caused by differences in 
study design—differences in feeding status before the start of infusion, duration of 
fasting, and total time of infusion. 
Comparing intraduodenal fat and glucose, fat is shown to be a more potent inhibitor 
of food intake compared to isocaloric CHO infusion (Table 2.2).17,26,50 Protein and fat 
both activate the duodenal brake in a dose-dependent fashion, probably due to 
interaction with a larger number of receptors within the small intestine.29,35 A specific 
threshold in caloric load is necessary for macronutrients to activate the duodenal 
brake. For protein, a caloric load of 3 kcal/min significantly reduced energy intake 
(26.3% reduction).28 CHO reduced energy intake by 17% when a caloric load of 
3.2 kcal/min was infused.25 Remarkably, infusion of fat at a caloric load of 




Table 2.2 Summary of the effects of the different macronutrients in the different sites in the small intestine 
on energy intake. 
Heading Average Decrease Energy Intake in %;  
Average Caloric Infusion Rate in kcal/min 
Energy Intake Reference 
Duodenum    
Protein 20.8%; 3.0 kcal/min ↓ 28–30 
CHO 20%; 2.85 kcal/min ↓ 23,25,26,32,33 
Fat 21.5%; 3.69 kcal/min ↓ 26,30,35,37,39 
Jejunum    
Protein * *  
CHO 11%; 1 kcal/min ↓↓ ° 32 
Fat 50%; 4.9 kcal/min ↓↓ 39 
Ileum    
Protein 22%; 0.57 kcal/min ↓↓↓ 42 
CHO 32%; 0.57 kcal/min ↓↓↓ 42 
Fat 21.7%; 2.02 kcal/min ↓↓ 39,42,44 
* No data; ° Directly compared jejunal infusion and duodenal infusion (1413 ± 62 kcal vs. 1252 ± 97 kcal); ↓: <10% 
decrease energy intake at a caloric infusion rate of 1 kcal/min; ↓↓: >10% and <20% decrease energy intake at 




Combining fat with protein or glucose shows no effect on food intake and satiety.30,38 
The absence of these additive effects can be caused by the assumption that not a 
specific caloric load, but a specific concentration threshold of fatty acids, 
monosaccharides, or free amino acids is required to be present in the lumen of the 
small intestine in order to activate a negative feedback mechanism. For example, 
infusion of the amino acid l-tryptophan at a caloric load of 0.15 kcal/min shows a 
significant effect on satiety and food intake (Table 2.1) (19% reduction).31 In addition, 
when a fatty acid (lauric acid, C12) is directly infused into the duodenum with a caloric 
load of 0.4 kcal/min, a significant effect on food intake was observed (reduction of 
20%) while no effects on satiety scores were seen (Table 2.1).40 These results suggest 
that increasing the release of degradation products of fat, protein, and CHO 
strengthens the effects on the inhibition of food intake. However, it should be noted 
that this effect is also dependent on the type of fatty acid or amino acid infused. It is 
hypothesized that, when a combination of macronutrients is infused at the same 
caloric load as a single macronutrient, the critical threshold of activating the duodenal 
brake is not reached by the reduced presence of degradation products of fat, 
glucose, and protein. 
The abovementioned results suggest that all three macronutrients activate the 
duodenal brake, though to a different extent. The three different macronutrients exert 
an effect on food intake and satiety by mediating different mechanisms of action. The 
data reported here support the assumption that fat requires the lowest amount of 
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calories infused per minute to trigger a significant reduction in food intake. 
Furthermore, combining fat with glucose or protein showed no additive effects. 
Infusion of nutrients at a higher rate than the normal gastric emptying rate 
(≈2-3 kcal/min) or in supraphysiological concentrations could activate the more distal 
regions of the small intestine, and thereby have a more potent effect on food intake 
and satiety. In addition, when directly infusing degradation products of fat, protein, or 
CHO, supraphysiological concentrations are reached within a short period. Thereby, 
the physiological concentration of these degradation products in the distal regions of 
the small intestine is varying and not completely known. Consequently, is it difficult to 
distinguish between specific effects contributing to the duodenal brake and the more 
distal parts of the small intestine. 
4. Site-dependent effects on food intake and 
satiety: Jejunal brake 
Several studies have shown that infusion of nutrients into the jejunum modulates 
intestinal transit time. At present, only few studies have explored the effects of jejunal 
nutrient infusion on food intake, appetite, and feelings of satiety. Welch, et al. infused 
a fat emulsion with a caloric delivery rate of 4.9 kcal/min in the ileum and jejunum in 
humans and found early satiety and a reduction in food intake at both sites (Table 
2.1).39 However, the reduction in food intake was larger after jejunal infusion (50% 
compared to the control). It is worth noting that the infusion rate of 4.9 kcal/min can 
be seen as supraphysiological and exceeds the rate of nutrients entering the small 
intestine in the postprandial state51; therefore, fat could have spilled into the more 
distal small intestine, thereby activating the more distal ileal brake. 
To the best of our knowledge, no studies have been published in which the effects of 
jejunal protein infusion on food intake and satiety have been investigated. Regarding 
CHO, one study compared the effects of jejunal and duodenal infusion on food intake 
and satiety. A significant decrease in satiety and food intake (11%) in favor of jejunal 
infusion was shown compared to duodenal infusion. These results suggest that 
jejunal infusion of nutrients has an effect on food intake, but expanding the area 
exposed to nutrients increases the impact on food intake. Comparable effects are 
observed after Roux-and-Y Gastric Bypass, in which nutrients bypass the duodenum 
and a large part of the jejunum. Hereby, a supraphysiological amount of non-digested 
nutrients is delivered to the distal small intestine and contributes to a more chronic 
and sustained activation of the jejunal and ileal brake. Compared to the duodenum 
and ileum, reports on effects of jejunal perfusion with nutrients on food intake and 
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satiety are scarce (Table 2.1). As stated before, positioning of a catheter or tube in the 
more distal regions of the small intestine is invasive and time consuming. 
5. Site-dependent effects on food intake and 
satiety: Ileal brake 
Several studies have shown that infusion of fat into the ileum induces a brake effect on 
satiety and food intake8,39, delays gastric emptying, and reduces the secretion of 
gastric acid7 and pancreatic enzymes.5 Welch, et al. were the first to demonstrate the 
effects of nutrient-driven satiety in the ileum. These investigators infused an emulsion 
of 50% corn oil and 3% albumen into the ileum of healthy volunteers and measured 
the effect on food intake and satiety. Subjects had a significant reduction in energy 
intake (30%) during ileal infusion of fat, with a caloric load of 4.93 kcal/min compared 
with the control (Table 2.1).8 This caloric infusion rate is considered supraphysiological 
and it should be taken into account that some of the fat will have spilled over into the 
colon. The colon is capable of secreting Peptide YY (PYY) and Glucagon-like peptide-1 
(GLP-1)52,53 and may also have a role in regulating appetite and food intake. 
The ileal brake concept has traditionally been studied by directly infusing nutrients 
into the ileum, but information on this negative feedback mechanism on food intake 
and satiety is provided by studying surgical interventions in which the distal small 
intestine is exposed to an increased amount of nutrients. One such example is “ileal 
transposition”. In animal experiments, transposing 10 or 20 cm of lower ileum to mid 
duodenum or a jejuno-ileal bypass showed a sustained post-operative reduction in 
food intake and change in body weight.54 In addition, ileal transposition in Zucker obese 
rats, by transposing a 10 cm segment of the terminal ileum to the upper jejunum, 
caused long-term reduction in body weight and a persistent decrease in preference 
for dietary fat.55 In humans, the jejuno-ileal bypass (JIB) by Payne and De Wind was the 
first surgical treatment for morbid obesity.56,57 The weight loss observed after this 
procedure has at first been contributed to chronic malabsorption of nutrients. However, 
the loss in body weight was larger than could be accounted for via caloric loss in the 
stool. Näslund, et al. found significantly higher serum concentrations of distal gut 
hormones PYY and GLP-1 after JIB compared to pre-surgical levels, providing a 
possible explanation for the excess weight loss via neuro-hormonal feedback.41 
However, due to the high rate of complications after JIB, this surgical procedure is 
currently no longer performed in bariatric practice.58 
It has been well established that a high amount of fat activates the ileal brake. 
However, more recent studies indicate that much smaller amounts of fat can also 
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activate the ileal brake. Maljaars, et al. tested this hypothesis by conducting several 
studies on the satiating effects of small amounts of fat, and these authors 
investigated whether this effect is dose dependent. Healthy volunteers were 
intubated with a naso-ileal catheter and were randomized to the ileal infusion of 3 g 
or 9 g fat over a 45-min period, resulting in an infusion rate of 0.6 kcal/min and 
1.8 kcal/min. The control group received a fat-containing breakfast of 3 g with an ileal 
placebo infusion. Both the low and high ileal fat infusion resulted in a reduction in 
appetite and an increase in satiety, without any evidence for dose dependency43, in 
contrast to the dose-dependent effect of intraduodenal fat administration.35 A possible 
explanation for the absence of this dose-dependent effect could be related to the 
variety of lipolytic capacity of the different regions of the small intestine. It is known 
that the lipolytic capacity in the ileum is much smaller compared with the 
duodenum59, and therefore it is possible that a high dose of fat could not be fully 
hydrolyzed to fatty acids and monoglycerides before entering the colon. Currently, 
digestion of triacylglycerol is considered a necessary step for fat to establish its 
satiety-increasing properties.60 
Studies in humans evaluating the effects of all three macronutrients and their potency in 
inducing an ileal brake are limited. Van Avesaat, et al. tested the macronutrient-
specific effects in the ileum on eating behavior. In this single-blind randomized 
placebo controlled study, they compared the effects of six different interventions: 
saline, fat emulsion (51.7 kcal), low-dose protein (17.2 kcal), high-dose protein 
(51.7 kcal), low-dose CHO (17.2 kcal), and high-dose CHO (51.7 kcal) for 90 min (Table 
2.1). The low doses of macronutrients were infused at a rate of 0.19 kcal/min and the 
high doses at a rate of 0.57 kcal/min. Notably, these caloric infusion rates do not 
exceed the physiological gastric emptying rate, which is known to vary between 1 and 
4 kcal/min in healthy adults. These authors were the first to observe a suppression of 
food intake after CHO and protein infusion into the human ileum to the same extent as 
an equicaloric amount of fat (infusion rate 0.57 kcal/min). No effects were observed after 
infusion of 0.19 kcal/min of CHO or protein. Protein was the only macronutrient to 
influence satiety scores.42 This effect is not unexpected; protein is considered to be the 
most anorectic macronutrient. However, no significant differences in food intake 
between protein, CHO, and fat were observed at a caloric infusion rate of 
0.57 kcal/min.42 Therefore, it is still unclear whether differences between these 
macronutrients in terms of their ileal brake inhibitory effect on food intake exist. These 
results suggest that equicaloric amounts of protein and CHO in the ileum can induce an 
ileal brake and affect eating behavior to the same extent. This threshold for all three 
macronutrients is considerably lower than that in the duodenum. 
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6. The effects of length and site of intestinal 
contact on nutrient-driven satiety and food 
intake 
The different sites of the small intestine where nutrients are delivered are of utmost 
importance for the satiating effects. Table 2.2 provides an overview of the effects on 
food intake generated by the different macronutrients in the regions of the small 
intestine. This table provides evidence for a proximal to distal gradient in the small 
intestine; infusing nutrients in the distal small intestine generates a more potent effect 
on food intake. Figure 2.1 expands on the data from Table 2.2, revealing the 
percentage of decrease in energy intake in relation to the caloric infusion rate given 
for different locations with different macronutrients as well as the linear regression 
between the variables caloric infusion rate in kcal and the decrease in energy intake 
in % per location. With duodenal delivery of nutrients, the higher the infusion rate in 
calories, the stronger the inhibitory effect on food intake. With ileal delivery of 
nutrients, the inhibitory effect on food intake is more pronounced compared to 
















Figure 2.1 Caloric infusion rates (kcal/min) in the different regions of the small intestine and the decrease 
in food intake in percentage and linear regression for the duodenum and ileum. 
 
Based on the studies mentioned above, we may conclude that each site of the small 
intestine is, when exposed to undigested macronutrients, able to induce a so-called 
intestinal brake, while the magnitude of these effects is site dependent. Meyer, et al. 
Review	intestinal	brake	activation 
35 
and Lin, et al. demonstrated that increasing the small intestinal area exposed to 
nutrients induces more potent effects on gastric emptying rate and food intake.18,61 
Increasing the small intestinal area that is exposed to undigested nutrients may also 
cause a more potent effect on food intake in humans. Maljaars, et al. investigated this 
hypothesis and found no significant differences in reduction of food intake when 2 g 
of fat (0.6 kcal/min) was infused simultaneously (2 g each to all sites in the same time 
interval) or sequentially (2 g each to all sites in sequential time intervals) at different 
sites in the small intestine.44 A possible explanation is that in the study of Meyer, et al. a 
higher rate of infusion was chosen.61 Taken together, it can be suggested based on 
surgical techniques and intestinal infusion studies that increasing the caloric load of an 
infusion expands the small intestinal area exposed to nutrients and increases the 
effect on food intake and GI motility. 
7. The effect of BMI, age, and gender on the 
intestinal brake effect of nutrients 
BMI, age, and gender may influence the magnitude of the intestinal brake effects after 
infusion of nutrients. For BMI, Chapman, et al. compared the effect on food intake and 
satiety after intraduodenal infusion of fat and CHO between obese and non-obese 
men.34 Intraduodenal infusion of fat and CHO suppressed appetite and food intake in 
both obese and non-obese men. Thus, in this study, the effects of intraduodenal infusion 
of fat and CHO on food intake and satiety were not affected by BMI. In addition, Maljaars, 
et al. described altered gut peptide secretion and blunted vagal responses to nutrients 
when obesity develops.62 Thus, it can be suggested that obesity leads to altered 
gastrointestinal responses to nutrients. Still, the effect of an increase in BMI on the 
intestinal brake is not completely known. 
Aging results in a physiological decline in food intake. This phenomenon is called 
“anorexia of aging”. Cook, et al. studied the effect of intraduodenal nutrient infusion 
(fat and CHO) in older and younger subjects.17 They observed no significant difference 
in food intake from a buffet meal between older and younger subjects. Increased 
feedback from intestinal nutrient infusion in the elderly seems not to be responsible for 
the “anorexia of aging”. Other factors, for example alterations in taste and smell or 
changes in the gastrointestinal motility and secretion, may play a role. 





There is substantial evidence that all regions of the small intestine are able to 
generate negative feedback signals that influence the functions of the more proximal 
parts of the GI tract. Activation of the intestinal brake occurs after reaching a threshold 
to induce the release of mediators that are involved in intestinal brake activation. The 
inhibitory effect of this negative feedback mechanism differs between the different 
sites in the small intestine and the exposed area of infusion. The duodenum, jejunum, 
and ileum and their specific effects on the inhibition of motility, GI peptide release, 
food intake, and satiety are frequently evaluated in humans. However, several studies 
have used a caloric infusion rate that surpassed the normal gastric emptying rate, 
resulting in increased concentrations of undigested nutrients in the more distal parts of 
the small intestine. It is very likely that this effect is also created by bariatric surgery 
procedures such as RYGB, where a high amount of nutrients is delivered into the 
jejunum and causes chronically sustained ileal brake activation. 
Clinical studies evaluating the effect of small intestinal infusion of fat on food intake 
and satiety are numerous; these studies clearly demonstrate a suppression of food 
intake and increased satiety. Protein and CHO can suppress food intake and satiety to 
the same extent as equicaloric amounts of fat. It is concluded that a proximal to distal 
gradient exists with relation to the magnitude of the intestinal brake effect: the more 
distal the nutrients and their degradation products in the small intestine, the greater 
the effect on food intake and satiety (Table 2.2). 
Prolonged activation of the ileal brake by means of naso-ileal tubes is not feasible in 
daily practice and is therefore not an option as treatment for obesity. Alternatives such 
as efficient delivery of encapsulated nutrients into the ileum should be explored with 
focus on efficacy and safety. Taken together, the observations described in this review 
point to the ileal brake as the most potent small intestinal feedback mechanism for 
controlling food intake and satiety. Access of nutrients to the distal part of the small 
intestine is necessary in order to achieve the most potent effects on food intake and 
satiety. Taking all relevant factors into account, the ileal brake can be seen as a most 
interesting target for food-based approaches in the continuing battle against 
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Activation of the intestinal brake by infusing nutrients into the distal small intestine 
with catheters inhibits food intake and enhances satiety. Encapsulation of 
macronutrients, which protects against digestion in the proximal gastrointestinal tract, 
can be a non-invasive alternative to activate this brake. In this study we investigate 
the effect of oral ingestion of an encapsulated casein and sucrose mixture (active) 
targeting the distal small intestine versus a control product designed to be released 
in the stomach on food intake, satiety and plasma glucose concentrations. Fifty-nine 
volunteers received the active and control product on two separate test days. Food 
intake was determined during an ad libitum meal 90 min after ingestion of the test 
product. Visual analogue scale scores for satiety and blood samples for glucose 
analysis were collected at regular intervals. Ingestion of the active product decreased 
food intake compared to the control product (655 kcal compared with 699 kcal, 
respectively, p<0.05). The area under the curve (AUC) for hunger was decreased 
(p<0.05) and AUC for satiety was increased (p<0.01) after the ingestion of the active 
product compared to the control product. Ingestion of an encapsulated protein-
carbohydrate mixture resulted in inhibition of food intake compared to a non-
encapsulated control product. 
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1. Introduction 
The intestinal brake consists of a negative feedback mechanism from distal to more 
proximal parts of the gastrointestinal (GI) tract and is activated by intraluminal 
macronutrients and their digestive products. This brake controls not only GI motility 
and secretion but also food intake and feelings of satiety.1-3 Previously, it was shown 
that all types of macronutrients are able to activate this intestinal brake and thereby 
influence eating behavior.4 While all parts of the small intestine (duodenum, jejunum 
and ileum) are able to activate this ‘intestinal brake’, the ileal brake is considered to 
induce the most potent feedback signals in the control of food intake and satiety.5,6 
Therefore, ileal brake activation has emerged as a potential target to reduce caloric 
intake and, in the longer term, for weight management.7 
Up to now, intestinal brake activation in humans has mainly been studied via intestinal 
intubation, that is by positioning naso-intestinal feeding catheters in order to infuse 
nutrients directly into the small intestine.4,5 These studies have provided clear 
evidence that infusion of small amounts of either fat or protein or 
carbohydrates into the distal small bowel reduces food intake and increases satiety. 
For clinical applications, other less invasive strategies for macronutrient delivery into 
the small intestine ought to be developed. 
Schellekens et al. and Varum et al. both have successfully designed systems for 
targeted and site-specific drug delivery in the GI tract.8,9 A comparable approach can 
be used for targeted nutrient delivery. Encapsulation of nutrients with a food grade 
coating provides a barrier against digestion in the proximal GI-tract, and is considered 
to be a non-invasive alternative for targeted nutrient delivery. Previous studies have 
employed an oil emulsion product (Fabuless®, Olibra®) aiming at more distal delivery 
of fat. These products were based on specific physical-chemical properties of an 
emulsifier.10-12 The proposed mechanism for Fabuless is the activation of the ileal 
brake; the emulsified oils delay lipolysis and fat absorption from the proximal GI tract 
and consequently exposes the distal GI tract to a high intraluminal fat content. 
Fabuless was shown to decrease food intake and increase satiety in studies by Burns 
et al.7-9, although this was not confirmed by others.13-16 It was hypothesized that the 
processing of food may have diminished the ability of Fabuless to deliver undigested 
fat to the distal small intestine.16 
This proof of concept study aimed to investigate the acute effect of an orally 
administered encapsulated nutrient mixture, targeting at more distal intestinal 
release, on food intake and satiety compared to a control product that disintegrates in 
the stomach in healthy overweight subjects. We hypothesized that the encapsulated 
nutrient mixture more potently induces satiety and reduces food intake during an ad 
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libitum meal compared to control condition. We administered two macronutrients: 
protein (casein) and carbohydrate (sucrose). We chose not to administer fat, since 
administration of significant amounts of fat in the distal ileum may lead to GI 
discomfort.17,18 In addition, fat requires a different encapsulation technique compared 
to carbohydrates and protein.19 
2. Materials and methods 
The study was approved by the Medical Ethics Committee of Maastricht University 
Medical Center+ and was conducted in full accordance with the principles of the 
Declaration of Helsinki of 1975 as amended in 2013, and with the Dutch Regulations 
on Medical Research involving Human Subjects (1998). All subjects gave written 
informed consent before participation. This trial was registered at 
www.clinicaltrials.gov as NCT02635659. 
2.1  Subjects 
Subjects were recruited between December 2015 and June 2016. Healthy volunteers 
were eligible to participate if they were aged between 18 and 65 years and had a 
body mass index (BMI) between 25 and 30 kg/m2. Volunteers were recruited by local 
advertisements. Exclusion criteria were intake of more than 20 alcoholic 
consumptions per week, specific medication use or medical history of any relevant 
disorder or surgery possibly interfering with the study outcomes (as assessed by a 
physician), known GI symptoms and dieting. All subjects reported to be weight stable 
for at least 6 months before screening and to be unrestrained eaters (assessed by the 
Dutch eating behavior questionnaire20) and reported not be on a diet during study 
period. After providing initial information verbally or by email, detailed written study 
information was provided in case subjects were interested. All subjects had to 
understand the study procedures before the informed consent was signed. Written 
informed consent was obtained after an interval of at least 7 days.  
The power calculation was based on the decrease in food intake of 136 kcal found in 
ileal carbohydrate infusion study performed by our group.4 We expected to find a 
decrease of 50%, corresponding to 68 kcal. With a standard deviation of 175 kcal , a 
power of 80% and an alpha of 0.05, a total number of 54 subjects was needed. 
Anticipating a 10-15% dropout, we included 62 healthy subjects. 
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2.2  Study design 
This double-blind, randomized, controlled crossover study compared the effect of an 
encapsulated nutrient mixture targeting the distal small intestine with that of an 
identical control product (nutrient mixture with alginate encapsulation which 
disintegrates in the stomach). The study product was ingested 180 min after a 
standard breakfast, to allow the stomach to be emptied before ingestion of the test 
drinks. Test days were scheduled with a wash out period of 1 week in between to 
avoid possible carry-over effects. Test days were randomly assigned (by using 
Research Randomizer, www.randomizer.org). Subjects were randomized to treatment 
in randomized block designs. The primary randomization factors were gender and 
age.  
2.3  Study products 
The active product was an encapsulated nutrient mixture containing 16 g of sucrose 
(4 kcalg−1, van Gilse Automatensuiker, Oud Gastel, The Netherlands), 10 g of casein 
(energy density: 3.45kcal g−1, Dutch Protein Services, Tiel, The Netherlands) and 2 g of 
whey protein, which was used to fabricate the microencapsulate (AnaBio 
Technologies, energy density 112 kcal). The control product contained 16 g of sucrose 
and 10 g of casein (AnaBio Technologies, energy density 107 kcal). The 
macronutrients in the control product were encapsulated with a sodium alginate 
encapsulation system characterized by extrusion of the respective micronutrient 
using 1.8% (w/v) sodium alginate, with subsequent drying. Samples were dissolved in 
a total volume of 80 ml of water before consumption. The drinks were prepared by an 
independent researcher and offered in a black opaque bottle to blind both the 
investigator and the participant.  
2.4  Micro-encapsulation procedure 
The procedure of preparation of the micro-capsules is described in the patent WO 
2016/096931 A1.21 All materials were produced according to Good Manufacturing 
Practice (GMP) guidelines. The micro-encapsulation system utilizes clean-label, food-
grade sources of sucrose and casein to generate micron-sized capsules for 
controlled delivery of native casein and sucrose to the distal small intestine for 
stimulation of the intestinal brake mechanism. Gastro-resistant micro-capsules were 
produced when the sucrose and casein formulation was extruded through an 
apparatus comprising of an outer nozzle concentrically arranged around an inner 
nozzle, and in which a denatured protein solution is extruded through the outer 
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nozzle and the core-forming casein – sucrose solution is extruded through the inner 
nozzle. Micro-droplets were instantaneously polymerized in an acidic solution and 
batches were held at room temperature for max. 1 hour under aseptic conditions. This 
process avoids 1) blockage of sucrose – casein solution in the concentric nozzle and 
2) flow discrepancies during encapsulation process which would affect encapsulation 
efficiency of the sucrose-casein micro-capsules. 
2.5  Characterization of micro-encapsulates 
2.5.1  Size distribution and drying effects 
According to light microscopy, micro-beads demonstrated diameters of 
approximately 200 m with a narrow range size distribution (1.2 m). Laser 
diffractometry was also incorporated and confirmed a D (, 0.9) value for micro-
encapsulates, revealing a diameter of 201.7  0.90 m and 183.42  0.90 m, pre- and 
post-drying respectively.  
2.5.2  Stomach incubation and strength of micro-encapsulates 
Strength of micro-beads was analyzed as a function of gastric incubation time in vivo 
(pH 1.2-1.4; 37C). No difference in micro-bead strength was reported for stomach 
incubation and enzyme-activated stomach conditions did not significantly change 
micro-bead strength. Tensile strength of micro-beads remained unchanged with no 
reported leakage or loss of encapsulated casein, pea protein or sucrose. After 180 
min of gastric incubation, encapsulated casein, pea protein and sucrose 
microencapsulates maintained a high tensile strength 52.03  1.27nN, 60.31  0.27nN 
and 58.23 0.12nN, respectively, to support a robust and high-yielding encapsulation 
systems for macronutrients. 
2.5.3 Intestinal incubation and degradation 
Transit time of microencapsulates was investigated during in vivo trials and they 
observed that 35 min after oral ingestion there was no degradation of the micro-
encapsulates in the duodenum. The maintenance of micro-encapsulate integrity in 
small intestinal fluids was tested and degradation was not evident. As time 
progressed, the capsulate membrane gradually degrades to release to mononuclear 
core material.21 
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2.6  Protocol 
On each test day, subjects arrived at 0745 hours, after a 10-hour overnight fast, at the 
Metabolic Research Unit at the Maastricht University Medical Center+. Subjects were 
instructed to abstain from heavy exercise and consumption of alcoholic beverages 
the evening before the test day and to consume the same habitual meal on the 
evening before each test day. On both test days, an intravenous cannula was placed 
in a forearm vein for collection of blood samples. At 0800 hours, a fasted blood 
sample was taken and Visual Analogue Scale (VAS) scores for satiety, hunger, 
fullness, desire to eat and GI symptoms were obtained. Subsequently, a standardized 
breakfast meal (identical on both test days), consisting of a whole grain sandwich with 
cheese (Jumbo Supermarkt; energy 245 kcal per served portion, 13.05 g protein, 5.1 g 
carbohydrates, 1.75 g lipid) and a 200 ml water was consumed by each participant. 
Completion of the breakfast meal was considered as t=-180 min. (Figure 3.1). The 
subjects were allowed to drink 200 ml water until t=-60 min. 180 min after breakfast 
intake, subjects ingested the micro-encapsulated nutrient mixture or the control 
product in randomized order on different test days (t=0 min). The participant was 
instructed to ingest the test drink within one min. At 90 min after the intake of the test 
drink, volunteers received a standardized ad libitum lunch meal (Lasagna Meal Jumbo 
Supermarkt; energy density per 100 g: 144 kcal, 9.0 g protein, 15.2 g carbohydrates, 
and 4.9 g lipid) (t=90 min). The ad libitum lunch meal was offered in excess 
(approximately 1 kg of pasta meal) and subjects were instructed to eat until 
comfortably satiated. Ad libitum food intake was assessed by weighing the pasta meal 
that was not consumed and subtracting that from the weight of the provided meal. 












Figure 3.1 Timeline of the test day. A test drink (encapsulated nutrient mixture or control) was ingested 
180 min after finishing the breakfast. Blood samples, VAS scores for satiety and GI symptom 




2.7  VAS scores for satiety, fullness, desire to eat, hunger, 
and evaluation of GI symptoms 
Satiety, hunger, fullness and desire to eat were measured using VAS scores (0-100 
mm) anchored at the low end with the most negative of lowest intensity feelings 
(extremely unpleasant, not at all) and with the opposing terms at the high end 
(extremely pleasant, very high, extreme).22 GI symptoms were evaluated using a 
questionnaire which addressed complaints such as nausea, bloating, headache, and 
other symptoms. Symptoms were scored on a 4-point scale with grade 0 
representing ‘not present’ to 3 ‘strongly present’. Subjects were asked to mark the 
VAS and GI symptom scores before breakfast consumption. This was considered as 
T=-180 min. Subjects also marked the VAS and GI symptom scores before ingestion of 
the test drink. After ingestion of the test drink (between t=0 min and t=90 min), the VAS 
and GI symptoms were scored at 15 min intervals until starting the ad libitum lunch 
meal.  
2.8  Blood sample collection 
Venous blood samples were drawn before breakfast (fasted) and before ingestion of 
the test drink (t=0 min). After ingestion of the test drink, blood samples were obtained 
every 15 min until the start of the ad libitum meal (t=90 min) for glucose analysis. 
Glucose concentrations were analyzed as an indirect indicator for the site of delivery 
of the nutrients and subsequent nutrient absorption. Sodium fluoride tubes (Becton & 
Dickinson, New Jersey, USA) were used to collect blood samples for plasma glucose 
concentrations. Glucose measurements were performed using a Roche Cobas C701 
analyzer (GLUC3, Roche, Mannheim, Germany) with an inter-assay variation of 
0.02 mmol/l at glucose concentration 3.27 mmol/l.  
2.9  Statistical analyses 
Statistical analyses were performed with SPSS, version 22.0 (SPSS Inc., Chicago, IL, 
USA). Statistical analysis of food intake was performed on the amount of food eaten in 
kcal. Plasma glucose concentrations and VAS scores are displayed from before the 
start of ingestion of the test drink (t=0 min) until the ad libitum meal (t=90 min). All 
variables were compared with a mixed model analysis of variance including the fixed 
factor treatment (encapsulated nutrient mixture and control). For the VAS scores and 
plasma glucose concentrations, time and the interaction between treatment and time 
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were added to the model. To compare the intervention effects within subjects in this 
cross-over design, subject was included as a random factor. The mixed model 
included a random intercept model and a random slope (variance components) 
model. The final model was chosen based on the Akaike Information Criterion (AIC); 
the model with the lowest AIC was suitable for interpretation. Total VAS scores and 
plasma glucose concentrations in the 90 minute time frame after the ingestion of the 
test drink were expressed as the area under the curve (AUC), which was calculated 
with the use of the trapezoid rule and analyzed with the use of a paired t test. Data are 
presented as the means ± SD unless specified otherwise. p<0.05 was considered as 
statistically significant. 
3. Results 
Sixty-two subjects were included in this study (21 male, age: 43.3 ± 15.9 years, BMI 
27.8 ± 1.49 kg/m2). Two subjects were excluded from analysis, because we were not 
able to reliably measure their ad libitum intake of the test meal; since these subjects 
finished the whole meal without being satiated. One participant dropped out during 
















Figure 3.2 CONSORT flow diagram. 
3.1  Food intake 
Ingestion of an encapsulated nutrient mixture resulted in a significantly lower food 
intake during the ad libitum meal compared with control (655 ± 30 kcal compared with 
699 ± 30 kcal respectively, p=0.011, Figure 3.3). 
3.2  Satiety, hunger, fullness and desire to eat scores 
Ingestion of both products decreased hunger and desire to eat and increased satiety 
and fullness. While this effect was more pronounced for the active product for all VAS 
parameters, there was no significant treatment x time interaction observed for all the 
VAS parameters. With respect to the AUC (from 0 to 90 min), significant differences 
between the active and control product were observed for satiety (p<0.01) and for 

























































Figure 3.3 Food intake in kcal (mean ± SD) of the ad libitum meal offered 90 minutes after the ingestion of 
the active or control product. *p<0.05. 
3.3 GI symptoms 
Mean scores for pain, bloating, flatulence, heartburn, nausea, belching, cramps and 
urge to defecate did not differ between the ingestion of the encapsulated nutrient 
mixture and the control. Subjects did not experience any GI symptoms after ingestion 
of both treatments (data not shown).  
3.4 Glucose concentrations 
The plasma glucose concentration before ingestion of the products (t=0 min) did not 
differ between the test days (p>0.05). There was a treatment x time interaction for 
plasma glucose concentration; plasma glucose concentrations increased after 
ingestion of the control product over time, whereas the active product did not result 
in changes in plasma glucose concentrations, p<0.001. A significant increase in AUC 
of the plasma glucose concentration was observed after the control compared with 





































Figure 3.4 AUCs (0-90 min) for Satiety (A), Hunger (B), Fullness (C) and Desire to eat (D) (mean ± SD). VAS 
scores for Satiety (E), Hunger (F), Fullness (G), and Desire to eat (H) after intake of active or 
control product (mean ± SD). Ingestion of the test drink took place at t=0 min (180 min after 
consumption of the breakfast). An ad libitum meal was offered at t=90 min. AUCs were 
calculated by using the trapezoid rule. *p<0.05 and #p<0.01. 













Figure 3.5 AUC of the plasma glucose concentration (mean ± SD, A) and plasma glucose concentrations 
over time (mean ± SD, B) during the period after ingestion of the test drink (active and control) 
scheduled from 0 to 90 min. AUCs were calculated by using the trapezoid rule. $p<0.001. 
4.  Discussion 
In this proof of concept study, we have shown that oral ingestion of an encapsulated 
nutrient mixture of sucrose and casein, targeted at delivery into the more distal part of 
the intestine of healthy overweight individuals, resulted in a decreased caloric intake 
of a subsequent lunch intake when compared to the control product. The decrease in 
food intake was accompanied by increased feelings of satiety and decreased feelings 
of hunger.  
The effect of an orally ingested encapsulated nutrient mixture to reduce food intake 
has not been evaluated previously in humans. Our data confirm that the concept of 
inhibition of food intake by encapsulated nutrients indeed is effective in an acute 
intervention experiment. Our test product induced significant effects on food intake 
and satiety after one single administration of the orally ingested product. This finding 
is promising for clinical applications but needs confirmation in longer term, repetitive 
experiments. Previously van Avesaat et al., have investigated the effects of ileal 
infusion of protein and carbohydrate separately on the ileal brake targeting on food 
intake and satiety in normal weight subjects using a naso-ileal intubation technique.4 
It was shown that infusion of protein and carbohydrate in a total concentration of 
51.7 kcal resulted in a decrease in food intake of respectively 128.7 kcal and 
187.7 kcal.4 We here observed a decrease in food intake of 44 kcal, an effect of 
considerably lesser magnitude. A possible explanation for the less pronounced effect 
on food intake in our current study may result from several factors. First, it may be 
caused by the method of nutrient delivery, resulting in differences in amounts of the 
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macronutrients present in the more distal intestinal lumen during the study. Avesaat 
et al. infused 51.7 kcal of carbohydrate and protein separately over 90 minutes 
directly into the ileum. This resulted in a caloric load of 0.57 kcal/min. In our study 
protocol, subjects acutely and completely ingested both test drinks 90 minutes 
before start of the ad libitum meal. We are not informed about the amount of protein 
and carbohydrate calories present in the distal intestine (ileum and more distally) 
before start of the ad libitum meal in the present study, and thus on the magnitude of 
the intestinal brake activation. Furthermore, we chose a combination of two 
macronutrients. Several studies have shown that infusion of a combination of different 
macronutrients in the duodenum did not result in synergic effects on food intake and 
satiety.18,23 It is thought that a critical, minimum amount of amino acids and 
monosaccharides should be present in the intestinal lumen in order to reach a 
threshold value for activating the ileal brake.5 One of the two macronutrients may not 
have reached the critical threshold level for intestinal brake activation. It should also 
be taken into account that not all of the encapsulated nutrients will have reached the 
ileum, either through more rapid and proximal delivery or through spill over into the 
colon.  
The effect of the intestinal brake on food intake and satiety feelings has mainly been 
evaluated in normal weight subjects.24,25 The effect of distal delivery of nutrients and 
the effectiveness of the ileal brake is less well understood in overweight and obese 
subjects. For the duodenal brake, a less pronounced suppression of food intake was 
observed after intraduodenal lipid infusion in obese subjects compared to lean 
subjects.26,27 According to our study protocol we included healthy overweight 
subjects with a BMI between 25 and 30 kg/m2 and observed a significant decrease in 
food intake. It is not known whether the effect of more distally delivered nutrients on 
food intake is different in overweight compared to normal weight subjects. On the 
other hand, several studies investigating the mechanisms of weight loss after bariatric 
surgery, such as Roux-en-Y gastric bypass, have provided clear evidence of 
increased delivery of nutrients in the jejunum and ileum, ileal brake activation and a 
sustained decrease in body weight years after intervention.28 
This study was explorative in design: our aim was to deliver proof for the concept that 
encapsulates nutrients, targeting at a more distal intestinal release, will inhibit 
subsequent caloric intake. Ileal brake activation is associated with more pronounced 
release of distal gut peptide into the systemic compartment. We have not measured 
gut peptide release, so proof for more distal gut delivery of the encapsulated protein-
carbohydrates mixture cannot be delivered. However, we measured plasma glucose 
concentrations at regular intervals for 90 min after ingestion of the encapsulated 
mixture and after ingestion of the non-encapsulated identical mixture. While plasma 
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glucose concentrations increased significantly within thirty min after ingestion of the 
non-encapsulated product, this increase was not found after ingestion of the 
encapsulated nutrient mixture, pointing to at least delayed, more gradual and 
possibly more distal delivery of the sucrose from the encapsulate.  
Several limitations of this study should be acknowledged. First, our study was 
designed to deliver evidence for the proof of concept, providing first-in-human data 
whether an encapsulated nutrient mixture is able to reduce food intake in an acute 
intervention setting. Second, we have not measured timing or location of release of 
nutrients from the encapsulate into the lumen nor have we measured distal gut 
peptide like PYY and GLP-1 to obtain further insight whether the more distal part of 
the small intestine indeed was activated. Subsequent studies are needed to deliver 
further proof of ileal brake activation. Third, we evaluated food intake in the acute 
setting, that is after intake of only a single ingestion of the encapsulated nutrient mix. 
Fourthly, it is not known whether encapsulated nutrients are able to repetitively 
activate ileal brake mechanisms and hereby result in a sustained effect on food intake 
and satiety. Due to the encapsulation material, the encapsulated nutrient mixture 
consisted of slightly more calories than the control product. It is however not 
expected that this small difference would have affected the results. Increasing the 
number of calories in the test drink would lead to more potent ileal brake activation 
and consequently a more pronounced effect on the inhibition on food intake. While 
the decrease in food intake in terms of calories appears rather modest after a single 
use, future studies should reveal whether this effect is sustained after repetitive 
ingestion of this encapsulated nutrient mixture. Another focus for future studies is on 
the exact behavior of the encapsulated nutrient mixture in the GI tract, to provide 
proof of ileal brake activation. The question needs to be answered whether such a 
slow release, repetitive ingestion strategy wil have a potential role in long term 
weight management. 
In conclusion, this is the first-in-human study to demonstrate that ingestion of an 
encapsulated protein and carbohydrates mix targeting the distal small intestine is 
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The ileal brake mechanism, which induces satiety after sensing nutrients or their 
metabolites in the ileum, is considered a potent feedback mechanism. Triggering this 
mechanism through oro-ileal lipid delivery could be the basis for a weight 
management strategy. We hypothesize that emulsion–alginate beads prevent 
proximal digestion and absorption of the encapsulated lipid, and that its more distal 
(ileal) release induces feelings of satiety and reduces food intake. 
 
Objective 
This study investigates the ability of ingested emulsion–alginate beads to decrease 




Thirty-three healthy overweight volunteers (mean age: 43 yrs.; mean BMI: 27.7 kg/m2; 
14 male) received two treatments in a randomized placebo-controlled trial with cross-
over design. Test days started with intake of a standardized small breakfast (t=0), 
followed by a yogurt (t=90 min) that contained either encapsulated lipid as emulsion–
alginate beads (active) or an equicaloric mixture of non-encapsulated nutrients with 
similar sensory properties (control). Feelings of satiety and GI symptoms were 
monitored prior to and after consumption of the yogurt, and food intake was 
measured during ad libitum pasta meal consumption (t=210 min). 
 
Results 
Food intake was significantly reduced with 51 ± 20 kcal (p=0.016) after intake of the 
active yogurt (770 ± 38 kcal) compared to the control (821 ± 40 kcal). Satiety was 
increased after intake of the active yogurt compared to the control (p=0.013), but 




Ingested emulsion–alginate beads reduce food intake, suggesting that release of 
encapsulated lipids in the distal small intestine activated the ileal brake. These 
findings have important implications for understanding satiety mechanisms, and 
moreover, the development of a product for weight management. 
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1. Introduction 
The worldwide rapid expansion of obesity demands new noninvasive treatment 
strategies, which may be obtained via dietary interventions that suppress appetite 
sensations and regulate food intake.1,2 Among others, oral and gastrointestinal (GI) 
processes involved in food intake regulation, and nutrient sensing in the small 
intestine can induce negative feedback signals to the proximal GI tract and central 
nervous system to inhibit digestion, appetite sensations, and food intake.3,4 The 
ileumis believed to provide the strongest signal, through “the ileal brake”.5,6 Ileal brake 
activation has been proven via direct intraileal infusion of macronutrients, applying 
nasointestinal feeding catheters in human volunteers.6 Already 30 years ago, ileal 
infusion of lipids was shown to reduce food intake7,8; however, as part of a long-term 
weight management strategy, ileal lipid delivery needs to be achieved via oral 
ingestion, so without need for intubation. 
The degradation products of lipid digestion (ie, free fatty acids, monoglycerides) 
activate the ileal brake more than the intact lipids itself1,9,10, but to achieve this lipid 
degradation, products need to be delivered to the ileum without proximal absorption. 
Under physiological conditions, orally ingested lipids are not likely to deliver 
discernible amounts of such degradation products to the ileum due to a range of 
processes that allow efficient lipolysis and absorption in the proximal small intestine.11 
To enable delivery of the lipolysis products, lipids need to be protected by a carrier 
that remains intact under the acidic conditions in the stomach and that slowly 
releases degradation products in the distal small intestine.1 
Many attempts have been made to control in vitro lipid digestion, mainly through 
designing a protective interface structure around nanometer- or micrometer-sized 
emulsion droplets.12 However, such strategies are not effective enough to deliver 
lipolysis products to the distal small intestine even when sophisticated particle-
stabilized interfaces13,14 or multilayered interfaces15,16 are used. This has led us to 
conclude that to truly control lipolysis, a different approach is needed that focuses on 
controlling the exposure of the lipids to digestive enzymes in the GI tract by 
incorporating lipids in a gel.17 Oilin-water emulsions encapsulated in calcium-alginate 
beads (named emulsion-alginate beads from hereon) have been suggested for this 
purpose, as the indigestibility of alginate preserves the structure of the beads, and the 
pH-dependent response favors lipase diffusion toward encapsulated emulsified lipids 
in the small intestine; namely, the beads shrink under acidic conditions and have a 
smaller mesh size, thereby protecting the encapsulated emulsion in the stomach. At 
increasing pH, such as in the small intestine, the beads swell and increase in mesh 
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size.18-22 This makes the oil droplets more accessible for lipase, but lipase diffusion in 
the beads is still considerably lower compared to free diffusion. 
Emulsion-alginate beads have been shown to improve the integrity of the 
encapsulated lipids (as observed bymicroscopy) during gastric transit and to delay 
intestinal lipid absorption compared to free emulsion droplets or emulsion 
microclusters in rats.23 These findings were in line with a human trial in which large 
(0.5 cm) lipid-core alginate-shell capsules were shown to delay intestinal lipolysis and 
absorption.24 For the current human intervention study, small alginate beads 
(d32=0.5-1.2 mm) that encapsulate emulsion droplets (d32 ~25 μm; safflower oil as 
appetite suppressor25) were developed to delay intestinal lipolysis. In earlier work, it 
was shown that these beads can be designed to control in vitro lipolysis after prior 
gastric incubation by altering bead and mesh size.22 Monitoring dynamic in vitro 
lipolysis of such emulsion-alginate beads confirmed lipolysis at time scales relevant 
for delivery to the more distal part of the small intestine, whereas in vitro lipolysis of 
nonencapsulated emulsions was almost completed when leaving the duodenal 
compartment.26 
The hypothesis for this study was that delayed release of encapsulated lipids 
suppresses appetite sensations and reduces food intake. The primary objective was 
to investigate the efficacy of encapsulated emulsions in calcium-alginate beads at 
reducing food intake during ad libitum meal consumption. The second objective was 
to investigate the efficacy of these beads at suppressing appetite sensations. The 
emulsion-alginate beads were ingested in a yogurt (active) and compared to a yogurt 
with an equienergetic mixture of nonencapsulated nutrients with comparable sensory 
properties (control) in a randomized placebo-controlled trial with crossover design. 
The present work is an explorative study to prove the concept of ileal brake activation 
in healthy overweight individuals. 
2. Materials and methods 
2.1 Materials 
Safflower oil was purchased from De Wit Specialty oils (19200 Safflower Oil High 
Linoleic Refined; de Waal, the Netherlands), whey protein isolate (WPI) from Davisco 
Foods International (BiPro, purity 97.5%; Eden Prairie, MN, USA), calcium chloride from 
Boom BV (Prills Food grade; Meppel, the Netherlands), and sodium alginate 
(W201502) from Sigma Aldrich (St Louis, MO, USA). Fat-free yogurt, bread, 
marmalade, lemon juice, and the pasta meals were purchased at a local supermarket. 
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All materials were certified for food-grade use and used directly without further 
purification. 
2.2 Preparation of the enriched yogurts 
Commercial fat-free yogurt (Campina Magere yogurt; Amersfoort, the Netherlands; 
energy density per 100 g: 39 kcal (163 kJ), 0 g lipid, 4 g carbohydrates, 4.7 g protein) 
was enriched with emulsified safflower oil (6 g) being either encapsulated in alginate 
beads (active) or nonencapsulated (control; in presence of “empty” beads), as 













Figure 4.1 Overview of the study design on the effect of encapsulation of lipids on appetite sensations and 
food intake. Yogurts were enriched with 2 types of lipid carrier: either encapsulated as emulsion-
alginate beads for ileal delivery (active) or nonencapsulated with comparable sensory properties 
(control). *VASs were used for 9 attributes per time point. 
 
2.2.1 Emulsion 
Safflower oil was added to a WPI solution (20 wt% oil, 10 g∙L−1 WPI in the aqueous 
phase) and mixed using a rotor stator homogenizer (Ika T18 basic Ultra-Turrax 
homogenizer equipped with a S18N-19G dispersion tool, Staufen, Germany) for 
5 minutes at 13 000 rpm to obtain an emulsion with a droplet size (d32) of 25 μm. 
2.2.2 Emulsion-alginate beads 
Fresh emulsion (<5 minutes after production)was mixed with an alginate solution 
(36 g∙L−1) in volume ratio 1:1 (final composition: 10 wt% oil, 20 g∙L−1 alginate in the 
aqueous phase, Table 4.1). This alginate-emulsion mixture was added drop wise to a 
gently stirred calcium bath (5 wt% CaCl2 with some drops of lemon juice to lower the 
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pH and fully dissolve the calcium), as described previously.22 The needle tip (inner 
diameter 0.41 mm; Nordson EFD, Dunstable, UK) was positioned 5-6 cm above the 
calcium bath, and a syringe pump was used to regulate the flow rate (3.0 ml/min). To 
control the bead size, an air flow was applied (Jun-Air 86R-4B compressor, Benton 
Harbor, MI, USA) such that it passed the needle in a homogeneous way, resulting in a 
bead size (d32) of 1.10 ± 0.05 mm. After production, the emulsion-alginate beads were 
stored at 4°C at least overnight to harden completely and not more than 4 days to 
prevent microbial spoilage. On the test day, the beads were filtered and washed with 
tap water (10 times volume, >10 minutes) and filtered again to obtain weighable 
beads. 
2.2.3 Empty beads 
Alginate beads were produced from 20 g∙L−1 alginate solution in the same way as 
described above22 but not mixed with emulsion. The bead size was 1.21 ± 0.02 mm, so 
it was similar to the emulsion-alginate beads. These beads were also stored at 4°C for 
1 to 4 days and washed and filtered before use. 
2.2.4 Active yogurt 
Fat-free yogurt (120 g) was mixed with 60 g emulsion-alginate beads (containing 6 g 
safflower oil). The composition was matched to the control yogurt by adding 24 g 
water. The active yogurts contained 105 kcal (439 kJ), of which 51 kcal% came from 
the encapsulated lipids (Table 4.1). 
2.2.5 Control yogurt 
Fat-free yogurt (120 g) was mixed with 30 g emulsion (containing 6 g safflower oil), 
and 54 g empty beads to match the composition and sensory properties of the active 
yogurt. This makes the control yogurt an equienergetic mixture of nonencapsulated 
nutrients that also contained 105 kcal (439 kJ), of which 51 kcal% came from the 
nonencapsulated lipids (Table 4.1). 
2.2.6 Particle size distribution 
The particle size distribution of the emulsions and beads was determined using static 
light scattering (Mastersizer 2000 with Hydro SM dispersion unit, Malvern Instruments, 
UK). For the emulsions, the refractive index of safflower oil was set at 1.460 and that of 
the dispersant at 1.333. For the beads, the refractive index was set at 1.470 (with an 
absorption index of 0.02) and the refractive index of the dispersant at 1.333. 
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Table 4.1 Composition and energy content of the studied yogurts. 
Name  Active  Control  
Safflower oil (g)  6.0  6.0  
Whey protein (g)  ≤0.24  0.24  
Alginate (g)  1.08  1.08  
Water* (g)  76.9  76.9  
Yogurt (g)  120  120  
Total (g)  204  204  
Total (kcal)  105  105  
Lipid contribution (kcal%)  51%  51%  
* Sum of the water added (in emulsion) and the water in beads. 
 
2.3 Study population 
The study population included 33 healthy overweight volunteers (male and female, 
18-65 years, body mass index [BMI] 25-30 kg/m2). Participants received 75 euro after 
completing the study. Thirty-one subjects were needed to complete the study based 
on an a priori power analysis for expected effect on our primary outcome, i.e., food 
intake, so 33 subjects were included to account for possible dropouts. The expected 
effect size was based on differences in reduction of energy intake of the next meal 
from previous4,5 and unpublished work: average difference of 82 kcal (343 kJ) with an 
average SD of 156 kcal (653 kJ). 
The volunteers were recruited from a pool of subjects and via advertisements. 
Subjects were excluded from participation when they reported milk (protein or 
lactose) allergy/intolerance, dieting, pregnancy, lactation, excessive alcohol 
consumption (>20 U per week), intention to stop smoking, self-admitted HIV-positive 
state, abnormal eating behavior, or unexplained weight loss/gain in the month prior 
to screening. Subjects were also excluded when taking medication that may affect 
appetite and sensory function or who reported metabolic or endocrine disease, GI 
disorders, or a history of medical or surgical events that may have affected study 
outcome. All included subjects (n=33; mean age: 43 years; mean BMI: 27.7 kg/m2; 
14 male) completed the protocol. 
2.4 Study design 
In this randomized, single-blind, placebo-controlled trial, the effect of 2 enriched 
yogurts was compared in a crossover design and focused on food intake and appetite 
sensations. The yogurts differed in the carrier of the lipid: either encapsulated inside 
alginate beads for ileal delivery (active) or nonencapsulated with comparable sensory 




Every subject received 2 treatments on 2 different days with at least 1 week of 
washout period, following a randomized crossover design. On each test day, the 
subject arrived after a 10-hour fast at the Metabolic Research Unit at the Maastricht 
University Medical Center+. Per test day, 1 to 4 subjects were present simultaneously 
and were allowed to bring a book or laptop, but they could not see each other during 
meal intake. First, compliance to the previously mentioned rules was checked, and 
baseline measurements were done for appetite sensations and GI symptoms. The 
experiment started with intake of a standardized small breakfast (bread with 
marmalade; overall composition per 100 g breakfast: 235 kcal (983 kJ), 0.8 g fat, 6.8 g 
protein, 48 g carbohydrate, 3.5 g fiber; with 150 mL water or tea; t=0 minute) that was 
identical on both test days. This small breakfast was provided because ileal brake 
feedback is less pronounced after a prolonged fasting state. When all or most of the 
breakfast was expected to have been emptied from the stomach (t=90 minutes), the 
subject received 1 of the 2 yogurts (active or control) with 150 ml water or tea. Visual 
analog scale (VAS) scores for appetite sensations and GI symptoms were collected at 
a 30-minute interval before ingestion of the yogurt and a 15-minute interval after 
ingestion. Ad libitum food intake was assessed 2 hours after intake of the test yogurts, 
as this reflects the anticipated application of an ileal brake–inducing food product, 
which targets to decrease energy intake during a subsequent meal. Food intake was 
calculated (kcal) from the difference in weight of the plate before and after ad libitum 
food intake of a large pasta meal (>1 kg; Lasagna Bolognese, PLUS Supermarket; 
Utrecht, the Netherlands; energy density per 100 g: 152 kcal (636 kJ), 8.6 g lipid, 11.0 g 
carbohydrates, 7.1 g protein). After meal consumption, the test day finished. 
2.5.1  Appetite sensations and GI symptoms 
VAS scores27,28 were used to determine appetite sensations (satiety, fullness, hunger, 
desire to eat, desire to snack) and GI symptoms (bloating, discomfort, pain, nausea), in 
total at 12 time points (t=0, 30, 60, 90, 105, 120, 135, 150, 165, 180, 195, and 210 minutes) 
per test day. All attributes were measured using a VAS from 0 to 100 mm, with the 
most negative or lowest-intensity feelings at the low end and the opposing terms at 
the high end. The subjects indicated their feeling at that moment; scoring forms were 
collected immediately to prevent use as reference for later scorings. 
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2.6 Ethics 
The study was approved by the Medical Ethics Committee of the Maastricht 
University Medical Center+ and was conducted in full accordance with the principles 
of the Declaration of Helsinki of 1975 as amended in 2013 and with the Dutch 
Regulations on Medical Research involving Human Subjects (1998). All participants 
gave written informed consent before participation. This trial was registered at 
clinicaltrials.gov as NCT03025997 and was performed at the Maastricht University 
Medical Center+ from January until March 2017. 
2.7 Statistical analyses 
The SPSS statistical software package Version 23.0.0.2 (IBMSPSS Statistics, Chicago, 
IL, USA) was used for statistical analysis. Statistical significance was set at p<0.05 in all 
tests. A descriptive analysis of the study population was performed first, including the 
independent variables age, sex, and BMI, and reported as means ± standard errors of 
the means (SEMs). According to an a priori power analysis based on the expected 
effect size, 31 subjects needed to complete the study for a power of 80% and P value 
of 5% (2-sided significance level). The dependent variables were checked to meet 
homogeneity of variance, and normality was checked and tested (Shapiro-Wilk test). 
To compare food intake (kcal) after intake of the control and active yogurt, a paired-
samples t test was performed (n=33). 
Because the raw VAS data did not meet the requirements of normality, we tested the 
difference between control and active yogurt (n=33) through area under the VAS 
curves from ingestion of the yogurt (t=90 minutes) until ad libitum meal consumption 
(t=210 minutes). Total areas under the curve of VAS scores were calculated using the 
trapezoid rule27 and did meet normality (Shapiro-Wilk test) for satiety, fullness, 
hunger, and desire to eat. Therefore, the effect of yogurt on these area under the 
curve (AUC) VAS scores was tested with paired-samples t tests (n=33), with Bonferroni 
correction for multiple comparisons to eliminate type I errors. For GI symptoms, 
scores were all very low, and the difference in AUC VAS did not meet normality 
(Shapiro-Wilk test), so nonparametric tests for related samples (Wilcoxon signed 
















Figure 4.2 Food intake (mean ± SEM) measured during ad libitum meal consumption, 2 h after ingestion of 
the active yogurt (black bar) or control yogurt (light bar). The difference is significant in a paired-
samples T-test (* p≤0.05). 
3. Results 
3.1 Food intake 
The primary goal of the study was to assess the efficacy of emulsion-alginate beads 
to reduce food intake through activation of the ileal brake. Figure 4.2 shows the food 
intake during ad libitum meal consumption 2 hours after ingestion of the active yogurt 
(black bar; 770 ± 38 kcal (3222± 159 kJ)) or control yogurt (light bar; 821 ± 40 kcal 
(3435 ±167 kJ)). After ingestion of the active yogurt, food intake was significantly lower 
(51 ± 20 kcal (213 ±84 kJ); p=0.016) compared to the control, which accounts for a 
reduction of 6.2% in energy intake. 
3.2 Appetite sensations 
The efficacy of the test product to suppress appetite (increased feelings of satiety 
and fullness; reduced feelings of hunger, desire to eat, and desire to snack)was 
determined as secondary study parameter by comparing VAS scores. Figure 4.3 
shows comparable VAS scores for appetite sensations after ingestion of the active 
yogurt (filled symbols) and control yogurt (open symbols). 
None of the attributes differed significantly in AUC VAS scores when comparing 
active and control (Figure 4.4; AUC VAS for satiety, p=0.5; for hunger, p=0.8; for desire 
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Figure 4.3 Evolution of Visual Analog Scale (VAS) scores (mean ± SEM) for a) satiety, b) fullness, c) hunger, 
d) desire to eat, and e) desire to snack, after ingestion of the active yoghurt (filled symbols) and 
control yoghurt (open symbols), measured on a 100 mm scale. The yoghurt was ingested at t=90 





Figure 7.3. Evolution of Visual Analog Scale 
(VAS) scores (mean ± SEM) for a) satiety, b) 
fullness, c) hunger, d) desire to eat, and e) 
desire to snack, after ingestion of the active 
yogurt (filled symbols) and control yogurt 
(open symbols), measured on a 100 mm scale. 
The yogurt was ingested at t = 90 min (90 min 
after breakfast) and ad libitum meal was 

















Figure 4.4 Total AUCs of VAS scores for appetite sensations from ingestion of the active (black bar) or 
control (light bar) yogurt (t=90 minutes) until ad libitum meal consumption (t=210 minutes).Values 
are means ± SEM. No significant differences (n = 33, paired-samples t tests). 
 
3.3 GI symptoms 
Figure 4.5 shows that all measured GI symptoms were low (<10 mm, measured on a 
100-mm scale) and none of the attributes differed significantly in AUC VAS scores 
between active and control (Wilcoxon signed ranks test, n=33; bloating, p=0.9; 
discomfort, p=0.5; pain, p=0.5; nausea, p=0.4). Evaluation of adverse events only 
showed 3 subjects with short-term diarrhea: 2 on the day of the control yogurt and 1 
on the day after the active yogurt. 
3.4 Subject expectation of ingested intervention 
After finishing the second test day, subjects were asked to indicate on which test 
day(s) they thought to have consumed the active and control yogurt; 15 subjects 
indicated correctly the test day on which they consumed the control yogurt (feeling 
hungrier), and 7 subjects indicated the wrong intervention; 11 subjects indicated to 
have perceived no difference in hunger feelings between the 2 days. 


























Figure 4.5 Evolution of Visual Analog Scale (VAS) scores (mean ± SEM) for a) bloating, b) discomfort, c) pain, 
and d) nausea, after ingestion of the active yogurt (filled symbols) and control yogurt (open 
symbols), measured on a 100 mm scale. The yogurt was ingested at t = 90 min (90 min after 
breakfast) and ad libitum meal was consumed at t = 210 min. 
4.  Discussion 
We have shown that ingestion of a yogurt containing emulsion-alginate beads results 
in a small but statistically significant reduction in food intake during a subsequent 
meal (−6.2% energy intake) compared to the control yogurt that contained an 
equienergetic mixture of nonencapsulated nutrients with comparable sensory 
properties. We therefore accept the hypothesis that delayed release of encapsulated 






reduction of 155 kcal (649 kJ) could be achieved for a 2500-kcal (10460 kJ) intake. This 
is considered to be a relevant reduction, as a daily reduction of 50 kcal (209 kJ) could 
already prevent weight gain in about 90%of the population.29 
To the best of our knowledge, this is the first human intervention study exploring the 
effects of emulsion encapsulation in calcium-alginate beads on food intake and 
appetite sensations. In other studies, lipid-core alginateshell capsules have been 
shown to control the gastrointestinal fate of lipids and to slightly increase satiety 
scores24, but in the present work, we use smaller lipid droplets and therefore smaller 
beads. 
None of the appetite attributes differed significantly between active and control 
(satiety, fullness, hunger, desire to eat, and desire to snack). Thus, although emulsion-
alginate beads clearly affect eating behavior, no relevant change in appetite 
sensations was observed. 
Reduced food intake through activation of the ileal brake has previously been proven 
with direct intraileal infusion of lipids4,5,7 but not after oral ingestion. Up until now, the 
most promising emulsion system to deliver degradation products of lipid digestion in 
the distal small intestine was an emulsion of palm oil and oat oil fractions that 
naturally contain galactolipids, which was commercialized as Fabuless, Olibra, and 
Reducal. The galactolipids were expected to induce nucleation and growth of 
saturated fatty acids crystals, which are absorbed more slowly from the intestine30 
and were claimed to improve weight management.31 However, Fabuless loses its 
functionality during normal food-manufacturing processes (thermal and shear 
processing).32 Compared to intubation studies that deliver exact amounts of lipids 
directly to the target position6, the effect that we find here is less pronounced. This 
may be related to less optimal timing and dosages of the release of lipids. Secondly, 
lean subjects were used in the intubation studies, whereas we studied overweight 
subjects, who are known to be less sensitive for intraluminal lipids.33 
We also anticipated that part of the encapsulated lipids will have remained 
unabsorbed. Ad libitum food intake was assessed 2 hours after intake of the test 
yogurts, as this reflects the anticipated application of an ileal brake-inducing food 
product, which targets to decrease energy intake during a subsequent meal. Within 
this time scale, we observed no significant effect of the yogurt type on scores of 
appetite sensations. Based on the average gastric emptying profile of yogurt, about 
half of the emulsion-alginate beads was expected to reach the small intestine within 
45 minutes after ingestion34, and once in the small intestine, half of the lipid digestion 
products was expected to be released within 2.5 hours based on previous 
observations in a static in vitro model.22 Based on the in vitro observations, it is likely 
that only a part of the encapsulated lipids will have been digested before subsequent 
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meal consumption started. This may explain why both interventions did not show 
differences in appetite sensations. 
Further optimization of the emulsion-alginate beads is still possible to increase 
practical significance for the treatment of obesity. To tailor the release of lipids, not 
only the size of the beads and/or the mesh size can be considered as described 
previously for in vitro studies22, but also the emulsion droplet size can be used to 
greatly influence lipolysis by changing the available interfacial area.35-37 Increasing the 
amount of lipids per bead volume is not considered an option because this decreases 
density and will result in floating of the beads in the stomach38 and, thus, delays 
emptying of the active components into the small intestine. 
The control yogurt is considered an appropriate reference for the active yogurt, as the 
free emulsion is rapidly digested and the lipid metabolites will probably be absorbed 
completely before reaching the distal small intestine.1,9,10 Moreover, the empty beads 
can be conveniently used to design equienergetic products that have no difference in 
mouth feel, as none of the subjects indicated a difference in sensory properties 
between the 2 yogurts. 
A limitation of the present study is that the distal release of lipids from the used 
encapsulates was not tested during the in vivo experiment, but instead, the digestion 
dynamics of the encapsulated lipids were anticipated based on in vitro observations. 
Additional mechanistic studies would be the next step to take, which includes 
measuring delivery of lipids from ingested emulsion-alginate beads in vivo in the 
intestinal lumen. Besides, although we took the best possible care, it is always 
possible that, in single-blind design, the researcher may (un)intentionally have given 
subconscious cues which influence the subjects. A third limitation of the present 
study is the rather short period of controlled behavior prior to starting the test day in 
the research facility (10-hour fast). This might have been too short to minimize 
influences from the day before on the test day, such as within-person variation in 
eating behavior and physical exercise. The crossover study design minimized the 
influence of between person variations. 
Before this product can be used in weight management applications, additional 
studies will need to be conducted. The duration and impact of the single-dose effect 
will have to be determined, with concomitant assessment of biological markers (ie, 
gut hormones as PYY and GLP-1) to gain insight in the involved satiating mechanisms. 
In a next phase, the effects of this product concept on body weight regulation will 
have to be investigated in long-term intervention studies, while also charting possible 
habituation and compensation. 
The future perspectives of emulsion-alginate beads for noninvasive weight 
management are promising because these beads can be incorporated into a yogurt-
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like food product that is part of a normal diet. It is also good to mention that there are 
positive developments in production technology to produce similar emulsions and 
beads at a large scale.39 
In conclusion, we demonstrated that ingested emulsionalginate beads significantly 
decreased food intake in overweight individuals compared to an equienergetic 
mixture of nonencapsulated nutrients with comparable sensory properties. We 
hypothesize that this reduction in food intake is caused by delayed release of 
encapsulated lipids in the distal small intestine, which activates the ileal brake 
mechanism. To gain further understanding of ileal brake activation via dietary routes 
for weight management, additional studies on dose-response relations and long-term 
effectiveness need to be conducted. If successful, this strategy could result in 
noninvasive methods for weight control. 
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Food intake is partly regulated by feedback mechanisms within the gastrointestinal 
tract. One of those is distension of the stomach which leads to activation of 
mechanoreceptors in the gastric mucosa resulting in food intake termination. We 
investigated whether signals of distension can be blunted by administration of a local 
anaesthetic into the stomach. To this end the effect and safety of infusion of lidocaine 
into the stomach of healthy volunteers on food intake and appetite was measured. 
 
Design 
Twentysix healthy male volunteers completed a doubleblind, randomised crossover 
study. After a standardised breakfast, volunteers received lidocaine infusion (200 mg) 
or placebo infusion (100 mL water) via a nasogastric catheter. Fifteen min after the 
end of the infusion, an ad libitum meal was provided. Pulse rate and blood pressure 
were monitored. Gastrointestinal (GI) symptoms and appetite feelings were measured 
by using visual analogue scales (VAS) scores at regular time intervals. 
 
Results 
Lidocaine infusion of 200 mg into the stomach resulted in a modest nonsignificant 
increase in food intake on condition of a preceding familiarisation with the procedure. 
GI symptoms and appetite feelings recorded with VAS scales confirmed this lidocaine 
effect. No cardiovascular safety issues were detected. 
 
Conclusions 
Infusion of lidocaine in the stomach of lean healthy male volunteers was safe and 
resulted in a modest nonsignificant increase in food intake. An order effect was 
observed for test days: food consumption was significantly higher on test day 2 
compared to test day 1. 
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1. Introduction 
Overweight and obesity are major health problems in the western world.1,2 One of the 
causal factors for overweight is the overconsumption of energyrich food items that 
are widely available.3,4 Despite these overweight problems, there still are large groups 
of subjects suffering from malnutrition. This is especially true for patients with chronic 
or oncological disorders, for hospitalised patients, and for patients with 
gastrointestinal disorders.57 Oncology patients8,9 and many elderly1015 not only suffer 
from malnutrition but also from cachexia, which is often correlated with early 
death.1618 The underlying causes of low food consumption are often unknown, but it is 
well accepted that these patients will benefit from measures that result in an increase 
in energy intake.1922 Thus, there is an urgent need for interventions or drugs that help 
to increase food intake in chronic or critically ill subjects. 
Local mechanisms in the gastrointestinal (GI) tract are important in the regulation of 
food intake. The satiating effect that occurs after ingestion of a meal mainly results 
from distension of the stomach wall. Several studies have investigated the effect of 
gastric balloon distension in humans and observed that hunger feelings are 
negatively correlated with gastric distension.23,24 During gastric distension, stretch and 
tension mechanoreceptors are triggered that activate vagal and splanchnic nerve 
endings, which relay their information to several brain areas resulting in satiation and 
meal termination.25 In elderly subjects, postprandial fullness and satiation are 
increased when compared to younger subjects. This has been related to a delay 
gastric emptying with a larger antral area and an overactive sensing profile of 
gastrointestinal mechanoreceptors.26 
We hypothesise that inhibition of the mechanoreceptors in the mucosa of the 
stomach will allow a greater distension of the stomach during a meal. A diminished 
perception of fullness will possibly result in an increase in food intake. 
In animal studies, it has been shown that application of a local anaesthetic into the 
stomach of rats indeed results in a significant increase of food intake during a 
subsequent meal.27 
Aim of the present study was to explore the effect of lidocaine infusion into the 
stomach, on food intake, as primary parameter, and appetite feelings in  healthy 
young male volunteers. Moreover, we wanted to explore the tolerability (GI 
symptoms) and safety (cardiac side effects) during and after infusion of lidocaine into 
the stomach in this population, with the purpose to check whether this drug can be 




2. Subjects and methods 
The study was approved by the Medical Ethics Committee of Maastricht University 
Medical Centre+ and was conducted in full accordance with the principles of the 
Declaration of Helsinki of 1975 as amended in 2013, and with the Dutch Regulations 
on Medical Research involving Human Subjects (1998). All volunteers gave written 
informed consent before participation. This trial was registered at 
www.clinicaltrials.gov as NCT03227900. 
2.1 Subjects 
Healthy male volunteers were included in this study. Inclusion criteria were an age 
between 18 and 50 years, a body mass index (BMI) between 20 and 25 kg/m2 and no 
history of GI diseases. Females were excluded in order to avoid a possible influence 
of the hormonal cycle on eating behaviour. Exclusion criteria included intake of more 
than 20 alcoholic consumptions per week, specific medication use or medical history 
of any relevant disorder or surgery possibly interfering with the study outcomes, 
allergy to lidocaine in the past, known GI symptoms, dieting or eating disorder. After 
providing initial information verbally or by email, detailed written study information 
was provided in case volunteers were interested and understood the study 
procedures. Written informed consent was obtained after an interval of at least 
7 days. 
2.2 Study design 
This was a randomised, doubleblind, placebocontrolled crossover study with two 
different treatments with a minimum washout period of 7 days between test days. On 
each test day, volunteers received intragastric lidocaine dissolved in water for 
injection or a placebo (water for injection). Treatment order (lidocaine on first test day 
and placebo on second test day, or vice versa) was randomly assigned to each 
participant after inclusion by an independent researcher (using Research Randomizer, 
www.randomizer.org). Volunteers were instructed to abstain from alcohol 
consumption and exhaustive physical exercise on the day prior to testing. Two days 
prior to both test days subjects received the proton pump inhibitor (PPI) pantoprazole 
(3 times 40 mg) in order to inhibit gastric acid production to avoid protonation of 
lidocaine in the gastric lumen. 
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2.3 Intervention 
Volunteers were requested to arrive at 08:15 am at the Metabolic Research Unit of the 
Maastricht University Medical Centre+ (Figure 5.1). Volunteers received a standardised 
250 mL liquid breakfast meal (a diary product of Friesland Campina; energy 152.5 kcal 
per served portion, 8.5 grams (g) protein, 21.25 g carbohydrates, 2 g lipid) provided by 
the researchers. After finishing breakfast, a nasogastric feeding catheter was placed 
(Nutricia Flocare ® Pur) with the catheter tip positioned in the stomach. The position 
of the catheter was checked by infusing 10mL of air via the catheter whilst 
simultaneously auscultating (with stethoscope) the stomach region. After correct 
positioning of the catheter, volunteers waited 150 min to get used to the catheter. The 
infusion started 180 min after the ingestion of the standardised breakfast. Hereby, the 
infusion of lidocaine or placebo in the stomach took place in an empty stomach 
(standardised condition). Start of the infusion was considered as t=0 min and the 
volunteers were connected to an infusion pump, which infused the solution at a 
speed of 6.67 mL/min for 15 min. This infusion rate was chosen in order to infuse a 
large volume (100 mL in 15 min). The catheter was removed directly after the 
discontinuation of the infusion. At 15 min after the discontinuation of the  infusion, the 
volunteers received a standardised ad libitum chili con carne meal (vanBLIKTM; energy 
density per 100 g: 98 kcal, 6.5 g protein, 9.5 g carbohydrates, and 3.5 g lipid). Ad 
libitum food intake was assessed by weighing the chili con carne meal that was not 
consumed, subtracting that from the weight of the provided meal and finally 












Figure 5.1 Timeline of the test day. The catheter was placed after finishing the standardized breakfast. 
Infusion of lidocaine or placebo took place 180 min after the standardized breakfast. After 15 min 
infusion, the catheter was removed and infusion of lidocaine stopped. Fifteen min after cessation 
of the infusion, an ad libitum meal was offered to each subject. VAS scores for appetite and GI 





2.4 Preparation of the solutions 
An independent researcher prepared the solutions prior to the test day. The solutions 
were both transparent and therefore the type of solution in the syringe was blinded 
for the researcher and the participant. The amount of 10 mL of lidocaine HCl 
20 mg/mL (B. Braun Melsungen, Germany) was dissolved in 90 mL water for injection 
(B. Braun Melsungen, Germany). A total dose of 200 mg lidocaine was infused per 
subject. The reported maximum single dose of lidocaine parenterally administered is 
200 mg. Due to the low bioavailability and a relatively strong liver first pass effect of 
lidocaine, we did not expect side effects to occur with administration of this dose.28 
For the placebo infusion, 100 mL of water for injection (room temperature) was 
prepared in a syringe. 
2.5 VAS scores appetite and GI symptoms 
VAS scores for appetite (hunger, satiation, fullness and desire to eat) and GI 
symptoms (stomach pain, belly pain, heartburn, cramps, belching, bloating, 
flatulence, nausea) were collected at t=15, 0, 15, 30, 45, 60, 75, and 90 min. Appetite 
and GI symptoms were measured by using VAS scores (0–100 mm) that were 
anchored at the low end with the mostnegative or lowestintensity feelings (e.g., 
extremely unpleasant and not at all) and with opposing terms at the high end (e.g., 
extremely pleasant, very high, and extreme). 
2.6 Cardiac side effects 
The occurrence of cardiac side effects was measured by continuous recording of the 
heart rate during the test procedure. Blood pressure was measured at baseline (t=0 
min), during and immediately after the infusion period. Mean arterial pressure (MAP) 
was calculated. 
2.7 Statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics for Windows (Version 
25.0 Armonk, NY: IBM Corp.). Normal distribution was tested by the Shapiro Wilk test, 
models with and without interaction terms. 
Analysis of food intake was performed on the amount of food eaten in kilocalories 
(kcal). A linear mixed model analysis was performed, where treatment (lidocaine or 
placebo), test day (1 or 2) and interaction between treatment and test day were 
included as fixed factors. A random intercept for volunteers was included to account 
for the correlation between repeated measures. In case the interaction was not 
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significant, this interaction term was removed from the model and only main effects, 
corrected for the other variable in the model, were reported. 
For the VAS scores for appetite or GI symptoms, blood pressure and heart rate, a 
threeway interaction between treatment, time and testday was performed. Time was 
entered in the model as fixed factor, next to treatment and testday, where twoway 
interactions between time, treatment and testday were included as well.  As a 
sensitivity analysis, a threeway interaction between treatment, time and test day was 
added to the model in order to analyse whether the treatment effect over time was 
different for the two test days. A random intercept and/or slope (time) were included 
and different covariance structures (unstructured and variance components) were 
considered for these random effects, where the final structure was chosen based on 
Akaike’s information criterion (AIC). 
Data are presented as the mean (standard error of the mean, SEM) unless specified 
otherwise. A twosided p-value ≤0.05 was considered as statistically significant. The 
normality assumption for residuals was checked. 
2.8 Sample size calculation 
A sample size calculation was based on the average food intake during a previous 
crossover intervention study from our department (mean intake 586 kcal) and on the 
increase in food intake after gastric administration of lidocaine in animals (16%).27,29 
Since it was unknown whether the same increase of 16% could be expected in 
humans, we performed the calculation with a smaller margin. Therefore, we 
decreased the margin from 94 kcal to 76 kcal (13%). Using the withinpatient standard 
deviation of 93 kcal that was found in our previous study15, a power of 80%, and an 
alpha of 5%, a total number of 26 participants was needed. Anticipating on possible 
dropouts of 30% during screening and test days, a maximum number of 38 volunteers 
was considered necessary for inclusion. 
3. Results 
Thirty healthy male participants were assessed for eligibility. Two volunteers were 
excluded after the screening visit because they did not meet the inclusion and 
exclusion criteria. Two volunteers dropped out of the study before completing the 
first test day (Figure 5.2). Twentysix healthy male volunteers completed this study 





















Figure 5.2 CONSORT flow diagram. 
 
3.1 Primary outcome: food intake 
The data showed a normal distribution (Shapiro Wilk test: model with  interaction term 
p-value 0.493 and model without interaction term p-value 0.498). As there was no 
significant interaction between treatment and test day (p-value=0.921), overall effects 
were reported. Infusion of lidocaine in the stomach of healthy volunteers resulted in a 
mean, nonsignificant increase in food intake during the ad libitum meal of 31 kcal 
compared to placebo (estimated mean (95% CI) for lidocaine: 1022.0 (8931150.9) kcal 
vs. placebo: 990.8 (861.81119.7) kcal, p-value=0.294). The amount of total food intake 
for both interventions was significantly different between test days (day 1: 967.1 
(62.9) kcal vs. day 2: 1045.6 (62.9) kcal, p-value=0.013). 
The effects of lidocaine on food intake at individual level are shown in Figure 5.3. As 
we observed a significant testday effect, the individual results are presented by  
sequence (lidocaine first, placebo first). In Figure 5.3A the treatment effect (lidocaine 
versus placebo) minus testday effect (day 2 versus day 1) is presented, while the 
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18 out of 26 volunteers (69%) consumed more of the ad libitum meal after lidocaine 











Figure 5.3 Individual data points for food intake during the ad libitum meal. Figure A represents all 
participants who received lidocaine on the first test day and placebo on the second test day 
(n=14). Figure B represents all participants who received the other sequence (n=12). The black 
lines represent all participants who consumed more calories during the ad libitum meal after 
lidocaine infusion compared to placebo infusion. T1: test day 1; T2: test day 2. 
 
3.2 VAS scores appetite 
As shown in Figure 5.4, neither infusion of lidocaine nor of placebo influenced pre 
meal VAS scores. Consumption of the meal resulted in significant increases in 
satiation and fullness, and significant reductions in hunger and desire to eat. For the 
appetite scores, no significant interactions between treatment, time and test day were 
obtained (all p-values ≥0.093). As a consequence, the results for appetite were 
reported for both test days combined. 
3.3 VAS scores for GI symptoms 
For the GI symptoms, no significant interaction between treatment, time and test day 
was observed for stomach pain (p-value 0.540), belly pain (p-value 0.122), heartburn 
(p-value 0.706) or cramps (p-value 0.665) (Figure 5.5). There was a significant 
interaction between treatment, time and test day for the VAS scores bloating (p-value 
0.001), flatulence (p-value 0.041), nausea (p-value 0.024) and belching (p-value 0.006). 
3.4 Cardiac side effects 
There were no significant differences in mean arterial blood pressure (MAP) and pulse 
rate at baseline, during and at the end of the infusion between infusion of the placebo 
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Figure 5.4 VAS scores for Satiation (A), Fullness (B), Hunger (C) and Desire to eat (D) (estimated means ± 
SEM). Because the treatment effect over time was not significantly different between the two 
test days, no separate plots were made for test day 1 and test day 2. Grey box 0-15 min: infusion 
period. Dashed line: ad libitum meal. P-values presented in the figures represent the statistical 






























































Figure 5.6 VAS scores for Stomach Pain (A), Belly Pain (B), Bloating (C) and Flatulence (D), Heartburn (E), 
Nausea (F), Belching (G) and Cramps (H) (means ± SEM). Grey box 0-15 min: infusion period. 
Dashed line: ad libitum meal. 
4.  Discussion 
This is the first-in-human explorative study that investigated the safety and acute 
effects of infusion of 200 mg lidocaine into the stomach on food intake and appetite 
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feelings. The most salient findings of this study are 1) that local administration of 
lidocaine in the stomach was demonstrated to be safe and was well tolerated by all 
participants; no cardiac side effects occurred. 2) that administration of lidocaine into 
the stomach resulted in a modest but nonsignificant increase in food intake of the ad 
libitum meal compared to placebo 3) an order effect was observed for test days: food 
consumption was significantly higher on test day 2 compared to test day 1. 
The study design we employed was chosen, based on previous investigations.2931 In 
the crossover design in those studies no clear differences in response were observed 
between treatment day 1 and day 2. In the present study it was observed that 
participants ate on average more during the second test day compared to the first 
test day. This can be understood in view of subjects not being familiar with the 
procedures of catheter placement and removal, resulting in stress and discomfort. 
Stressors are known to influence food intake be it in either direction, dependent on 
the type, strength and impact of the stressor.3234 
In the present study, only young male volunteers with  an  age between 18 and 
50 years were included. This strict inclusion criterion was based on the possible 
chance of inducing cardiac side effects during intragastric lidocaine 
administration.35,36 Changes in cardiovascular function are known to be age related 
and to result in an increased risk for cardiovascular morbidity.37 Lidocaine did not 
induce any effects on heartrate or blood pressure in the young study population. 
Previously we have shown a significant increase in food intake in an animal study, 
where 20 mg/kg bodyweight lidocaine was infused into the stomach.10,25 In the 
present study, we observed only a modest, non significant increase in food intake. 
This lack of a significant effect may be related to several factors. First, the dose per kg 
infused in our study (2.6 mg/kg body weight)  was much lower compared with the 
lidocaine of 20 mg/kg bodyweight infused into the rats’ stomach. Second, it should 
be noted that not the systemic exposure of lidocaine is important, but the local 
concentration around the stretch receptors in the stomach wall. It is therefore difficult 
to compare the doses between species with different stomach sizes and anatomies. 
Third, the order effect with a significant larger food intake on the second test day may 
have influenced the results. This indicates that familiarisation with the procedure is 
important and should be taken into account in future study designs. 
The study was explorative in design, therefore we additionally screened with the 
Thompson Tau test for outliers. In fact, three outlier subjects were identified who all 
consumed a very large amount of chili con carne (>1500 kcal) after placebo infusion. 
We speculated that in these young male healthy participants, maximum distension of 
the stomach had occurred after food intake. In case the stomach is already distended 
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to a maximum degree, no further distension by administration of a local anaesthetic is 
to be expected. 
The VAS scores for appetite are in line with the data of food intake: no significant 
differences were present between lidocaine and placebo, neither before nor after the 
meal intake. It should be noticed that we studied healthy volunteers and not patients 
with disturbed gastrointestinal sensory perception. Previous studies have shown that 
sensory pathways in the gastrointestinal tract are affected by age.3840 Healthy aging is 
associated with a reduction in appetite and food intake, which may predispose to 
pathologic weight loss and malnutrition. We hypothesise that the effect of lidocaine 
infusion in the stomach on food intake will be of a greater magnitude in older 
subjects. This may also hold true for patients with chronic or malignant disorders. 
In conclusion, this explorative study showed that infusion of lidocaine in the stomach 
of lean healthy male volunteers was safe and resulted in a modest nonsignificant 
increase in food intake. The effect of lidocaine on food intake deserves further 
evaluation in conditions with impaired food intake such as in the elderly or in patients 
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Intraintestinal delivery of tastants using a naso-
duodenal-iIleal catheter does not influence 


























Intraduodenal activity of taste receptors reduces food intake. Taste receptors are 
expressed throughout the entire gastrointestinal tract. Currently, there are no data 
available on the effects of distal taste receptor activation. In this study, we investigate 
the effect of intraduodenal and/or intraileal activation of taste receptors on food 
intake and satiation. In a single-blind randomised crossover trial, fourteen participants 
were intubated with a naso-duodenal-ileal catheter and received four infusion 
regimens: duodenal placebo and ileal placebo (DPIP), duodenal tastants and ileal 
placebo (DTIP), duodenal placebo and ileal tastants (DPIT), duodenal tastants and 
ileal tastants (DTIT). Fifteen minutes after cessation of infusion, subjects received an 
ad libitum meal to measure food intake. Visual analogue scale scores for satiation 
feelings were collected at regular intervals. No differences in food intake were 
observed between the various interventions (DPIP: 786.6 ± 79.2 Kcal, DTIP: 803.3 ± 69.0 
Kcal, DPIT: 814.7 ± 77.3 Kcal, DTIT: 834.8 ± 59.2 Kcal, p=0.59). No differences in satiation 
feelings were observed. Intestinal infusion of tastants using a naso-duodenal-ileal 
catheter did not influence food intake or satiation feelings. Possibly, the burden of the 
four-day naso-duodenal-ileal intubation masked a small effect that tastants might 





Obesity is considered a major healthcare problem with worldwide obesity almost 
being tripled since 1975.1 Therefore, there is an increasing need for non-invasive 
therapies for weight management. Gastrointestinal (GI) hormones, such as 
cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), have been shown to 
reduce food intake and hunger after intravenous administration.2-4 Therefore, the GI-
tract is an interesting target for non-invasive therapies to reduce food intake and 
induce satiety/satiation.  
Intestinal macronutrient infusion decreases food intake and induces the release of 
CCK, GLP-1, and peptide YY (PYY).5 This mechanism is commonly referred to as 
intestinal- or ileal brake.6,7 A recent review proposed a proximal to the distal gradient 
in the small intestine, where a more profound effect on food intake can be found after 
distal compared to proximal macronutrient infusion.8 Previous studies have 
demonstrated that besides macronutrients, substances referred to as tastants are 
able to activate certain taste receptors in the GI-tract which are coupled to 
enteroendocrine cells (EEC) and can trigger the release of satiety hormones (i.e., CCK, 
GLP-1, and PYY).9-13 These taste receptors can be found throughout the entire GI-
tract. Expression levels for the various taste receptor differ throughout the gut. Table 
6.1 gives a simplified visual representation of the relative expression of taste 
receptors throughout the human gut based on current literature.14-17 
In a recent study, van Avesaat et al. have shown that duodenal infusion of a 
combination of sweet, bitter, and umami tastants significantly decreased ad libitum 
meal intake, whilst increasing satiation and decreasing hunger feelings. These effects 
were not accompanied by changes in systemic levels of GLP-1, PYY, and CCK.18 Up to 
now, no data are available on the effect of activation of taste receptors in the more 
distal small intestine. Since one of the functions of taste receptors in the gut is to 
sense food being present in the lumen, it should be investigated whether the before 
mentioned proximal to distal gradient found for the intestinal brake is operative for 
taste receptor activation. 
Therefore, in the present study, we compared the effects of intraduodenal infusion 
versus intraileal infusion of a combination of tastants (sweet, bitter, and umami) on ad 
libitum food intake, satiation, and GI-complaints in healthy subjects. Since sweet and 
umami taste are sensed by various subtypes of the taste receptor family 1 (TAS1R) 
taste receptor family and bitter taste is sensed by the taste receptor family 2 (TAS2R), 
the combination will activate a wide range of taste receptors. We hypothesised that 
infusing tastants at both infusion sites (duodenum and ileum) will decrease food 
intake and increase satiation to the greatest extent when compared with infusion of 
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placebo or single port infusion. Infusing in solely the duodenum or the ileum will also 
decrease food intake and increase satiation when compared to placebo, albeit to a 
lesser degree than infusing at both infusion sites simultaneously. Furthermore, we 
expect intraileal delivery of tastants will decrease food intake and increase satiation 
to a greater extent when compared with intraduodenal delivery of tastants. 
 
Table 6.1 A simplified visual representation of the relative expression of taste receptors and gustducin 
throughout the human GI-tract. 
 Stomach Duodenum Jejunum Ileum Colon 
TAS1R1 
(Bezencon et al.14) 
++ + ++ + +/− 
TAS1R2 
(Bezencon et al.14) 
− ++ + +/− + 
TAS1R2 
(Young et al.15) 
−−$ + ++ # N/A N/A 
TAS1R3
 
(Bezencon et al.14) 
+ ++ ++ + + 
TAS1R3 
(van der Wielen et al.16) 
N/A + + + + 
TAS1R3 
(Young et al.15) 
+$ ++ ++ # N/A N/A 
TAS2R102–TAS2R144  
(Gu et al.17) 
N/A + + + N/A 
Gustducin 
(Bezencon et al.14) 
−− ++ ++ + − 
Gustducin 
(Young et al.15) 
−$ + ++ # N/A N/A 
Expression levels are relative to each other and a simplified visual representation with ++ indicating very high 
expression, + indicating high expression, +/ indicating medium expression, − indicating low expression, and 
−− indicating very low expression. $ Young et al. displayed the stomach as fundus, body, and antrum. For 
details, please refer to Young et al.15 # Young et al. displayed jejunum as proximal jejunum and distal jejunum. 
For details, please refer to Young et al.15 N/A: not available. * T2R family is expressed throughout the entire 
small intestine in a comparable fashion with some subtypes more abundant proximally and some distally. For 
details, please refer to Gu et al.17 
2. Materials and methods 
This study was approved by the Medical Ethics Committee of the Maastricht 
University Medical Centre+ (MUMC+), Maastricht, the Netherlands, and performed in 
full accordance with the Declaration of Helsinki (latest amendment by the World 
Medic Association in 2013) and Dutch Regulations on Medical Research Involving 
Human Subjects (WMO, 1998). This study was registered in the US National Library of 
Medicine (http://www.clinicaltrials.gov, ID NCT03140930). All subjects gave written 




Healthy men and women were recruited by local advertisements. Inclusion criteria 
were age between 18 and 65 years, a body mass index (BMI) between 18 and 
25 kg/m2, with a stable weight over the past six months (<5% body weight change). 
Exclusion criteria were gastrointestinal complaints, history of chronic or severe 
disease, use of medication influencing endpoints within 14 days prior to testing, 
administration of investigational drugs which interfere with this study, major 
abdominal surgery, dieting, pregnancy or lactation, excessive alcohol consumption 
(>20 alcoholic consumptions per week), smoking, weight <60 kg, non-tasters of 
sweet, bitter or umami stimuli, evidence of monosodium glutamate (MSG)-
hypersensitivity. 
Prior to testing, screening was performed where abovementioned inclusion and 
exclusion criteria were checked, and a taste perception test was performed. Subjects 
tasted quinine (0.5 mmol/L), Reb A (50 mmol/L), MSG (50 mmol/L), and tap water 
blindly and had to indicate their sense of taste. Subjects had to identify each taste 
correctly in order to be eligible for the study. Furthermore, their length and weight 
were measured to calculate their BMI.  
A sample size calculation was based on the difference in meal intake between 
duodenal infusion of a combination of tastants and duodenal infusion of placebo as 
reported by van Avesaat et al.18 Using a difference in means of 64 Kcal, a standard 
deviation of difference of 63, a power of 80%, and an alpha of 1.67%, a total number of 
13 subjects were needed. An alpha of 1.67% was used to correct for multiple testing. 
2.2 Study design 
In this single-blind randomised, placebo-controlled crossover study, subjects 
received the combination of tastants (sweet, bitter, and umami) and/or placebo (tap 
water) in the duodenum and/or the ileum for four consecutive test days. This results 
in four combinations which were infused on the various test days: duodenal placebo 
and ileal placebo (DPIP), duodenal tastants and ileal placebo (DTIP), duodenal 
placebo and ileal tastants (DPIT), duodenal tastants and ileal tastants (DTIT). 
2.3 Catheter positioning 
A 305 cm long silicon 9-lumen (8-lumen, 1 balloon inflation channel, the outer 
diameter of 3.5 mm) custom-made naso-ileal reusable catheter (Dentsleeve 
International, Mui Scientific, Mississauga, Canada) was used for intubation.  
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One day prior to the first test day, subjects arrived at 7:40 AM at the Maastricht 
University Medical Centre+ (MUMC+) after an overnight fast. If preferred by the 
subject, local anaesthesia of nasal mucosa using xylocaine (10% spray, AstraZeneca, 
Zoetermeer, the Netherlands) was applied. After placement of the catheter in the 
stomach, the catheter was guided through the pylorus and into the duodenum under 
intermittent fluoroscopic control. Progression of the catheter from duodenum to 
ileum was performed as described earlier.19 Fluoroscopy was used to check the 
positioning of the catheter on the first and the last test day. Radio-opaque markers 
were added to the infusion ports on the catheter, which accounted for the 
determination of the catheter position. On all test days, intestinal fluid was sampled 
from various infusion ports, and pH was measured using pH strips (MColorpHast™, 
Merck, Darmstadt, Germany) in order to estimate the catheter positioning. 
2.4 Preparation and infusion of tastants 
The combination of three tastants was infused in the duodenum, the ileum, or both 
the duodenum and the ileum. In order to prevent side effects from occurring, 75% of 
acceptable daily intake (ADI) of these tastants was infused. 540 mg Rebaudioside A 
(Reb A, Stevija Natuurlijk, Drachten, the Netherlands), 75 mg Quinine (Arnold Suhr, 
Hilversum, the Netherlands), and 2 g Monosodium Glutamate (MSG, Ajinomoto, 
Hamburg, Germany) were dissolved in 120 mL tap water and was used as tastant 
mixture for infusion, as was done by van Avesaat et al.18 All tastants used were non-
caloric and yielded no nutritional value. The placebo infusion consisted of 120 mL of 
tap water. A magnetic stirrer was used to dissolve the tastants. The mixture was 
infused over a 60-min period with an infusion rate of 2 mL/min. This was consistent 
with the infusion rate of van Avesaat et al. mimicking the slow influx from the stomach 
to duodenum and slow transit through the gut in the ileum. 
2.5 Protocol 
On each test day, after an 8 h overnight fast, subjects arrived at 8:00 AM at the 
MUMC+. Subjects were instructed to consume the same habitual meal on the evening 
prior to testing. Hereafter, at t=0 min, a standardised liquid breakfast meal (250 mL 
Goedemorgen drinkontbijt (Vifit); energy 145 Kcal per portion, 20.25 g carbohydrates, 
8.5 g protein, and 2 g fat) was consumed. One hundred and fifty min (at t=150 min) 
after breakfast consumption, a syringe containing the mixture for infusion was 
connected to the duodenal and ileal infusion port. The infusion was performed in 
60 min at an infusion rate of 2 ml/min. Subjects received a standardised ad libitum 
lunch meal (Lasagne Bolognese (Plus supermarket); energy density per 100 g: 
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152 Kcal, 11 g carbohydrates, 7.1 g protein, and 8.6 g fat) fifteen min (at t=225 min) after 
cessation of the infusion. The test meal was offered in excess and subjects were 
instructed to eat until they felt satiated. 
2.6 VAS for satiation and GI-complaints 
Feelings of satiation-/satiety and GI-complaints (e.g., satiation, hunger, stomach pain, 
and nausea) were measured using visual analogue scales (VAS, 0-100 mm) scores at 
various time points (t=−30, 30, 90, 150, 165, 180, 195, 210, and 240 min) during the day. 
Subjects were asked to indicate on a line, anchored at the low end with the lowest 
intensity feelings, with opposing terms at the high end, which place on the scale best 
reflected their feeling at that moment.20 
2.7 Statistical analyses 
Data were analysed using IBM SPSS statistics 24 (IBM Corporation, Armonk, NY, USA). 
A visual check of the normality of the data was performed. The primary outcome of 
this study was the amount of food intake in Kcal during an ad libitum lunch meal. 
Secondary outcomes were VAS scores for satiation-/satiety feelings and GI-
symptoms.  
Age, BMI, and gender were calculated by descriptive statistics. Food intake in Kcal 
and area under the curve (AUC) for VAS scores were compared using a linear mixed 
model with intervention (DTIP, DPIT, and DTIT, and DPIP), test day and the interaction 
of intervention × test day as fixed factors. When no significant interaction was found, 
the interaction was removed from the model to get the best model fit. 
For VAS scores, a linear mixed model that included abovementioned fixed factors 
with the addition of fixed factors time and time × treatment interaction was also 
performed. 
Data are presented as mean ± standard error of the mean (SEM) (unless specified 
otherwise), and a p<0.05 was considered statistically significant. 
3. Results 
3.1 Subjects 
In total, 19 subjects met the inclusion and exclusion criteria. Two subjects dropped 
out due to discomfort induced by the naso-ileal catheter, two subjects dropped out 
due to incorrect position of the catheter on the first test day, and one subject was 
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excluded after not properly following the instructions for the ad libitum meal on the 
first test day. Therefore, 14 healthy volunteers (11 female, age 25.6 ± 10.5 years, BMI 22.3 
± 1.7 kg/m2) completed the study protocol and were included in the analyses. 
3.2 Food intake 
No intervention × test day interaction was found. No differences in ad libitum food 
intake in Kcal were observed after intraduodenal, intraileal or combined infusion of 
tastants versus placebo infusion (DPIP: 786.6 ± 79.2 Kcal, DTIP: 803.3 ± 69.0 Kcal, DPIT: 
814.7 ± 77.3 Kcal, DTIT: 834.8 ± 59.2 Kcal; p=0.59) (Figure 6.1). Furthermore, as depicted 












Figure 6.1 The amount eaten in Kcal (mean + SEM) 15 min after cessation of the infusion of placebo both 
intraduodenal and intraileal (DPIP), tastants intraduodenal and placebo intraileal (DTIP), placebo 
intraduodenal and tastants intraileal (DPIT), and tastants both intraduodenal and intraileal (DTIT). 
Based on a linear mixed model, no difference in food intake was observed between the 
conditions (p=0.59). 
3.3 Satiation/Satiety scores 
The mean VAS scores for the desire to eat, hunger, satiation, and fullness are 
depicted in Figure 6.3. No differences in area under the curve (AUC150–210) for these 
VAS scores were observed between the various interventions. Furthermore, no 













































Figure 6.2 An individual representation per subject of amount eaten in Kcal 15 min after cessation of the 
infusion of placebo both intraduodenal and intraileal (DPIP), tastants intraduodenal and placebo 
intraileal (DTIP), placebo intraduodenal and tastants intraileal (DPIT), and tastants both 
intraduodenal and intraileal (DTIT). Treatment order was randomised for each subject. Each line 
with a unique symbol represents an individual subject. Based on a linear mixed model, no 
difference in food intake was observed between the conditions (p=0.59). 
 


















Figure 6.3 VAS scores for desire to eat (A), hunger (B), satiation (C), and fullness (D) (mean + SEM) before, 
during, and after the infusion of placebo both intraduodenal and intraileal (DPIP), tastants 
intraduodenal and placebo intraileal (DTIP), placebo intraduodenal and tastants intraileal (DPIT), 
and tastants both intraduodenal and intraileal (DTIT). VAS scores were measured at t=−30, 30, 90, 
150, 165, 180, 195, 210, and 240 min. No VAS scores were taken at t=225 min. At t=0 min, subjects 
received a standardised breakfast, infusion of mixtures was performed from t=150 until t=210 min, 
and ad libitum test meal was presented at t=225. Based on a linear mixed model of mean scores 
and area under the curve (AUC150–210), no differences in desire to eat, hunger, satiation, and 

























































































































































































The mean VAS scores for stomach pain, bloating, and nausea are depicted in Figure 
6.4. No differences in area under the curve (AUC150–210) for these VAS scores were 
observed between the various interventions. Furthermore, no intervention × time point 
interactions were found for these VAS scores. 
 




















Figure 6.4 VAS scores for stomach pain (A), bloating (B), and nausea (C) (mean + SEM) before, during, and 
after the infusion of placebo both intraduodenal and intraileal (DPIP), tastants intraduodenal and 
placebo intraileal (DTIP), placebo intraduodenal and tastants intraileal (DPIT), and tastants both 
intraduodenal and intraileal (DTIT). t=−30, 30, 90, 150, 165, 180, 195, 210, and 240 min. No VAS scores 
were taken at t=225 min. At t=0 min, subjects received a standardised breakfast, infusion of 
mixtures was performed from t=150 until t=210 min, and ad libitum test meal was presented at 
t=225 min. Based on a linear mixed model of mean scores and area under the curve (AUC150–210), 
no differences in stomach pain, bloating, and nausea were observed between the various 
conditions. 





















































































































Our results do not reveal any difference in satiation or food intake between duodenal 
and ileal administration of placebo, duodenal administration of-, ileal administration 
of-, or combined duodenal and ileal administration of a tastant mixture (sweet, bitter, 
and umami). Moreover, no GI-complaints were caused by infusing a tastant mixture or 
placebo into the duodenum and/or the ileum. 
Van Avesaat et al. have investigated the effect of intraduodenal infusion of the same 
tastant mixture on food intake.18 In that study, intraduodenal infusion of this 
combination of tastants, in similar study design, using the same amount of tastants 
significantly reduced food intake by 64 Kcal and was accompanied by changes in 
satiation/satiety feelings. However, it must be noted that this is a small difference, 
which on its own might not be clinically significant. Repeating this effect multiple 
times per day with each meal might result in a clinically significant decrease of caloric 
intake. This difference in results of food intake between the two studies may be 
related to differences in study design. In the study of van Avesaat et al., the subjects 
were intubated with a naso-duodenal catheter on every test day for the 
administration of tastants. The catheter was removed immediately thereafter before 
the subjects were presented with the ad libitum test meal. In the present study, 
subjects were intubated for several days with a naso-ileal catheter, and therefore this 
catheter was present while meals were offered and ingested. We hypothesise that 
having a naso-ileal catheter in situ for multiple days negatively influences meal 
ingestion to such a degree that this masks the smaller magnitude of effect that 
infusion of non-caloric tastants into the intestine has. On the other hand, mean caloric 
intake showed no major differences between the two studies. 
Previous studies from our group investigating the ‘intestinal brake’ by infusing 
macronutrients in the ileum have repeatedly shown that infusion of even low doses of 
macronutrients results in a significant reduction of food intake, ranging between 64–
188 Kcal, corresponding to a percentual decrease of 11.7%–32% of caloric intake 
during a single meal.5,21 This indicates a negative feedback mechanism on food intake 
that arises from nutrient sensing. These data demonstrate that magnitude of the 
effect of macronutrient infusion on food intake is greater than the effects of infusing 
tastants.  
Conclusively, studies investigating differences in food intake should be aware that 
naso-ileal intubation might mask a small effect. Therefore, other delivery options, 
such as encapsulation, should be considered in the future. 
Results of studies investigating the effects of single tastants on food intake, 
satiation/satiety, and GI peptides are not consistent. An initial strong decrease of 
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hunger with a steep increase thereafter has been observed after administration of a 
non-caloric sweetener.22 Ingestion of low caloric sweeteners did not influence energy 
intake compared with a control condition (intake of water).23 Adding an umami tastant 
to a meal did not affect appetite sensations but has been shown to result in an 
increase of subsequent food intake.24 Recently, increased attention has been given to 
the effects of bitter substances on satiation and food intake. Intake or infusion of bitter 
substances (quinine, denatonium benzoate) not only reduced antral motility25,26 but 
also increased satiation/satiety scores and resulted in a significant decrease in food 
intake.27 A possible mechanism explaining the strong aversive effects of bitter 
tastants is that bitter taste is evolutionarily linked to toxic substances, as has been 
showed by presenting new-born infants with bitter substances.28 
Alleleyn et al. have shown that the inhibition of food intake shows a proximal to the 
distal gradient, with higher effects observed after distal versus proximal 
administration of nutrients.8 Based on our data, such a gradient was not observed for 
intestinally administered tastants. Intestinal taste receptor expression varies for 
various taste receptors, where some taste receptors are more profound proximally in 
the GI-tract, while expression of other taste receptors is higher in the more distal 
intestine.14-17 
We thought the proximal to distal gradient found for macronutrient infusion might be 
operable for taste receptor activation, which was clearly not the case. It is possible 
that taste receptors inhibit food intake in a different fashion than macronutrients. For 
instance, it has been speculated that taste receptors function by sensing the type of 
food (i.e., sweet for carbohydrates, umami for amino acids, and bitter for toxic 
substances).29 Since bitter tastants are linked to toxic substances, another working 
mechanism for bitter tastants could be through an aversive reaction of subsequent 
food intake.  
From an evolutionary perspective, a more pronounced inhibitory or aversive effect for 
toxic substances could be expected to occur in the most proximal parts of the GI 
tract. However, there are no data available with respect to activation of oral (bitter) 
taste receptors on subsequent food intake. It is therefore unclear, whether activation 
of more proximal taste receptors will reveal more pronounced effects on food intake 
and satiation/satiety. Consequently, further studies are needed to investigate 
whether more proximal activation of taste receptors results in a stronger decrease in 
food intake. 
Published data on the role of GI peptides in the regulation of food intake after 
administration of tastants are not in line. Van Avesaat et al. found a clear effect of 
intraduodenal administration of tastants on food intake that was not accompanied by 
changes in GLP-1- or PYY level.18 Other studies, however, did show a decrease in 
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systemic ghrelin- and motilin levels25,26 and an increase in systemic CCK levels27 after 
administration of a bitter tastant. 
A limitation of our study is that the wash-out period consisted of only one day. 
Prolonging the wash-out period over one day would have resulted in a longer period 
of naso-ileal catheter intubation increasing the discomfort to our volunteers. No 
interaction effect between intervention and test day was found on food intake, 
satiation scores or GI-complaints, indicating that no carry-over effect was present. 
Another limitation of the present study was the absence of systemic GI hormone 
measurements. This would have provided a complete analysis of the effects of 
intestinal tastant administration on eating behaviour. However, van Avesaat et al. 
showed a decrease in food intake and an increase in satiation scores, which was not 
accompanied by changes in systemic GI hormone levels.18 Therefore, no systemic GI 
hormone measurement was conducted in the present study. 
It has to be noted that the ideal duration of administration of the intervention and of 
the timing between intervention and serving the ad libitum meal is unknown. We 
employed a design similar to that of van Avesaat et al. based on their positive 
results.18 Future research protocols should consider these factors.  
Studies investigating the effects of tastants on food intake up to now focus on only 
acute effects in a single ad libitum meal. It is not known whether repetitive or chronic 
administration of tastants will lead to other results. More data are needed on the long-
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Esophageal pain is mediated by sensory nerves, most importantly via the activation of 
the Transient Receptor Potential Vanilloid 1 (TRPV1) capsaicin receptor. TRPV1 is 
activated and sensitized by a broad range of pungent compounds, as well as 
inflammatory mediators and tissue irritants. Luminal stressors are suggested to impair 
the barrier function, which results in consequent activation of these sensory nerve 
terminals and pain. Here we investigated the role of esophageal TRPV1 activation by 
capsaicin perfusion on mucosal barrier integrity and pain in healthy humans. 
 
Methods 
Thirteen volunteers completed a single blind, saline-controlled, randomized 
crossover study. Capsaicin or saline was perfused for 30 min in the distal oesophagus. 
Visual Analogue Scale (VAS) pain intensity scores and intraluminal impedance 
indicating mucosal integrity were determined. Distal and proximal biopsies were 
obtained 10 min later to measure TRPV1 mRNA and immunopositivity, as well as the 
intercellular space width. 
 
Results 
Capsaicin perfusion resulted in significantly greater pain intensity (p=0.047) and 
impaired recovery of the baseline impedance compared to saline-treated controls 
(p=0.027). Pain response was significantly associated with decreased baseline 
impedance. Similar dynamics were seen in the proximal esophagus, but baseline 
impedance recovered entirely to the pre-infusion values there. There was a 
significant association between baseline impedance and intercellular space width in 
the distal esophagus. TRPV1 transcription and expression were not significantly 
altered within this observation period. 
 
Conclusions 
Esophageal TRPV1 activation results in pain, which is likely to be explained by an 
impaired mucosal barrier and the defective restoration capacity in the distal 
esophagus. 
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1. Introduction 
Gastroesophageal reflux disease (GERD) is a highly prevalent disorder characterized 
by reflux of gastric contents that cause pain symptoms.1 In patients with erosive 
esophagitis, macroscopic disruption of the mucosa is apparent. However, in a 
substantial proportion of patients with reflux symptoms, there is no evidence of 
macroscopic damage of the mucosa and symptoms can therefore be attributed to 
non-erosive gastroesophageal reflux disease (NERD).2 Several studies have identified 
subtle mucosal injury at microscopic level in these patients.3,4 It is hypothesized that 
this disruption of the esophageal mucosal barrier is an important factor in the 
generation of reflux symptoms in NERD by facilitating excitation of mucosal neural 
afferents responsible for pain signaling. 
The question however arises whether such mechanism is primarily related to 
impaired mucosal integrity or rather increased sensitivity of afferents in an otherwise 
intact mucosa. In order to understand these mechanisms, baseline impedance has 
been introduced to determine esophageal mucosal integrity.5 Another tool to 
investigate the mucosal barrier is the evaluation of dilated intercellular spaces (DIS). 
The presence of DIS within the squamous epithelium is believed to be a marker for 
esophageal mucosal barrier damage.6 
For the investigation of sensory nerve function, previous studies have focused on 
molecules responsible for nociceptive signalling. Transient Receptor Potential (TRP) 
cation channels, particularly the Vanilloid 1 (TRPV1) capsaicin receptor, play an 
important role in nociceptive signaling of somatic and visceral pain. Capsaicin 
perfusion in the esophagus leads to the sensation of heartburn.7 TRPV1 expression 
was shown to be upregulated in the esophageal mucosa of NERD patients.8,9 In a 
mouse NERD model, TRPV1 overexpression and impaired mucosal integrity were 
detected in comparison with control animals.10 In addition, proximity of sensory 
afferents to the lumen is also believed to contribute to increased hypersensitivity in 
NERD.11 These results suggest that an impairment of the mucosal barrier results in an 
increased exposure of the sensory nerve endings to the refluxate and consequently 
pain generation via TRPV1 receptor activation.   
Several studies have shown that the threshold for induction of symptoms in GERD 
patients and controls is lower in the proximal compared to the distal part of the 
esophagus.12-15 Woodland et al. observed that nerve endings in the proximal 
esophageal mucosa are closer to the proximity of the lumen compared to the distal 
esophagus.16 The proximal to distal gradient in afferent sensitity of the esophagus 
may reflect an important biological and homeostatic function.   
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There were 3 main aims of the present study performed in healthy volunteers: 1) to 
test the hypothesis that exposure of the esophageal mucosa to the TRPV1 agonist 
capsaicin results in an impairment of the mucosal barrier function, measured by 
baseline impedance and DIS in the ‘exposed’ distal segment of the esophagus; 2) to 
assess these effects in the ‘non-exposed’ proximal segment of the esophagus; 3) to 
study the relation between symptom perception, mucosal integrity and TRPV1 
expression. 
2. Materials and methods 
The study was approved by the Medical Ethics Committee of Maastricht University 
Medical Center+ and was conducted in full accordance with the principles of the 
Declaration of Helsinki of 1975 as amended in 2013, and with the Dutch Regulations 
on Medical Research involving Human Subjects (1998). All volunteers gave written 
informed consent before participation. This trial was registered at 
www.clinicaltrials.gov as NCT02603783. 
2.1 Subjects 
Subjects between 18 and 65 years with a body mass index (BMI) between 18 and 
25 kg/m2 were enrolled in this study. Subjects were recruited by local 
advertisements. Subjects were excluded if they: 1) had any history of gastrointestinal 
diseases including esophageal motility disorders, reflux disease or any previous 
esophageal or gastric surgery; 2) intake of more than 14 alcoholic consumptions per 
week or smoking; 3) regularly use of capsaicin-containing foods (>1 per week); 
4) known allergy to capsaicin. Informed consent was obtained after an interval of at 
least 7 days. 
2.2 Experimental design 
Participants underwent esophageal perfusion of capsaicin and physiological saline 
(control) in a randomized order with a minimal wash-out period of 10 days in between 
the two test days. Only the participant was blinded for the type of solution perfused. 
Therefore, the researcher was able to stop the infusion of capsaicin when the 
participant experienced maximun pain scores. Randomization occurred using 
randomizer.org. Participants were requested to arrive at 9.00 am after an overnight 
fast at the motility lab of the Gastroenterology-Hepatology department of the 
Maastricht University Medical Centre+. First, esophageal manometry was performed 
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to locate the proximal margin of the lower esophageal sphincter (LES). A single lumen 
naso-esophageal infusion catheter G-84300 (Medical Measurement Systems, 
Enschede, The Netherlands) was placed 12 cm proximal to the upper margin of the 
LES and connected to an infusion pump (Perfusor Space Infusion Pump System, B. 
Braun, Melsungen, Germany). Impedance measurements were performed using a 
combined pH-impedance catheter assembly that consisted of six impedance 
segments located at 3, 5, 7, 9, 15 and 17 cm above the upper border of the LES and 
one ISFET pH electrode (Unisensor AG, Attikon, Switzerland). The pH electrode was 
positioned 5 cm above the upper margin of the LES. Baseline impedance and pH 
signals were stored on a digital data logger (Ohmega, Medical Measurement 
Systems, Enschede, The Netherlands), using a sampling frequency of 50 Hz. The 
position of which the baseline impedance was measured in the more proximal 
esophagus was at 15 cm above the upper border of the LES. The distal esophagus 
was considered at 5 cm above the upper border of the LES.17 
After positioning of the catheters, the subjects were instructed to stay in a semi-
recumbent position. Prior to the start of the perfusion, esophageal impedance was 
recorded for 20 min under basal conditions. Perfusions were performed at an rate of 
2.5 mL/min for 30 min or until participants experience maximum tolerable discomfort 
(a single Visual Analogue Scale (VAS) score of 100 mm or two subsequent VAS scores 
of ≥80 mm). After esophageal perfusion was ended, recording of impedance was 
continued for 10 min. Directly after the removal of both catheters, a standard 
gastroscopy was performed by an experienced gastroenterologist (JC) to obtain eight 
esophageal biopsies (4 distal at 3-5 cm above LES and 4 proximal 15-17 cm above 







Figure 7.1 Timeline of the test day. Infusion of capsaicin solution or NaCl started at t=0 min after an 
overnight fast. 10 min after the end of the perfusion an endoscopy was performed to obtain 
biopsies from the esophageal mucosa. VAS scores for retrosternal pain and heartburn were 
collected at regular intervals as indicated. Baseline impedance was measured according to the 
following protocol; 20 min before (calibration phase), 30 min during perfusion and 10 min after 





The total amount of capsaicin administered in this study was 1.5 mg in 75 mL solution 
(Capsaicine Oleoresina 8.3% capsaicin, Tiofarma BV, Oud Beijerland, the Netherlands). 
This dose is equivalent to the allowed maximum daily intake according to the 
Scientific Committee on Food of the European Commission18 and has been used by 
our group in previous studies for duodenal stimulation.19 In brief, first, 24 milligrams of 
Capsicum Oleoresin was dissolved in 1 mL 96% ethanol (Brouwland bvba) and diluted 
with saline to 100 mL (Fresenius Kabi). Of this solution, 75 mL was infused. The pH of 
the capsaicin solution was 5.5. A total 75 ml of physiological saline (Braun Melsungen 
AG, Germany) (pH 6.2) was used as control solution, similar to previous studies 
investigating esophageal mucosal integrity.5,17 
2.4 Baseline impedance measurements 
Baseline impedance was measured according to the following protocol; 20 min 
before (calibration phase), 30 min during perfusion and 10 min after the end of the 
perfusion (see Figure 7.1). Following the positioning the catheters a 10 min 
acclimatization period was allowed, thereafter registration was started. We calculated 
the mean impedance value over a 10 min period before the start of the perfusion. The 
impedance recovery after perfusion was calculated as follows; we included the mean 
impedance during the period between the third and the fifth minute after cessation of 
perfusion. The baseline impedance in the first two min after the cessation of the 
perfusion was not included in the analysis in order to allow for complete 
capsaicin/saline bolus clearance from the distal esophagus. We excluded all reflux 
events and belching events from this calculation. 
The analysis of impedance changes before, during and after the perfusion was 
performed by one of the investigators (JC) with extensive experience in the 
interpretation of these impedance measurements who was blind to the treatment 
order. 
2.5 VAS scores for heartburn and retrosternal pain 
All participants scored the intensity of heartburn and retrosternal pain, measured 
using VAS scores (0-100 mm) anchored at the low end with the most positive or 
lowest intensity feelings (extremely pleasant, not at all) and with the opposing terms 
at the high end (extremely unpleasant, very high, extreme).20 The VAS scores were 
collected at t=-5, 0, 5, 10, 15, 20, 25, 30 and 35 min. 
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2.6 TRPV1 immunohistochemistry and scoring  
4 μm sections from paraffin embedded esophagus biopsy blocks were stained with a 
1:100 dilution of guinea pig polyclonal anti-TRPV1 (GP14100, Neuromics, Edina, MN, 
USA) primary antibodies. Slides were incubated VECTASTAIN® ABC-Peroxidase Kit- 
Guinea Pig IgG (PK-4007, BioMarker Ltd., Budapest, Hungary). The reaction was 
visualized by 0.01% hydrogen peroxide containing 3,3-diaminobenzidine tetrachloride, 
histological counterstaining was performed with hematoxylin.21 TRPV1 
immunopositivity was quantified by the individual assessment of 100 cells on each 
slide scored between 0 - 3 (0 - negative, 1 - minimal positivity, 2- moderate, 3- strong 
positivity), performed by an experienced pathologist who was blind to the treatment 
order (BK). A histological H-score was determined by the sum of the scores of the 
individual cells on each slide (ranging between 0-300). Incubating esophagus mucosa 
with Tris-buffered saline instead of the primary antibodies served as the negative 
control, while sections of human dorsal root ganglia expressing TRPV1 abundantly 
were used as positive controls. The antibody specificity has been validated by 
preabsorption of the respective blocking peptide (P14100 Neuromics, Edina, MN, USA) 
as described previously.22 
2.7 Trpv1 mRNA analysis 
Sample homogenization was performed in 1 mL TRI Reagent (Molecular 
ResearchCentre Inc., Cincinatti, OH, USA) and total RNA was isolated with Direct-Zol 
RNA MiniPrep isolation kit (Zymo Research, Irvine, CA) following the manufacturer’s 
protocol. Samples were then measured by NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies Inc., Wilmington, DE) to assess RNA quantity and purity. 
After treatment with deoxyribonuclease I enzyme (Zymo Research, Irvine,CA) total 
RNA (100 ng) was reverse transcribed with Maxima First Strand cDNA Synthesis Kit 
(Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's instructions. 
To amplify trancripts real-time qPCR was performed on a Stratagene Mx3000P 
qPCRSystem (Agilent Technologies, Santa Clara, CA) using Luminaris HiGreen 
LowROX qPCR Master Mix (Thermo Fisher Scientific) (Bohonyi et al, 2017).  The 
following primer pairs were used  to  amplify the genes of interest: Trpv1 
(NM_080706.3) (sense): 5'-CAGCTCAATTGCTGTGCAGGTTA-3' and (antisense): 
5'-TGCCAGTATGGATGGAGTGGAA-3'. All reactions were measured in triplicates and 
the geometric mean of their Ct values were calculated which was normalized to 
transcripts of the glyceraldehyde 3-phosphate dehydrogenase (Gapdh) 
(NM_001289746.1) (sense): 5-́ CCTGCACCACCAACTGCTTA -3 ́ and (antisense): 
5-́TAGAGGCAGGGATGATGTTCTG-3;́ used as reference gene. Primers with similar 
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efficiencies were used and melt curve analyses were performed to verify primer 
specificity. The determination of relative messenger RNA (mRNA) expression levels 
was performed according to the comparative DCt method. Analyses were performed 
by an investigator (KC) blind to the treatment order. 
2.8 Transmission electron microscopy   
A single esophageal biopsy was directly immersed in 3% glutaraldehyde fixative 
buffered in 0.09 M KH2PO4 at pH 7.4 at room temperature. After a minimum of 24 
hours of immersion, samples were then washed in 0.09 M KH2PO4 buffer with 7.5% 
sucrose and transferred to a 1% OsO4 + 1.5% ferrocyanide solution and buffered to pH 
7.4 with 0.1 M veronalacetate for subsequent post-fixation for 1 h at 4°C. After washing 
in phosphate veronalacetate buffer containing 7% sucrose at pH 7.4, dehydration was 
carried out rapidly in graded ethanol series followed by embedding in Epon. Ultrathin 
tissue sections were cut and examined with a Philips CM 100 electron microscope. Of 
each biopsy specimen 3-5 TEM photographs were taken. TEM photographs were 
obtained from the basal and suprabasal layers of the epithelium at x4000 
magnification by an independent researcher, who was experienced in the recognition 
of the different layers of the epithelium and blinded for the status of the subject. 
2.9 Intercellular space width  
Intercellular space area (ISA) was evaluated in 3 representative TEM photographs per 
subject. For the assessment, based on the division of the area by the corresponding 
length (an estimation of the perimeter of the cell), first a single line was drawn 
through the intercellular space around 2-3 cells in the microphotograph. The 
researcher was blinded for the treatment order. Multiple lines were drawn which 
were optically the most suitable for calculation of cellular space. A region of interest 
(ROI) around this line was defined to include the intercellular space between the two 
cells, without inclusion of intracellular content. The software allowed us to customize 
a ROI of different μm in each case. Then, the pixel threshold was chosen to include 
only pixels from the intercellular space. Pixels considered for the analysis were 
visualized in yellow. Based on this threshold, the area around the line included in the 
ROI was automatically calculated and divided by the length of this line using 
custom‐written image analysis software in IGOR Pro (WaveMetrics Inc., Oregon, USA). 
Per subject, the average of the area of different regions of interest from the 3 TEM 
photographs was used for the analysis (Figure 7.2). 












Figure 7.2 Illustrative image of assessment of intracellular space area (ISA). A) Multiple lines (red) are drawn 
through the intercellular space. Crossings where intercellular spaces merge are not included. 
B) A region of interest is marked around the lines to cover the selected intercellular space. 
C) Based on the pixel threshold, the intercellular space area is then calculated and divided by its 
corresponding length. 
 
2.10 Statistical analyses 
Statistical analyses were performed with SPSS, version 25.0 (SPSS Inc., Armonk NY, 
USA).  
A linear mixed model was performed to analyze the baseline impedance in the 
proximal and distal esophagus separately and VAS scores and the relation between 
these two variables. For the baseline impedance and VAS scores for heartburn and 
retrosternal pain, a three way interaction between intervention (capsaicin or control), 
time (pre, post or -5, 0, 5, 10, 15, 20, 25, 30, 35 min) and test day (1 and 2) with all lower 
terms were included in the model to check whether the intervention effect over time 
depends on test day. In case the interaction was not significant, this interaction term 
was removed from the model and the intervention effect at each time-point was 
reported for both test days combined. For baseline impedance, solely the time points 
pre (between -10 and 0 min) and post infusion (between +32 and +35 min) were 
included in the model in order to ignore the effect of the fluid perfusion and bolus 
clearance on baseline impedance. A random intercept and/or slope (time) were 
included and different covariance structures (unstructured and variance components) 
were considered for these random effects, where the final model was chosen based 
on Akaike’s information criterion (AIC).  
For both locations separately, TRPV1 expression, transcription, and intercellular space 
area were analyzed with a linear mixed model which included a two way interaction 
between treatment and test day. In case the two way interaction was non significant, 
the intervention effect was reported for the two test days combined. 
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Data are presented as means ± (SEM) unless specified otherwise. P-value ≤0.05 was 
considered as statistically significant. 
2.11 Sample size calculation 
Data for executing this sample size calculation were retrieved from Farré et al. with 
the following parameters for mucosal integrity: alpha ()=0.05, power=0.80, mean 
difference=716 Ohm (control vs. esophageal acid perfusion=2960 Ohm vs. 2244 Ohm), 
standard deviation ()=690.5 According to this sample size calculation, we needed to 
include 14 healthy volunteers to be able to reject the null hypothesis that the 
capsaicin infusion has a similar effect as control solution on baseline impedance with 
a probability (power) of 0.80. With regards to dropouts, we were able to include up to 
15 healthy volunteers. 
3. Results 
Fifteen volunteers were included in this study. Two participants dropped out after 
screening and randomization; 1 volunteer was not able to schedule the test days and 
1 volunteer became ill due to reasons unrelated to the study and discontinued study 
participation. 13 volunteers were included in the study analysis (4 males; mean ± SD 
age: 27.6 ± 14.3 years, BMI 22.5 ± 1.3 kg/m2) for analysis of baseline impedance. This 
included one study participant who only completed one test day (saline condition) 
and dropped out prior to the second test day. As for the analysis of TRPV1 
immunohistochemistry and mRNA expression, only samples from participants who 
completed both test days were included (n=12). Similarly, for DIS analysis, each group 
contained 12 samples, except for the proximal biopsies in the saline group, which 
included 11 samples due to fixation artefacts. 
3.1 Effects in the distal esophagus 
Perfusion of capsaicin into the distal esophagus resulted in significantly higher scores 
for heartburn (overall p-value 0.004) and retrosternal pain (overall p-value 0.047) over 
time (Figure 7.3). Notably, both pain and retrosternal pain persisted after cessation of 
capsaicin during the timeframe of the experiment. 












Figure 7.3 VAS scores for Heartburn (A) and Retrosternal Pain (B) (estimated means ± SEM). Grey box 0-30 
min: perfusion period. Overall p-value heartburn: 0.004. Overall p-value retrosternal pain: 0.047. 
*p-value<0.05, **p-value<0.01, ***p-value<0.001. VAS: visual analog scale. 
 
 
These effects were accompanied with changes in baseline impedance in the distal 
esophagus (Figure 7.4A). Both capsaicin and saline perfusion resulted in decreased 
baseline impedance. However, this decrease was of greater magnitude after 
capsaicin perfusion compared to saline, albeit this difference was not significant. After 
discontinuation of capsaicin perfusion, baseline impedance remained lower 
compared with the value before perfusion. Following the perfusion of saline, baseline 
impedance increased above pre-perfusion levels. We therefore observed a 
significant difference in recovery of 966 ohm (estimated mean (SEM) for capsaicin pre 
and post: 3468 (257) Ω and 3313 (277) Ω vs. saline pre and post: 2918 (261) Ω and 3728 













Figure 7.4  Baseline impedance over time in the distal (A) and proximal (B) esophagus. Grey box: infusion 
period. * significant difference between capsaicin and control perfusion, pre vs. post. Proximal: 
significant difference pre and post perfusion between the two treatments, p-value: 0.007. Distal: 
significant difference pre and post perfusion between the two treatments, p-value: 0.027. 
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There was a significant inverse association between VAS scores for retrosternal pain 
and mucosal integrity for capsaicin and saline conditions combined (slope -0.006, p-
value: 0.031, 95% CI [-0,011; -0.001]). For heartburn, there was a non-significant relation 
between baseline impedance and heartburn in the distal esophagus (slope -0.007, 
p-value: 0.080, 95% CI [-0,015; 0,001]).  
Baseline impedance before the start of the perfusion on both test days was not 
significantly different (p-value 0.369). The fluctuation of the baseline impedance in an 
empty esophagus ranges between 2000 and 4000 Ω in normal adults.23 
3.2 Effects in the proximal esophagus 
Distal perfusion of both solutions resulted in a decrease in baseline impedance in the 
proximal esophagus over time (Figure 7.4B). Comparable to the distal esophagus, this 
decrease was also of greater magnitude after capsaicin perfusion compared to saline 
in the proximal esophagus. However, the decrease was less pronounced compared 
to the distal esophagus for both conditions. After cessation of the perfusions, baseline 
impedance recovered above pre-perfusion levels for saline. For capsaicin, baseline 
impedance fully recovers to the value before perfusion, contrary to what was 
observed in the distal esophagus. This difference in recovery was 1139 ohm 
(estimated mean (SEM) for capsaicin pre and post: 3017 (294) Ω and 3047 (310) Ω vs. 
saline pre and post: 2329 (294) Ω and 3497 (301) Ω, p-value for difference in change 
scores 0.007). 
3.3 Intercellular space area 
The intercellular space width was not significant different between the type of 
solution in the proximal (p-value 0.330) and distal esophagus (p-value 0.171) 
(Figure 7.5). 
However, there was a significant negative association between the intercellular space 
area and baseline impedance just prior to obtaining the biopsy in the distal 
esophagus (slope -0.001, p-value 0.002, 95% CI [-0.0001; -0.00003]). 
 


















Figure 7.5 Mucosal intercellular space diameter in biopsies from the proximal and distal esophagus in 
healthy volunteers after exposure to capsaicin and control. There was no significant significant 
difference for the treatment in both locations (p-value proximal esophagus 0.330, p-value distal 
esophagus 0.171). n=12, proximal control n=11. 
 
3.4 TRPV1 immunohistochemistry and mRNA expression 
There was no significant difference in H-scores for Trpv1 between the type of solution 
after correction for location (distal p-value 0.970 and proximal p-value 0.761) (Figure 
7.6A). There was no significant difference in TRPV1 mRNA levels between between 
the type of solution after correction for location (distal p-value 0.829 and proximal p-


















Figure 7.6 A) TRPV1 immunohistochemistry: H-score for Trpv1. There was no significant difference between 
the treatments after correction for location (distal p-value 0.970 and proximal p-value 0.761). 
B) TRPV1 mRNA expression: delta Ct value for TRPV1. There was no significant difference 
between the treatments after correction for location (distal p-value 0.829 and proximal p-value 
0.186). n=12. TRPV1: transient receptor potential vanilloid 1. 
 
4. Discussion 
The present results suggest a role for impaired mucosal integrity in the generation of 
esophageal pain induced by TRPV1 receptor activation. Perfusion with the TRPV1 
agonist mucosal stressor capsaicin in the distal esophagus resulted in decreased 
baseline impedance, and in particular an impaired capacity to restore impedance 
following perfusion, indicating impaired mucosal integrity for a prolonged time period. 
This was accompanied by larger intercellular space widths leading to more exposure 
of the sensory nerve endings of the esophageal mucosa to capsaicin and other 
noxious stimuli. In addition, pain scores during the perfusion showed a significant 
association with the decreased baseline impedance of the distal esophagus.  
 
Besides the impaired mucosal integrity, pain generation can also be related to 
primary dysfunction of the afferent nerve endings (i.e. through sensitization). It has 
been hypothesized that increased transcription of the TRPV1 receptor may contribute 
to the perception of hearburn in NERD patients.8,9,24 Furthermore, the release of 
neuropeptides, such as substance P and calcitonin‐gene related peptide, from 
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TRPV1-expressing nerves, may result in neurogenic inflammation and consequent 
activation of the inflammatory cascade in the esophageal mucosa leading to mucosal 
afferent hypersensitivity. In addition, this inflammatory cascade can also contribute to 
the impairment of the mucosal barrier.25 We did not observe significant alterations of 
TRPV1 expression either at mRNA or protein levels, albeit prompt changes within this 
relatively short timeframe are unlikely to occur. In the esophageal mucosa, the TRPV1 
receptor is expressed both on the sensory nerves and epithelial cells26, but its mRNA 
is more likely to be derived only from the epithelial cells. The role of epithelial TPRV1 
in relation to pain signaling remains to be established. On the other hand, it has been 
reported that peripheral inflammation induces axonal transport of TRPV1 mRNA from 
dorsal root ganglia to central and peripheral axon terminals27, and such phenomena 
may also occur as a result of esophageal acid exposure.28 
 
Regardless of the localization within the esophageal mucosa, it appears that pain 
intensity is not related to the amount of the TRPV1 receptor. Indeed, pain sensation is 
a complex process, which is not only determined by mucosal mechanisms, but also 
by central sensory and autonomic processing at the spinal cord and brain levels. 
Nevertheless, this study provides substantiation for the postulate that esophageal 
pain generation depend on the mucosal barrier resistance and consequently the 
exposure of TRPV1-expressing sensory terminals to different stimuli, rather than 
TRPV1 upregulation. We provide an overview of the postulated mechanisms in 
Figure 7.7. 
 
The impedance value as an indicator of the mucosal barrier function, remained 
permanently reduced in the distal, capsaicin-perfused esophagus even after 
completing the stimulation. In the proximal esophagus, impedance fully recovered to 
the pre-perfusion control values after a moderate, transient decrease during the 
intervention, and the intercellular space width was not altered. However, it should be 
noted that baseline impedance and the intercellular space width do not necessarly 

































Figure 7.7 Schematic depiction of the hypothesized effects of esophageal perfusion with capsaicin. NTS: 
nucleus tractus solitarius. DRG: dorsal root ganglion. TRPV1: transient receptor vanilloid 1. 
 
 
Interestingly, pain sensation persisted even after cessation of the capsaicin infusion. 
We speculate that the recovery of the baseline impedance in both locations after the 
stimulation reflect to the mucosal barrier restoring mechanisms to protect the 
mucosa from potentially noxious substances. This reinforcement of the mucosal 
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barrier leads to a less permeable epithelium and reduces interactions between 
noxious substances and the nociceptive afferents. The differences between the distal 
and proximal esophagus can be explained by the higher sensitivity of the proximal 
part to noxious stimuli as a defence mechanism to protect the airways29 from the 
influx of potentially noxious substances. This is supported by results demonstrating 
that nerve endings in the proximal esophagus are closer to the lumen compared to 
the distal part.16 
 
In contrast to the present results demonstrating no intercellular space changes in the 
proximal biopsies after distal capsaicin perfusion, earlier studies with acid (both pH 2.0 
and 5.5) perfusion in a similar way in 14 healthy volunteers induced significantly 
enlarged intercellular space area in both esophageal parts.17 Although protons also 
mainly activate the TRPV1 ion channel similarly to the selective agonist capsaicin, the 
bindig sites and the activation mechanisms are different.30 Furthermore, acid 
perfusion elicited almost no symptoms17 in agreement with the observation that 
esophageal submucosal injection of capsaicin but not acid was able to induce pain.31 
Therefore, we hypothesize that the reflectory reinforcement of the mucosal barrier, in 
particular in the proximal esophagus, is specifically induced when pain signals are 
generated.   
 
An intriguing observation was that after 30 min saline perfusion the baseline 
impedance increased above the pre-perfusion values after the cessation of the 
stimulus in both the proximal and distal esophagus. This phenomenon was also 
observed in a previous study.5 The saline infused in our study had a pH of 6.2, 
whereas the solution in the Farré study had a pH of 7.2.5 The pH of physiological 
saline can vary between 6.15-8.15.32 In this sense, our control condition rather 
resembles the effect of a weak acid than neutral solution and may therefore have 
resulted in the observed decrease of baseline impedance. It appears that the same 
underlying mechanisms might be at operation during both conditions. Nevertheless, 
even when the direction of changes are comparable between capsaicin and saline, 
the effects of capsaicin infusion are significantly larger in magnitude and this 
difference might be related to the degree of the mucosal barrier impairment and the 
pain response elicited. 
 
Besides the important outcomes and novelties, there are some limitations of this 
study, such as the relatively small sample size that might have resulted in a type II 
statistical error. This means that some results cannot be treated as firmly conclusive, 
in particular with regards to the secondary endpoints, such as the effect on 
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intercellular cell width. In addition, the timing of the endoscopy and biopsy retrieval 
might have influenced the accuracy by which we were able to detect any findings on 
intercellular space level. It may be possible that any alterations occurred were 
(partially) reversed at the moment of the biopsy retrieval. Regarding baseline 
impedance measurements, technical factors, such as attachment of the catheter to 
the esophageal mucosa or fluid on the catheter, might have influenced 
measurements which can render values less accurate as surrogate markers for 
epithelial integrity. In addition, we cannot rule out that the proximal part of the 
esophagus was also exposed to capsaicin through regurgitation. As this was a study 
performed in healthy voluneers, it remains to be established what the exact role of 
the described phenomena is in patients with reflux/heartburn symptoms.  
 
In summary, the most important novel findings of this study are that i) TRPV1 
activation by capsaicin infusion in the distal esophagus resulted in an impaired 
mucosal barrier and ii) pain intensity (sensory response) was related to the magnitude 
of this impairment but not to TRPV1 expression. Therefore, pain is likely to be the 
result of increased exposure of the sensory nerve terminals to stimulants through 
barrier impairement. Our results provide important novel insight into esophageal pain 
generation which has clinical relevance for treating heartburn and related symptoms, 
as well as for providing rationale for esophageal barrier protection as a therapeutic 
modality.33 
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Dilation of intercellular spaces is considered as an early marker for gastroesophageal 
reflux disease (GERD). Traditionally, evaluation of intercellular space diameter (ISD) is 
performed by placement of random transects in 10 transmission electron microscopy 
(TEM) photographs per subject. This method may not take the irregularity of the 
intercellular space fully into account and is time consuming. We present the relative 
intercellular space area (ISA) as an alternative method for a more representative 
evaluation of ISD.  
 
Methods 
21 GERD patients with and without endoscopic esophagitis (EE) and 12 healthy 
volunteers were enrolled and biopsies were obtained for TEM. ISD was assessed 
using the classic method (ISDc) and ISA by two investigators that worked 
independently. ISA was assessed in 3 TEM photographs by measuring the area of the 
intercellular space divided by its corresponding length.  
 
Results 
ISA-values showed a high correlation with corresponding ISDc-values (r: 0.84, 
p<0.001). However, ISDc-values were larger when compared to ISA-values (1.32 μm ± 
0.05 vs. 0.90 μm ± 0.04, p<0.001). Both methods showed an excellent intraobserver 
and interobserver agreement (resp ISA:  0.9, ISDc:  0.92 and ISA:  0.81, ISDc  0.80). 
Comparison between subgroups showed an increased ISD only in patients with EE by 
both methods but not in EE-negative patients.  
 
Conclusion 
Evaluation of the ISD using ISA showed a high intra- and interobserver agreement, a 
strong correlation with values obtained with ISDc and the ability to discriminate the 
presence of DIS in patients with EE. This more representative and less time-
consuming approach can be used to reliably assess the ISD in GERD patients in future 
studies. 
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1. Introduction 
Gastroesophageal reflux disease (GERD) affects 10-20% of the adult population 
worldwide and has a great impact on  quality of life of individuals affected and health 
care costs.1 The cardinal symptom in GERD is heartburn, which is thought to originate 
from direct exposure of acid reflux to sensory nerve endings in the deeper layers of 
the esophageal mucosa.2,3 Exposure of acid reflux to sensory nerve endings is 
obvious when patients present with large mucosal breaks (i.e. erosive esophagitis) in 
the distal esophagus. The majority of GERD patients present with an intact 
esophageal mucosa on endoscopy and are classified as non-erosive reflux disease 
(NERD) in case of abnormal acid exposure; as reflux hypersensitivity (RH) in case of 
normal acid exposure but positive symptom correlation and as functional heartburn in 
case of normal acid exposure and negative symptom association.4 In the EE-negative 
patients, the sensory nerve endings are not directly exposed and the route of 
activation by acid is less clear. In order to understand the origin of heartburn in 
absence of erosions, research has focussed on histological changes of the 
esophageal mucosa that may facilitate the passage of acid to the sensory nerve 
endings. Dilation of intercellular spaces (DIS), first described in 1979 in patients with 
erosive esophagitis (EE) and more recently also in EE-negative patients, was 
presented as the missing link in the pathogenesis of heartburn in NERD and RH.3,5-7 
Since the introduction of the concept of DIS, different methods have been used to 
evaluate the intercellular spaces from esophageal biopsies. Some studies have used 
light microscopy, although transmission electron microscopy (TEM) is now 
recognized as the superior technique to determine DIS.8 The classic evaluation of the 
intercellular space (ISDc) was first described by Tobey et al and consists of the 
measurement of the intercellular space diameter (ISD), based on 10 randomly drawn 
perpendicular transects from the cell membrane of a central cell to the opposing cell 
membranes per microphotograph in a total of 10 TEM photographs of a single 
subject.6 Although this method has been used in several studies, it is also frequently 
disputed.9-11 One of the concerns is that ISDc may not fully take the irregularity of 
intercellular space delineation enough into account, especially if dilatation of the 
intercellular space is absent. The intercellular space between esophageal epithelial 
cells is highly irregular and even completely absent when neighbouring cells are 
connected by multiple interdigitations. Furthermore, it has been argued that the 
placement of 10 transects in a TEM photograph is not completely at random and 
evaluation of 10 TEM photographs per subject is time consuming.  
Farré et al described an alternative method to assess ISD in rabbits: the relative 
intercellular space area (ISA). In 3 TEM photographs the intercellular space area is 
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divided by the corresponding length, resulting in a mean intercellular space diameter 
over the covered area, including both retracted and dilated segments.12,13 As ISA 
covers large areas of the intercellular space, it only requires the analysis of 3 non-
overlapping TEM photographs of the basal and suprabasal layers for a representative 
ISD value. ISA may therefore be a more representative approach that is less prone to 
bias and less time consuming. 
In this study, we present ISA as an alternative method for the evaluation of ISD in 
human biopsy samples. We aim to evaluate the inter- and intra-observer variability as 
well as the time consumption of this alternative method in comparison with ISDc. A 
second aim is to evaluate the ability of ISA to identify differences in ISD between 
patients with erosive esophagitis (EE) and EE-negative patients and healthy 
volunteers (HVs). 
2. Methods 
2.1 Study protocol 
The current study is part of a study protocol investigating the mucosal barrier function 
in GERD patient with both with and without EE, and healthy volunteers (HVs).14 Written 
informed consent was obtained from all subjects before enrolment. The study was 
approved by the Medical Ethics Committee of the Maastricht University Medical 
Center and registered in a clinical trial register (NCT01867931).  
2.2 Study population 
From the outpatient clinic of the Gastroenterology and Hepatology division of the 
Maastricht University Medical Centre+, patients with chronic (>6 months) heartburn 
and/or regurgitation that had previously been diagnosed with GERD were included. 
GERD patients were categorized into two endoscopic phenotypes: with EE and EE-
negative. Patients with esophageal erosions on previous or current endoscopy were 
categorized as EE. Patients without erosions on previous and current study 
endoscopy underwent 24-h MII-pH monitoring to establish either abnormal or normal 
acid exposure (abnormal: >4% of time pH<4) and positive or negative association 
between symptoms and reflux episodes (SAP≥95%). Furthermore, we included 
healthy volunteers, without any gastrointestinal symptom, especially heartburn or 
regurgitation that underwent a standardized screening including assessment of Rome 
III criteria.   
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2.3 Endoscopy 
Before the endoscopy all patients were required to stop PPI-therapy for 7 days. 
Erosive esophagitis, when present, was graded according to the L.A. classification. 
Biopsies were obtained 5 cm above the gastro-esophageal junction using standard 
disposable biopsy forceps (Radial Jaw 4 forceps, Boston Scientific, Natick, MA) by an 
experienced endoscopist (JMC) using the same biopsy taking technique. In patients 
with erosive esophagitis, biopsies were taken from non-eroded mucosa.  
2.4 Transmission electron microscopy   
A single esophageal biopsy was directly immersed in 3% glutaraldehyde fixative 
buffered in 0.09 M KH2PO4 at pH 7.4 at room temperature. After a minimum of 
24 hours of immersion, samples were then washed in 0.09 M KH2PO4 buffer with 7.5% 
sucrose and transferred to a 1% OsO4 + 1.5% ferrocyanide solution and buffered to pH 
7.4 with 0.1 M veronalacetate for subsequent post-fixation for 1 h at 4°C. After washing 
in phosphate veronalacetate buffer containing 7% sucrose at pH 7.4, dehydration was 
carried out rapidly in graded ethanol series followed by embedding in Epon. Ultrathin 
tissue sections were cut and examined with a Philips CM 100 electron microscope. Of 
each biopsy specimen 10 TEM photographs were taken. TEM photographs were 
obtained from the basal and suprabasal layers of the epithelium at x4000 
magnification by an independent researcher, who was experienced in the recognition 
of the different layers of the epithelium and blinded for the status of the subject. 
2.5 Assessment of intercellular space diameter 
Intercellular space diameter was assessed using both methods by two blinded 
investigators that worked independent of each other.   
2.5.1 Relative intercellular space area (ISA) 
ISA was evaluated in 3 representative TEM photographs per subject. For the 
assessment, based on the division of the area by the corresponding length (an 
estimation of the perimeter of the cell), first a single line was drawn through the 
intercellular space around 2-3 cells in the microphotograph (Figure 8.1A). Multiple 
lines were drawn which were optically the most suitable for calculation of cellular 
space. A region of interest (ROI) around this line was defined to include the 
intercellular space between the two cells, without inclusion of intracellular content. 
The software allowed us to customize a ROI of different μm (Figure 8.3B blue circles). 
Then, the pixel threshold was chosen to include only pixels from the intercellular 
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space. Pixels considered for the analysis were visualized in yellow (Figure 8.3C). 
Based on this threshold, the area around the line included in the ROI was 
automatically calculated and divided by the length of this line using custom‐written 
(by PVB) image analysis software in IGOR Pro (WaveMetrics Inc., Oregon, USA). Per 
subject, the average of the area of different regions of interest from the 3 TEM 
photographs was used for the analysis.  
2.5.2. Classical ISD assessment (ISDc) 
ISD was calculated in 10 TEM photographs per subject by drawing 10 random 
transects perpendicular to the opposing cell membranes across the intercellular 
spaces from a single cell using the computer software Image J (National Institute of 
Health, USA), as previously described (Figure 8.1D).7,15 This resulted in 100 ISD values 




















Figure 8.1 Alternative assessment of ISD (ISA). A) Multiple lines (red) are drawn through the intercellular 
space. Crossings where intercellular spaces merge are not included. B)  a region of interest is 
marked around the lines to cover the selected intercellular space. C)   Based on the pixel 
threshold, the intercellular space area is then calculated and divided by its corresponding 
length. D) Classic assessment of ISD (ISDc) using 10 transects to the opposing cell membrane. 
E) Detail of a microphotograph showing the interdigitations of the esophageal epithelial cells 
(black arrow) and the intercellular space (open arrow). 
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2.6 Intra- and interobserver variability and time 
consumption 
The calculation of the ISD of all TEM photographs using both methods was 
performed twice by a single investigator. After the initial assessment of ISD using both 
methods, the investigator (FR) was blinded for the previous results and the analyses 
were repeated one week later. Interobserver agreement for both methods was also 
assessed in all microphotographs by a second investigator (LL) that worked 
independently and was blinded for the results of the other investigator. The time 
consumed by evaluation of ISD in 5 subjects by both methods was recorded and 
compared.  
2.7 Statistical analysis 
Data are expressed as mean ± standard error of the mean (SEM). Simple comparisons 
between the two different methods were performed using the independent samples 
t-test. Correlations between outcomes of ISA and ISDc were calculated using the 
Pearson correlation coefficient. Cohen’s Kappa coefficient was used to analyse inter- 
and intraobserver variability. Comparison of ISD between groups was performed 
using the one-way ANOVA to determine whether significant differences exist 
between groups, then the Tukey’s post-hoc test was applied. A p-value below 0.05 
was considered statistically significant. All statistical analyses were performed using 
commercially available computer software (IBM SPSS Statistics for Windows, Version 
22. Armonk, NY: IBM Corp.). 
3. Results 
3.1 Subject characteristics 
Twenty-two GERD patients and 12 HVs were included in the study. All patients were 
on proton-pump inhibitory (PPI) therapy before inclusion of the study. One patient was 
not able to stop PPI therapy and was excluded before the endoscopy. In another 
patient, measurement of ISD failed as the biopsy did not contain sufficient basal cell 
layers.  Furthermore, two healthy volunteers showed esophagitis despite not having 
any symptoms and were excluded from the study.  
In the final analysis 10 EE patients (6 men, mean age 62 years (range 45-77)), 10 EE-
negative reflux patients (6 men, mean age 48 years (range 28-70)) and 10 HVs (5 men, 
mean age 35 (range 21-65)) were included. All EE patients showed active esophagitis 
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during the study endoscopy. Grade A esophagitis according to the L.A. classification 
was present in 6 patients; grade B in 3 patients and grade C in 1 patient. Of the EE-
negative patients, 6 had abnormal acid exposure: non-erosive reflux disease (NERD). 
The other 4 had normal acid exposure but had a positive symptom association and 
were classified as reflux hypersensitivity (RH).   
3.2 Relative intercellular space area (ISA) 
ISA showed a high correlation with corresponding ISDc-values (r: 0.84, p<0.001) 
(Figure 8.2). A comparable correlation was observed in EE-negative reflux patients (r: 
0.92, p<0.001) and healthy volunteers (r: 0.73, p=0.02). In EE patients, the correlation 













Figure 8.2 Correlation between intercellular space diameter (in μm) as assessed with ISA and ISDc. A 
positive correlation (r=0.084) was found comparing both methods of measuring intercellular 
spaces (p<0.001). 
 
3.3 Intra- and interobserver variability 
Both methods showed an excellent intraobsever agreement, with comparable ĸ-
values (ISA: 0.91 and ISDc: 0.92). Interobserver agreement of both methods was good, 
with again comparable ĸ-values (ISA: 0.81 and ISDc 0.80).   
3.4 Time analysis 
The analysis using the ISA method proved to be more time consuming per TEM 
photograph when compared to ISDc (ISA: 119 s ± 8 vs. ISDc: 63 s ± 2, p<0.001). 
However, when comparing the time consumption of the analysis of the mandatory 10 
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TEM photographs per subject with ISDc versus 3 microphotographs with ISA, the 
latter is less time consuming (ISA: 350 ± 13 s vs ISDc: 628 ± 15 s, p<0.001).  
3.5 Direct comparison ISA vs ISDc  
Although ISA and ISDc values showed a strong correlation, a large difference in the 
mean ISD-value per subject was found between the two methods. Mean difference 
between the methods was 0.44 μm (p<0.001). Therefore, it was not able to perform a 
Bland Altman plot (difference plot). As ISDc values were derived from 10 TEM 
photographs and ISA-values from 3 microphotographs, we performed another 
comparison of both methods using the same 3 microphotographs. Also in this 3 by 3-
analysis, ISDc-values were significantly larger when compared to the mean diameter 
as assessed with ISA (Table 8.1). This finding was consistent in EE, EE-negative 
patients and HVs (Table 8.1) and was found in the analysis of the second observer 
(data not shown).  
 
Table 8.1 Comparison of outcomes of ISA and ISDc in EE, NERD and HVs in the same 3 TEM photographs. 
ISD  ISA (μm) ISDc (μm) p-value 
All subjects  0.90 ± 0.04 1.32 ± 0.05 <0.001 
   EE  1.08 ± 0.07 1.61 ± 0.07 <0.001 
EE-negative 0.83 ± 0.07 1.20 ± 0.07 <0.001 
   HV 0.79 ± 0.06 1.14 ± 0.06 <0.001 
EE, erosive esophagitis; HV, healthy volunteers. The ISD was expressed as mean ± SEM. 
 
3.6 Differences in ISD between subsets of GERD and healthy 
volunteers  
Both methods showed a clear difference in ISD of patients with erosive esophagitis 
vs. non-erosive reflux disease patients and healthy volunteers (Figure 8.3). However, 
no difference in ISD was found between EE-negative patients and HVs, regardless of 






































































Figure 8.3 Comparison of ISD in different phenotypes of GERD (EE and EE-negative) and healthy volunteers 
(HV), using the ISDc (a) and the ISA (b) method. * p<0.05. 
4. Discussion 
In the present study, we aimed to evaluate the relative intercellular space area (ISA) 
as an alternative, more representative and efficient approach to calculate the 
intercellular space diameter (ISD) in TEM microphotographs.  
Our main findings were: 1) ISA showed an excellent intra- and interobserver 
agreement and a strong correlation with ISD-values obtained with the classic method; 
2) as ISA requires only 3 TEM photographs, the analysis is less time consuming; 
3) direct comparison of both methods showed that the average ISD obtained with ISA 
was significantly smaller, but the ability to differentiate EE, EE-negative and HVs was 
comparable for both methods.  
The need for an alternative method to calculate ISD from TEM photographs has been 
previously acknowledged; the placement of transects during the ISDc assessment in 
a highly irregular intercellular space with dilated and retracted segments may not 
lead to a representative mean intercellular space diameter. In addition, the placement 
of the transects is not fully at random and therefore susceptible to bias. Furthermore, 
the classical method requires 10 TEM photographs per subject to obtain 100 ISD 
values for a single subject. To obtain 10 non-overlapping TEM photographs of the 
basal and suprabasal layers from a single biopsy is laborious and the subsequent 
analysis is time consuming.  
Other research groups recognized these shortcomings of ISDc and described 
alternative methods to assess ISD over the past years. Vaezi et al. tried to overcome 
the possibility of a selection bias by superimposing computer generated lines over 10 
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TEM photographs, that subsequently randomly allocated the placement of transects 
between two cell membranes.10 However, by using this method the authors were not 
able to identify differences in ISD between GERD patients and controls. As the authors 
did not re-analyse the TEM photographs using ISDc, it is unknown whether this 
negative result was related to the samples or to the method used in that study.10 
Neumann et al. used Delesse’s principle as previously described by Weibel to 
calculate the intercellular space volume from 2-D TEM photographs.16,17 Delesse’s 
principle states that the planimetric fraction of a section occupied by sections of a 
given component corresponds to the fraction of the tissue volume occupied by this 
component. A point grid was superimposed on each of 10 microphotographs per 
subject and based on the fraction of points within the intercellular space in relation to 
points of the total mucosa, a relative volume fraction of the intercellular space was 
calculated. The volumetric assessment was not compared to ISDc. The concept of 
the intercellular ratio, introduced by Johanessen et al, resembles parts of the 
volumetric assessment described by Neumann et al: a grid containing 150 line-
crossing points is imposed over 10 microphotographs per biopsy, and the number of 
crossing points within the intercellular space are divided by the total number of grid 
points.18 The intercellular space ratio showed high intra- and interobserver 
agreement, but a poor correlation with ISDc. Although the above-mentioned methods 
clearly overcome the possible bias of subjective transect placement, the analysis of 
150 crossing points in each of 10 TEM photographs of a single subject is still time 
consuming. Weijenborg et al. also reported an intercellular space ratio, however, 
based the ratio on the difference in contrast between inter- and intracellular space.11,19 
Although the investigators used 10 TEM photographs per subject, the computer-
generated ratio is possibly time saving and likely more representative compared to a 
150-point superimposed grid. Nevertheless, there may be another weakness when 
using the intercellular space ratio either by superimposing a grid or using contrast to 
differentiate inter- and intracellular space. To calculate the ratio between inter- and 
intracellular space, an entire TEM photograph with perfectly preserved tissue is 
demanded, without artefacts or tissue disruption by the handling of the biopsy. In our 
experience, it can be laborious to obtain 10 non-overlapping, TEM photographs from 
a single biopsy without inclusion of the metal grid or broken areas, frequently 
observed in most of the ultrathin sections.  
In the present study we evaluated an alternative method that was previously used to 
assess the intercellular space in rabbits12,13, but was never before validated or 
compared to the classic method. We show in the present study that the assessment 
of ISA has good intra- and interobserver agreement. Strength of ISA is the 
requirement of only 3 TEM photographs to reproduce similar results when compared 
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to ISDc. It is not only less time consuming to analyse, but also the process of 
obtaining non-overlapping, intact TEM photographs in the basal and suprabasal 
layers of the epithelium is much easier when only 3 TEM photographs are required.  
The analysis by ISA also includes the interdigitations (retracted segments) present in 
the intercellular spaces (Figure 8.1E) with limited space between two opposing cell 
membranes. Although a strong correlation between outcomes of ISA and ISDc were 
found, direct comparison of ISD-values show that ISA-values were consistently 
smaller compared to ISDc-values. This is most likely due to the inclusion of these 
interdigitations, areas in which ISD is small or even absent. These irregularities of the 
intercellular space may not be taken into account when using the ISDc. We therefore 
believe that ISA gives a more balanced representation of the intercellular space 
diameter and argue that ISA can provide a representative ISD-value in only 3 TEM 
photographs. In contrast to the methods that are based on the ratio between inter- 
and intracellular space, ISA can still be used in TEM photographs with small areas that 
are slightly damaged or with a preservation artefact, as they can be excluded from 
the analysis by selecting well preserved regions of the TEM photograph.  
A second aim of our study was to evaluate the ability of ISA to identify differences in 
ISD between subsets of the study population. ISA identified a clear difference 
between EE vs. EE-negative reflux patients and controls, similar to the results of the 
classic method. In the present study, the presence of DIS in EE-negative reflux 
patients could not be identified, irrespective of the method used. The presence of DIS 
in the mucosa of EE-negative reflux patients is widely accepted, however studies 
supporting this finding all used ISDc.7,15,20,21 Alternative methods are less conclusive 
about DIS in EE-negative reflux patients. The volumetric assessment of the 
intercellular space by Neumann et al. revealed an increased intercellular space 
volume in patient with EE, however the intracellular space volume of EE-negative 
reflux patients was not different from controls.16 The computer calculated 
intercellular space ratio of Weijenborg et al. showed no difference between EE, EE-
negative reflux patients and healthy volunteers, although group numbers were 
relatively small.19 Thus, so far no alternative method could identify DIS in EE-negative 
reflux patients, however a future study using a larger number of patients should be 
performed to provide a more conclusive answer. In addition, the fact that no 
difference was found in DIS between EE-negative reflux patients and healthy control 
could also be related to the fact that some EE-negative patients had pathological 
acid exposure (NERD) and some had normal acid exposure with positive symptom 
correlation: reflux hypersensitivity (RH). 
In summary, evaluation of the intercellular space diameter using the relative 
intercellular space area showed a high intra- and interobserver agreement and a 
 Evaluation of intercellular space diameter 
145 
strong correlation with ISD values obtained with the classical assessment. 
Furthermore, ISA was able to discriminate DIS in EE patients, similar to the classic 
assessment. Therefore, we conclude that this more representative and less time 
consuming approach can be used to reliably assess the intercellular space diameter 
in GERD patients in future studies. Nevertheless, future efforts should me aimed at 
applying analytical techniques to assess intercellular spaces in light microscopy as 
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General discussion 
The research findings presented in this thesis add to our knowledge on the role of the 
proximal part of the gastrointestinal (GI) tract in the maintenance of ‘gut health’. The 
term ‘gut health’ is becoming increasingly popular, reflected by its frequent use in 
scientific literature.1 The GI tract is able to contribute to health in many ways. This is 
not solely dependent on the food processing of nutrients and fluid secretion and 
absorption. The GI tract is a large sensory organ, which responds to a variety of 
signals which arise and are perceived in the lumen. It has a protective role against 
intraluminal noxious or toxic substances and is equipped to sense, digest and absorb 
nutrients. In this respect, sensing and signalling in the upper GI tract has a major role 
in gut and systemic homeostasis and consequently in preserving gut health and 
systemic health as it is able to discriminate between beneficial and potentially 
harmful stimuli and signals. The primary focus of this thesis was the role of the 
proximal GI tract and its ability to sense the chemical content in the lumen in order to 
orchestrate important responses to preserve GI homeostasis. We specifically focused 
on two areas: 1) mechanisms of the proximal GI tract to control satiety and food intake 
(nutrients, food components and mechanical sensing) and 2) the role of TRP channels 
and the mucosal barrier and their involvement in chemo-nociception and pain 
generation in the proximal GI tract. This final chapter summarizes the main findings 
presented in this thesis. These findings are discussed in the light of findings from 
previous publications and the current knowledge and understanding of its 
background and clinical relevance. Finally, suggestions and implications for future 
research are presented.  
Main findings 
In the first part of this thesis we focused on the gut as a potential target in the 
regulation of food intake and satiety. Previous work showed that all three 
macronutrients (lipids, proteins and carbohydrates) are able to activate the intestinal 
brake; a negative feedback mechanism to the motor, secretory and sensory functions 
of the more proximal parts of the GI tract, including food intake and satiety. In chapter 
2, we provided a detailed overview of the literature on published studies in which 
macronutrients have been infused in the different parts of the small intestine. We 
concluded that a proximal to distal gradient exists with respect to the magnitude of 
intestinal brake activation: the more distal the delivery of intact nutrients or 
degradation products in the small intestine takes place, the more pronounced the 
effect on food intake and satiety. The ‘proof on concept’ study described in chapter 3 
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showed that an encapsulated protein and carbohydrate mixture with “ileal release 
formula” resulted in a significant reduction in food intake and stronger feelings of 
satiety compared to a control product with proximal GI release. Ileal delivery of lipids, 
which were incorporated in emulsified alginate beads in order to delay the release 
and digestive breakdown of dietary lipids, was able to reduce food intake (chapter 4) 
to a similar extent compared to the protein and carbohydrate mixture in chapter 3. In 
chapter 5, we investigated mechanical sensing of the stomach and whether 
influencing this mechanical sensing was able to affect food intake and satiety. 
Lidocaine, known for its anesthetic effects, was infused into the stomach of healthy 
volunteers, to test the hypothesis that lidocaine via inhibition of mechanical distension 
might impair feelings of satiety/satiation and increase food intake. Lidocaine, 
however, did not result in an increase in food intake nor in a decrease in satiety.  
With regard to the satiating effect of tastants, a recent study from our group revealed 
that intraduodenal infusion of the combination of the tastants sweet, bitter and umami 
resulted in a significant decrease in food intake and a reduction of hunger scores. 
Based on the findings in chapter 2, where a proximal to distal gradient in ileal brake 
activation was observed, we investigated the effect on food intake of an identical 
combination of tastants when infused into the ileum and/or duodenum compared to 
a placebo infusion. For both locations, ileum and duodenum, and also for 
simultaneous infusion at both sites, no significant effects on food intake or satiety 
were observed after infusion with a combination of tastants compared to placebo 
infusion (chapter 6).  
In the second part of this thesis, we investigate the sensory function of the GI tract 
with respect to the detection of potentially noxious stimuli. Such stimuli generally 
elicit aversive responses such as pain, nausea and abdominal discomfort. To better 
understand pain generation in the esophagus, we conducted a study in which 
capsaicin was infused into the esophagus (chapter 7). Capsaicin is the pungent 
ingredient in chili peppers and a well-known TRPV1 receptor agonist. The TRPV1 
receptor plays a major role in nociception and pain signalling. We observed that an 
impaired (more leaky) mucosal barrier and consequently increased exposure of 
mucosal and submucosal sensory afferents to this noxious substance play a key role 
in the generation of pain symptoms. A protective reflex mechanism occurs in the non-
exposed more proximal part of the esophagus that results in an enforcement of the 
mucosal barrier. The measurement of intercellular spaces in the esophageal mucosa 
allows quantification of the barrier dysfunction. Finally, in chapter 8, we compared 
two methods to measure intercellular space area: the classic measurement of the 
intercellular space diameter (ISD) and the relative intercellular space area (ISA). A 
 General discussion 
153 
strong correlation between the two methods was observed with the advantage that 
ISA is significantly less time consuming.  
Nutrient sensing in food intake regulation  
Intestinal sensing of nutrients in the lumen of the GI tract plays a major role in the 
regulation of food intake and energy balance. The rapidly increasing prevalence of 
obesity and its associated comorbidities results in expanding impact on health care 
utilization and costs. Bariatric surgery is known to be highly effective in achieving 
sustained weight loss. On the other hand, this is a drastic measure with profound 
effects on gut function and is only available for a small subgroup of patients. The 
mechanism of weight loss after Roux-en-Y gastric bypass is based on both a 
restrictive and a malabsorptive component, in which nutrients are less rapidly 
digested and absorbed or even malabsorbed. The response to this increased amount 
of nutrients and their degradation products entering the more distal parts of the gut 
appears to play a key role in the sustained weight loss seen after bariatric surgery in a 
mechanism referred to as the intestinal brake. This implicates that the effect of these 
nutrients in the lumen of the more distal small intestine could be an interesting target 
for less invasive strategies for weight loss. Data about this distal to proximal feedback 
mechanism were first studied with ileal lipid infusion.2,3 The concept of this feedback 
mechanism was based on the weight loss observed in studies with morbidly obese 
patients after jejunoileal bypass (JIB).4 The results observed after JIB or ileal 
transposition in rats led to experiments in humans with intestinal catheter intubation 
and perfusion studies. Welch et al. were the first to observe a delay in gastric 
emptying and food intake reduction after ileal fat perfusion.5,6 In one of these studies, 
not only ileal but also jejunal fat infusion was performed and both infusions, ileal and 
jejunal, were able to significantly reduce food intake.6 Based on these landmark 
studies, this feedback mechanism became an interesting target for food-based 
strategies in the battle against overweight and obesity. Several groups of researchers 
have investigated whether this effect also occurs in other parts of the small intestine 
and they compared the magnitude of this feedback mechanism on food intake.7,8 
Even though proteins are regarded as the most satiating macronutrient, all three 
macronutrients were able to activate this intestinal brake to the same extent.9 In our 
literature review in chapter 2 we observed a proximal to distal gradient with regard to 
the magnitude of this feedback mechanism. We observed that the higher the caloric 
infusion rates, the stronger the inhibitory effect on food intake and that this effect is 
site-dependent. Increasing the small intestinal surface area exposed to nutrients 
reduces gastric emptying rate and food intake.10,11 Protein infusion into the duodenum 
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at a rate of >3 kcal/min was needed in order to induce a reduction in food intake.12 In 
the study performed by van Avesaat et al., lower protein infusion rates were chosen. 
Ileal infusion of protein at a rate of 0.9 kcal/min resulted in a significantly lower food 
intake compared to intraduodenal infusion of the same amount of protein.13 Potential 
mechanisms that can be held responsible for the difference in food intake after distal 
compared to proximal small intestinal administration of nutrients are related to the 
process of a delay in digestion and the presence of degradation products in the more 
distal small intestine, distribution and types of nutrient sensing receptors and the 
subsequent entero-endocrine responses. 
Digestion and absorption of nutrients 
Nutrient digestion starts immediately after ingestion, in the oral cavity. In the small 
intestine protein, carbohydrates and fat have already largely been broken down into 
respectively amino acids, monosaccharides and monoglycerides and fatty acids for 
detection and subsequent absorption. A possible explanation for the results observed 
in this thesis, relates to the magnitude of the intestinal brake effect on food intake. 
The sensing of degradation products of macronutrients appears to be more relevant 
and stronger compared to sensing of intact macronutrients for activation of small 
intestinal signals in satiety and food intake regulation. For example, duodenal infusion 
of a very small amount of the amino acid L-tryptophan (caloric load 0.15 kcal/min) 
was already able to induce a significant effect on food intake and satiety.14 Likewise, 
duodenal infusion of the fatty acid C12 at a caloric load of 0.4 kcal/min, was able to 
induce a significant reduction in food intake.15 It should be taken into account that 
these degradation products are rapidly absorbed from the duodenum and jejunum 
and do not progress to more distal parts of the small intestine under normal 
circumstances. Studies that have investigated the direct effects of ileal infusion of 
nutrient degradation products on ileal brake activation are lacking up to now. The 
obtained results thus far suggest that exposure of the more distal small intestine to 
nutrients or their degradation products could be an interesting and promising target 
for weight management strategies.   
Encapsulation of nutrients 
The majority of the studies investigating the acute effects of macronutrient infusion in 
the small intestine have been performed with naso-intestinal catheters. In case we 
intend to investigate the effects of repetitive administration of nutrients into the distal 
small intestine, this intubation method is not feasible: it is too invasive and associated 
with significant discomfort for the volunteer or patient. Therefore, it is necessary to 
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develop new methods in order to deliver the nutrients at a desired (distal) intestinal 
location. Currently, methodology is available with “slow intestinal release” of nutrients 
and of pharmaceutical products.  An elegant example is that of ileocolonic release of 
peppermint oil capsules, which have been used in a study on the efficacy and 
tolerability of small intestinal versus colonic release of peppermint oil using the 
ColoPulse technology.16,17 Another example is the Fabuless emulsion. This emulsion 
consists of very fine vegetable oil droplets made of naturally occurring palm oil 
coated with galactolipids as emulsifiers. Initially, a significant effect on food intake 
4-8 hours after intake of yoghurt with Fabuless was observed when compared with 
normal fat.18,19 It was hypothesized that this effect is related to the fact that the 
presence of the Fabuless emulsion in the small intestinal lumen allows the formation 
of fatty acid crystals that then act as slow-release capsules.20 The distal small 
intestine is, as a result, exposed to a higher intraluminal fatty acid content and 
consequently activates the ileal brake. Subsequent results revealed, however, that 
repetitive ingestion of Fabuless was not able to decrease energy intake and body 
weight.21 
Another interesting encapsulation technique is micro-encapsulation. Micro-
encapsulation technique creates the possibility to encapsulate large amounts of 
macronutrients for delivery in the distal small intestine. In this thesis, we investigated 
ileal delivery of a mixture of carbohydrate and protein (chapter 3). This study 
describes the acute effects of these micro-encapsulates on food intake and satiety. 
We observed a significant food intake reduction and increase in satiety after ingestion 
of the micro-encapsulates compared to the placebo mixture (with more proximal 
release). Evidence that is in line with a more distal release of the micro-encapsulates 
compared to placebo is the observation of a plasma glucose peak 30 min after 
ingestion of the placebo mixture, that was not observed after ingestion of the micro-
encapsulate mixture. This peak suggests that the placebo mixture is directly 
absorbed in the proximal small intestine resulting in an increase in plasma glucose 
concentration. A similar result was observed by Poppitt et al. where the ileal infusion 
of glucose prevented an increase in plasma glucose concentration to occur. These 
investigators observed an increase in Glucagon-like peptide 1 (GLP-1) release, which 
may explain the absence of the glucose peak after ileal glucose infusion.22 The study 
presented in this thesis was designed and carried out as a proof-of-principle test. We 
did not investigate the exact timing and location of release of the micro-encapsulates. 
More studies are needed to investigate the exact location of disintegration of micro-
encapsulates and whether repetitive ingestion is able to induce weight loss on the 
longer term. In chapter 4, lipids were encapsulated in calcium-alginate beads to delay 
lipolysis with the purpose to prevent absorption in the proximal small intestine and as 
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a result increase the exposure of the distal small intestine to lipid. It was shown that 
ingestion of this yoghurt containing emulsion-alginate beads resulted in a small but 
significant effect on food intake. This result on food intake was comparable to the 
effects on food intake observed in chapter 3. In that study, the digestion dynamics of 
the encapsulated lipids were anticipated via extensive in vitro experiments. For both 
studies, more detailed knowledge on the exact behavior (disintegration time) of the 
encapsulated lipids and carbohydrate and protein mixture in vivo in the small 
intestinal lumen is needed.  
The effects on food intake observed in chapter 3 and 4 are less pronounced 
compared to several intubation studies. A possible factor negatively interfering with 
intake of food is the use intestinal tubes for nutrient delivery. These tubes give rise to 
discomfort and thereby affecting eating behavior. Another important notification is 
that, as observed in Fabuless, the functionality of the micro-encapsulates and 
emulsion-alginate bead can be influenced by the thermal processing of food.23 This 
needs to be studied in more detail before these delayed delivery techniques can be 
effectively applied in daily life.  
Gastric sensing 
The stomach plays a major role in controlling satiety and food intake. The 
mechanisms of action of food intake regulation in the stomach differ from the 
mechanisms in the small intestine. The signals arising from the small intestine in 
response to the presence of nutrients in the lumen are mainly activated by chemo 
sensation of the intraluminal content. The satiating effect from the stomach is mainly 
caused by mechanical stimulation, from volume and pressure changes of the 
stomach wall, that lead to meal termination. Distension of the stomach wall activates 
mechanosensitive vagal afferents, sending signals to specific areas the brain that 
influence food intake and satiety. Human studies have shown that distension of the 
stomach wall via inflation of a balloon results in a reduction in hunger scores.24-26 In 
contrast to chapter 3 and 4, where nutrient sensing of the small intestine was 
investigated to help to reduce food intake, in chapter 5 we investigated a strategy to 
increase food intake via a gastric intervention. Despite the worldwide major health 
problems caused by overweight and obesity, there are still a lot of patients suffering 
from malnutrition. Especially elderly and patients with malignancies suffer from 
anorexia and malnutrition.27,28 In elderly, postprandial fullness and satiation are 
increased compared to younger subjects. This is associated with delayed gastric 
emptying, larger antral area and overactive sensing profile of the gastrointestinal 
mechanoreceptors.29 In chapter 5, we hypothesized that inhibition of the signals 
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arising from the mechanoreceptors in the stomach wall causes a greater distension 
during a meal. In rats, it was shown that gastric infusion of lidocaine, a local 
anesthetic, resulted in an increase in food intake.30 We were not able to fully replicate 
the impressive results from the animal studies in humans; we observed a modest, 
non-significant increase in food intake after infusion of 200 mg lidocaine directly into 
the stomach compared to placebo. Lidocaine was well tolerated by all the 
participants and did not cause more GI symptoms compared to placebo infusion. A 
possible explanation for the non-significant differences in our study is related to the 
fact that we included healthy male volunteers with normal eating behavior and intact 
gastric capacity. In the placebo experiment the volunteers already had near 
maximum intake of an ad libitum meal, a condition that could not be further improved 
via lidocaine infusion. Future experiments should focus on subjects with impaired 
gastric capacity such as dyspeptic patients, cancer patients or elderly. 
Another factor is related to the gastric area that was inhibited by lidocaine.  It is known 
that the both the proximal and distal stomach have a key role in the perception of 
fullness and meal termination. After oral ingestion a meal is initially stored in the 
proximal part of the stomach. When gastric emptying starts, the meal is gradually 
transported to the antrum. In our study, infusion of lidocaine may have blunted signals 
arising from mechanosensitive afferents in the distal instead of the proximal stomach, 
because of the more distal infusion catheter position. Impaired signalling from the 
distal stomach may have resulted in more rapid gastric emptying and activation of the 
duodenal brake, thereby inhibiting additional food intake of the meal.  
Sensing of non-caloric tastants in the proximal GI tract 
Gastric satiation is known to be volume, stretch and distension dependent, while 
intestinal satiation is primarily dependent on sensing of intraluminal nutrients and 
influenced by the caloric load of these nutrients. Non-caloric tastants (combination of 
bitter, sweet and umami) are able to exert food intake reduction when infused into the 
duodenum.31 Herewith, it was shown that satiety signals from the intestine are not 
solely related to the number of calories ingested, but also from other characteristics 
of food (‘taste molecules’). Taste receptors are expressed in the entire small intestinal 
tract, however it was unknown whether a proximal to distal gradient in food reduction 
is also present for this receptor activation.32 In chapter 6, it was shown that the effect 
of infusion of tastants solely into the duodenum or ileum, or infused simultaneously in 
both locations, were not able to decrease food intake. An explanation for the inability 
to replicate the results in the study of van Avesaat et al., may be related to the study 
protocol involving the catheter placement. In our study, participants were intubated 
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with a naso-duodenal-ileal catheter for four consecutive days and they consumed 
the ad libitum meal with catheter. In study protocol of Avesaat et al., the catheter was 
removed before the ad libitum meal and the meal consumption was not influenced 
by the presence of an intestinal catheter. From an evolutionary perspective it is 
apparent that taste receptors are more widely distributed and activated in the more 
proximal parts of the gastrointestinal tract. For example, bitter substances are linked 
to a potentially toxic effect, therefore sensing of these bitter compounds results in 
food aversion.33 Little is known about taste receptor expression and distribution 
throughout the GI tract. This information is relevant and may help to develop 
strategies for weight management.  
Nociceptive function of the gut: understanding pain 
mechanisms in the esophagus using capsaicin 
Pain mechanisms in the GI tract contribute to preserve gut health. Capsaicin, the 
pungent substance in chili peppers, is known to elicit a pain response via activation of 
TRPV1 receptors. In patients with complaints of heartburn or retrosternal pain but 
without esophageal erosions upon endoscopic examination, also referred to as non-
erosive reflux disease, the exact mechanism of generation of pain symptoms is not 
completely understood. An increased transcription and expression of the TRPV1 
receptor in these group of patients has been described in literature.34,35 In order to 
better understand the role of the esophageal mucosa in this complex process, we 
infused capsaicin into the distal esophagus. We observed in that experiment, that an 
impaired mucosal barrier plays a key role in the generation of symptoms. A reflex 
mechanism was activated in the proximal part of the esophagus in order to protect 
the afferent nerve endings from excitation resulting in pain. This effect is comparable 
to the effects observed in the small intestine: sensing a stressor (capsaicin), tastant or 
macronutrient results in an effect of the more proximally located parts of the GI tract 
(feedback inhibition or activation). We provided evidence that the mucosal barrier 
plays a key role in esophageal pain sensation. This pain response was not related to 
the amount TRPV1 mRNA or protein in the esophageal mucosa. These results provide 
additional insight into esophageal pain symptom generation that has clinical 
relevance for treatment of this symptom, providing rationale for “esophageal barrier 
protection” as a therapeutic modality.  
Implication and suggestions for future directions 
Sensing and signalling in the GI tract in order to maintain gut health is becoming an 
interesting research topic. An important aim is to better understand the physiology of 
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nutrients, gastric and food component sensing because this may provide leads to 
therapeutic interventions in pathological conditions such as obesity and malnutrition. 
In this thesis, several strategies have been presented. Here we provide suggestions 
for future research focusing on nutrient, food components and mechanical sensing.  
The research in strategies to increase satiety signals has focused on the negative 
feedback in the GI tract in order to explore whether this intestinal brake can be used 
as anti-obesity measure. In chapter 2, it was concluded that a proximal to distal 
gradient exists in relationship to intestinal brake activation and that the ileum has the 
most pronounced effect on satiety and food intake. This was studied for 
macronutrients and non-caloric tastants with naso-intestinal catheters. Distal 
intestinal delivery of a micro-encapsulate mixture of protein and carbohydrate 
(chapter 3) and lipids from emulsion alginate beads (chapter 4) was investigated and 
resulted in a decrease in food intake and increase in satiety. The exact intestinal 
behavior of these products and underlying mechanisms need to be investigated in 
more detail. In vivo studies, with biological markers (blood concentrations, intestinal 
aspiration at multiple sites, or on radiography), may help to provide more information 
of the exact site of release of the nutrients and in this way, help to design 
interventions aimed at maximizing biological effects. For clinical use, these products 
need to be studied over a longer period of time with multiple ingestions spread over 
the day. Moreover, long-term studies (weeks, months) are needed to demonstrate 
whether these products, after showing acute effects, are also able to exert long-term 
effects on food intake and on body weight. Human studies with these types of 
products focusing on the prevention of weight gain in pre-obese subjects would be 
of interest but are very demanding and costly. Up to now, little is known on ileal brake 
activation with slow release or encapsulated products in obese subjects. The majority 
of the human studies that investigated the mechanisms related to the intestinal brake 
have been performed in healthy volunteers. Some studies have suggested that 
intestinal brake activation is less pronounced in overweight and obese subjects 
compared to lean subjects.36,37 Moreover, it would be interesting to investigate the 
efficacy of encapsulation of macronutrients versus non-caloric tastants; it is 
hypothesized that non-caloric tastants exert their negative feedback on satiety in the 
more proximal parts of the small intestine, especially the bitter substance. We 
recommended to investigate encapsulation of the bitter substance and not of a 
mixture as desired effects on food intake might be blunted this way. From an 
evolutionary point of view, bitter substances are linked to food aversion. The strong 
bitter substance denatonium benzoate is added to household products to prevent 
ingestion of potential harmful noxious products through taste aversion.38,39 This bitter 
substance is known to suppress food intake and gastric motility in mice40 and 
Chapter 9 
160 
stimulate the in vitro release of GLP-1 and cholecystokinin (CCK), which increase 
satiety and satiation. It is crucial to investigate whether infusion of such a strong bitter 
substance in the proximal parts of the GI tract in humans will eventually result in a 
reduction in food intake. In addition, distribution of the tastants receptors in the small 
intestinal tract needs to be explored in more detail. This knowledge will also aid the 
development of more effective anti-obesity strategies based on the stimulation of 
intestinal test receptors. Taken together, more detailed understanding is crucial in the 
advancement of the intestinal brake research field as many experimental results have 
not been reproducible in the clinical setting. We need to return to basic science 
approaches to unravel the molecular background of intestinal sensing and investigate 
the physico-chemical properties, intestinal behavior and biological effects of novel 
encapsulated products aimed at effective stimulation of abovementioned sensing 
mechanisms. A promising strategy with the potential to decrease satiety signals was 
investigated for the first time in humans (chapter 5).   
Lidocaine infusion into the stomach did not result in significant effects on food intake 
or satiety. Several lessons were learned from that study. First, since lidocaine was 
well tolerated, in future studies, the dose of lidocaine should be further increased. 
Second, lidocaine can be dissolved in a larger volume in order to reach a larger 
surface area with more pronounced blunting of signals arising from the 
mechanoreceptors in the stomach wall. Third, the tip of the gastric catheter should be 
placed at the esophago-gastric junction in order to maximize exposure of the fundic 
region to lidocaine. Fourth, we also observed an order effect; participants ate 
significantly more on the second test day compared to first test day. We 
hypothesized that participants were more familiar with the study procedures 
(catheter placement and removal), which caused this significant test day effect. For 
future studies, it is recommended to choose a parallel study design instead of a 
crossover study. Fifth, the effect of lidocaine on food intake deserves further 
evaluation in conditions with impaired food intake, for example in patients with 
disturbed gastrointestinal sensory perceptions.  
Chapter 7 provided more insight in esophageal pain symptom generation and it was 
observed that the mucosal barrier plays a key role in this mechanism as part of the 
nociceptive sensing function of the upper GI tract. It would be of clinical relevance to 
investigate whether there are therapeutic modalities to enforce the mucosal barrier in 
order to prevent symptoms to arise, for example in patients with NERD. Several 
products aimed at esophageal mucosal protection are now available on the market, 
however, their exact efficacy and role in a therapeutic algorithm needs further 
clarification. These products could have an important therapeutic potential, since not 
all patients with GERD have a therapeutic response during acid suppressive therapy. 
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In Table 9.1 we summarized the existing compounds which are able to produce a 
therapeutic effect on the mucosal barrier. Many of these products are derived from 
natural compounds. One recent study of Leite Sales et al. studied the native sulfated 
polysaccharide Gracilaria Caudata and it was shown that this substance had a 
protective role in the esophageal mucosal barrier in NERD patients.41 There is in fact 
quite a long history of these products but there has not yet been a breakthrough in 
terms of their application in clinical practice. Perhaps this is related to our incomplete 
understanding of esophageal sensory physiology. The current findings can open the 
scientific discussion anew in order to establish the position of these products in the 
management of reflux symptoms. In this respect, it is interesting to further investigate 
which structural aspects of these mucoprotective compounds are responsible their 
beneficial effect. Studies investigating the esophageal barrier function in vivo (using 
for instance baseline impedance measurements) allow further insight into these 
mechanisms. 
 
Table 9.1 Mucosal protective compounds. 
Compound Composition Mechanism of action Clinical 
effectiveness 
Side effects Reference 
Sucralfate Aluminum salt 
of sucrose 
sulfate 








2. Healing erosive 
esophagitis 
3. Maintenance 






Alginate Seaweed Forms a raft floating 
over gastric contents 
1. Reduces the 
number of acid reflux 
2. Displace the 
postprandial acid 
pocket in patients 
with reflux 
3. Covers the 
esophageal luminal 
mucosa  












Dispersed in a bio 
adhesive carrier these 
compounds form 
macromolecular 
complex which coats 
the esophageal 
mucosa  
1. Short term 
symptom relief in 
patients with NERD 
and GERD.  
2. In combination with 
PPI, there was more 
symptom relief than 
PPI alone.  
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The gastrointestinal (GI) tract is a large sensory organ that responds to a wide variety 
of signals originating from the GI lumen, for example, nutrients and endogenous or 
exogenous substances that can have beneficial effects but also potentially noxious. 
Sensing of these substances via the mucosal receptors and the signals arising from 
these responses are crucial for maintaining physiological homeostatic processes. We 
focused on the ability of the GI lumen to sense nutrients or food components and 
consequently activating signals to influence food intake and satiety. Furthermore, we 
investigated the effect of a potentially noxious substance on pain regulation in the 
esophagus.  
 
In Chapter 2, we reviewed studies in which gastrointestinal nutrient (protein, fat and 
carbohydrates) infusion was performed. There was substantial evidence that all parts 
of the GI tract are able to activate the so-called ‘intestinal brake’, a negative feedback 
mechanism on food intake and satiety. We observed a difference between the site 
and the length of infusion in the small intestine and the magnitude of this effect on 
food intake and satiety. In several studies it was observed that the ileum had the most 
potent effect on food intake and satiety. A proximal to distal gradient with regards to 
gastrointestinal nutrient infusion seems to exist. 
 
In Chapter 2, we concluded that activation of the ‘ileal brake’ reduces food intake and 
alters satiety to the greatest extent. Other studies also showed the potential of 
repetitive ileal brake activation and its possible effect on long term weight 
management. These studies were performed with naso-intestinal catheters. To 
investigate the possible clinical application of ileal brake activation, less invasive 
strategies are needed. In Chapter 3, we performed a ‘proof of concept’ study in which 
we investigated the effect of encapsulated macronutrients (protein, fat and 
carbohydrates) targeting the distal small intestine. The effect on food intake and 
satiety was compared to a control product that integrated in the proximal GI tract 
(stomach). Fifty-nine healthy volunteers with overweight were included in this 
double-blind randomized, controlled, cross-over study. The study was performed 
within two test days in which the volunteers received in random order the 
encapsulated nutrient mixture or the control product. Visual analogue scale (VAS) 
scores for satiety and blood samples for glucose analysis were collected during the 
test day and food intake was measured with an ad libitum meal at the end of the test 
day. Ingestion of the encapsulated nutrient mixture decreased food intake compared 
to the control product. Moreover, VAS scores for hunger and satiety were significant 
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different from the control product. Plasma glucose concentrations immediately 
increased after ingestion of the control product, while the encapsulated nutrient 
mixture did not show an increase. This observation suggests more distal release of 
the encapsulated nutrient mixture and a proximal release of the control product. 
Future studies are needed to investigate whether this effect is sustained after 
repetitive ingestion of the encapsulated nutrient mixture. Future studies should also 
focus on long-term results after orally ingested macronutrients with distal release 
and whether this strategy can be used in weight management.  
 
In Chapter 4, we investigated whether lipids, encapsulated in calcium alginate beads, 
delay lipolysis with the purpose to prevent absorption in the proximal small intestine 
and as a result increase the exposure in the distal small intestine. These emulsion-
alginate beads were added to yoghurt and ingested by healthy overweight subjects 
in a cross-over design. The control product contained an equicaloric mixture of non-
encapsulated nutrients with similar sensory properties. Food intake was measured 
with an ad libitum meal and satiety scores were measured during the test day. We 
observed that food intake significantly reduced compared to the control product.  
 
In contrast to chapter 3 and 4, where nutrient sensing of the small intestine was 
investigated to reduce food intake and increase satiety, in Chapter 5 we investigated 
an intervention to increase food intake and alter satiety via a gastric intervention. 
Increasing food intake could be beneficial in the elderly population who suffer from 
‘anorexia of aging’ or patients with chronic diseases in which anorexia or cachexia (for 
example cancer cachexia) occur. We hypothesized that inhibition of signals arising 
from the mechanoreceptors in the stomach wall by lidocaine, a local anesthetic, 
caused a greater distension during a meal, and consequently have a negative 
feedback on satiety and food intake. In rats, it was already observed that this 
intervention increased food intake. In this human trial, we were not able to replicate 
the results observed in rats. We observed a modest, non-significant, increase in food 
intake after infusion of 200 mg lidocaine with a catheter in the stomach compared to 
placebo infusion. The small, non-significant increase can be explained by the fact that 
in this study we only include healthy participants and not patients with disturbed 
gastrointestinal sensory perception. Previous studies have shown that sensory 
pathways in the GI tract are affected by age. The results in Chapter 3, 4 and 5 show 
that the GI tract is an attractive target in altering food intake and satiety and this paves 
the way for future studies to further elucidate the concept of modifying responses 
arising from the GI tract to the content of the intestinal lumen and consequently 
influence food intake and satiety.  
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Another important function of the gastrointestinal tract is sensing different taste 
signals. There are five basics tastes: bitter, sour, sweet, salty and umami. The function 
of taste receptors in the GI tract is to sense food components. Several studies have 
shown that these taste receptors are expressed throughout the entire GI tract. It was 
already observed that duodenal infusion of a combination of sweet, bitter and umami 
significantly decreased food intake and increased satiety scores. In Chapter 6, we 
investigated whether the aforementioned proximal-to-distal gradient found for the 
intestinal brake (Chapter 2) is also operative for taste receptor activation. We 
conducted a single-blind randomized cross-over trial in which 14 participants where 
intubated with a nasoduodenalileal catheter. They all received four infusion regimens: 
duodenal and ileal placebo, duodenal tastants and ileal placebo, duodenal placebo 
ileal tastants, duodenal tastants and ileal tastants. We observed no differences in 
food intake or satiety between the various interventions. A possible explanation for 
not being able to replicate the results from a previous study is that all participants 
were intubated with a catheter for four consecutive days, which may have influenced 
small effects on eating behavior. 
 
The physiological role of the GI tract is to sense nutrients and activate appropriate 
effector mechanisms. Another important role of the intestinal lumen is to detect and 
eliminate potentially harmful substances and consequently initiate several protective 
responses. We investigated in Chapter 7 whether a possible protective response 
occurs after perfusion of a potentially harmful substance in the esophagus. Capsaicin, 
the pungent substance is known for its ability to induce pain via the Transient 
Receptor Potential Vanilloid 1 (TRPV-1) channel. This receptor plays an important role 
in nociceptive signalling of somatic and visceral pain. In this study, we investigated 
whether esophageal TRPV1 activation by capsaicin perfusion induces pain and affects 
the mucosal barrier integrity. The mucosal barrier integrity was evaluated by 
intraluminal impedance measurements and evaluation of intercellular space width by 
transmission electron microscopy (TEM). We observed that capsaicin perfusion 
resulted in TRPV1 activation and consequently induced more pain compared to the 
saline-treated participants. This is likely to be explained by an impaired mucosal 
barrier and defective restoration capacity in the esophagus. A disrupted mucosal 
barrier in the esophagus results in more TRPV1 activation by the phenomenon that 
the sensory nerve afferents which express the TRPV1 receptor are more exposed to 
capsaicin. The sensing mechanism of capsaicin in the esophageal lumen and the 
signals arising from this pain sensation could provide rationale for esophageal barrier 




In Chapter 8, we compared two different methods to evaluate intercellular space in 
esophageal biopsies. In this study we compared the classic evaluation of the 
intercellular space (ISDc) with an alternative method; the relative intercellular space 
area (ISA). The most important difference between these two methods is the number 
of transmission electron microscopy photos needed for analysis (10 vs. 3). Another 
importation concern is that ISDc may not fully take the irregularity of intercellular 
space delineation into account. The results showed that evaluation of the intercellular 
space using the alternative ISA method showed a strong correlation with the values 
obtained with ISDc. The alternative method (ISDc) is more representative and less 
time-consuming. ISA also showed a high intra and interobserver agreement. This 
more representative and less timeconsuming approach can be used to reliably 
assess the intercellular space in patients with gastroesophageal reflux disease (GERD) 
or nonerosive gastroesophageal reflux disease (NERD) in future studies. 
 
In Chapter 9, we summarized and integrated the key findings of the studies 
presented in this thesis. New findings in relation to previous described studies with 
regards to the 





Het maag-darmstelsel is een orgaan dat reageert op een breed scala aan signalen 
afkomstig vanuit het lumen van het maag-darmstelsel. Voorbeelden hiervan zijn 
voedingsstoffen, endogene of exogene stoffen met potentieel gunstige of potentieel 
schadelijke effecten. Het detecteren (‘sensing’) van deze stoffen via de mucosale 
receptoren en de signalen die hierna ontstaan zijn cruciaal voor het in standhouden 
van verschillende fysiologische homeostatische processen in het lichaam. We 
hebben ons in dit proefschrift gefocust op de eigenschappen van het lumen van het 
maag-darmstelsel om voedingsstoffen of voedselcomponenten te detecteren en als 
gevolg hiervan signalen te activeren om de voedselinname en verzadiging te 
beïnvloeden. Daarnaast onderzochten we het beschermende effect van een 
potentieel schadelijke stof en de relatie met pijnregulatie in de slokdarm. 
 
In Hoofdstuk 2 evalueren we studies waarin macronutriënten (eiwitten, vetten en 
koolhydraten) in verschillende delen van het maag-darmstelsel werden 
geïnfundeerd. Er is substantieel bewijs dat alle delen van het maag-darmstelsel de 
zogenoemde 'intestinal brake' kunnen activeren. Dit beschrijft een negatief 
feedbackmechanisme op voedselinname en verzadiging. We observeerden een 
verschil tussen de plaats en de lengte van de infusie in de dunne darm en de mate 
van dit effect op de voedselinname en verzadiging. Verschillende studies toonden 
dat het ileum het grootste negatieve effect had op voedselinname en verzadiging. Er 
lijkt een proximale naar distale gradiënt te bestaan met betrekking tot infusie van 
macronutriënten in de dunne darm en het effect op voedselinname en verzadiging.  
 
In Hoofdstuk 2 concludeerden we dat activering van de 'ileal brake' het grootste 
effect heeft op voedselinname en verzadiging. Andere studies toonden ook dat 
herhaaldelijke activering van de ‘ileal brake’ een mogelijk effect heeft op 
lichaamsreductie voor de langere termijn. Deze studies zijn uitgevoerd met neus-
darm katheters. Minder invasieve strategieën zijn nodig om de klinische toepassing 
van ‘ileal brake’ activering te onderzoeken.  
In Hoofdstuk 3 hebben we een proof of concept studie uitgevoerd waarin we het 
effect van ge-encapsuleerde macronutriënten (eiwitten, vetten en koolhydraten) die 
opgenomen werden in de distale dunne darm onderzocht. Het effect van deze ge-
encapsuleerde macronutriënten op voedselinname en verzadiging werd vergeleken 
met een controle product dat in het proximale deel van het maag-darmstelsel werd 
opgenomen. 59 gezonde vrijwilligers met overgewicht werden geïncludeerd in deze 
dubbelblinde, gerandomiseerde, placebo-gecontroleerde, cross-over studie. De 
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studie werd uitgevoerd op twee testdagen waarin de vrijwilligers in willekeurige 
volgorde of het actieve ge-encapsuleerde product of het controle product innamen. 
Gedurende de testdag werden VAS-scores voor verzadiging en bloedmonsters voor 
glucose verzameld en de voedselinname werd gemeten middels een ad libitum 
maaltijd aan het einde van de testdag. Inname van het actieve ge-encapsuleerde 
product resulteerde in een significante afname van de voedselinname in vergelijking 
met het controle product. Daarnaast zagen wij een significante afname van VAS-
scores voor honger en een significante toename van VAS-scores voor verzadiging na 
inname van het actieve ge-encapsuleerde product vergeleken met het controle 
product. Plasma glucose levels namen onmiddellijk toe na inname van het controle 
product, terwijl het actieve ge-encapsuleerde product geen toename liet zien. Deze 
resultaten suggereren dat het controle product direct in het proximale gedeelte van 
het maag-darmstelsel werd opgenomen en dat het actieve ge-encapsuleerde 
product mogelijk in het laatste stuk van het maag-darmstelsel werd opgenomen. 
Toekomstige studies zijn nodig om te onderzoeken of dit effect aanhoudt na 
herhaaldelijke inname van het ge-encapsuleerde product en zo te onderzoeken of 
deze strategie toepasbaar is voor gewichtsreductie op de lange termijn.  
 
In Hoofdstuk 4 hebben we onderzocht of vetten, ingekapseld in calcium alginaat 
korrels, lipolyse vertragen met als doel absorptie in de proximale dunne darm te 
voorkomen en als resultaat de blootstelling in de distale dunne darm te vergroten. 
Deze emulsie alginaat korrels werden toegevoegd aan yoghurt en ingenomen door 
gezonde proefpersonen met overgewicht in een cross-over design. Het controle 
product bevatte een equicalorisch mengsel van niet-ingekapselde voedingsstoffen 
met vergelijkbare sensorische eigenschappen. Voedselinname werd gemeten met 
een ad libitum maaltijd en verzadigingsscores werden gemeten gedurende de 
testdag. We observeerden dat de voedselinname significant verminderde na inname 
van het yoghurt product met de ingekapselde vetten in vergelijking met het controle 
product. 
 
In tegenstelling tot hoofdstuk 3 en 4, waar het detecteren van voedingsstoffen in de 
dunne darm werd onderzocht om voedselinname te verminderen en verzadiging te 
verhogen, onderzochten we in Hoofdstuk 5 een interventie om de voedselinname te 
verhogen en de verzadiging te beïnvloeden met een interventie via de maag. Het 
verhogen van de voedselinname kan gunstig zijn voor ouderen die lijden aan 
‘anorexia of aging’ of patiënten met chronische ziekten waarbij anorexia of cachexie 
(bijvoorbeeld kankercachexie) voorkomt. Onze hypothese was dat remming van 
signalen afkomstig van de mechanoreceptoren in de maagwand door infusie van 
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lidocaïne, een lokaal anestheticum, een negatieve feedback heeft op verzadiging en 
voedselinname. Bij ratten werd dit fenomeen al geobserveerd en toediening van 
lidocaïne zorgde voor een toename van de voedselinname. In deze humane studie 
waren we niet in staat om de resultaten die bij ratten werden waargenomen te 
repliceren. We zagen een kleine, niet-significante, toename van de voedselinname na 
infusie van 200 mg lidocaïne via een maagkatheter in vergelijking met infusie van de 
placebo. Deze, niet-significante toename kan worden verklaard door het feit dat we in 
deze studie alleen gezonde deelnemers hebben geïncludeerd en geen personen 
met een gestoorde gastro-intestinale sensorische functie. Eerdere studies hebben 
aangetoond dat de sensorische pathway in het maag-darmstelsel wordt beïnvloed 
door leeftijd. De resultaten van Hoofdstuk 3, 4 en 5 laten zien dat het maag-
darmstelsel een interessant target is om voedselinname en verzadiging te 
beïnvloeden. Dit maakt de weg vrij voor toekomstige studies om het concept van het 
modificeren van reacties die voortkomen uit het maag-darmstelsel als reactie op de 
inhoud van de intestinale lumen en als gevolg daarvan voedselinname en verzadiging 
te beïnvloeden verder te onderzoeken.  
 
Een andere belangrijke functie van het maag-darmstelsel is het waarnemen van 
verschillende smaaksignalen. Er zijn vijf basissmaken: bitter, zuur, zoet, zout en 
umami. De functie van smaakreceptoren in het maag-darmstelsel is het waarnemen 
van voedselcomponenten. Verschillende onderzoeken hebben aangetoond dat deze 
smaakreceptoren door het hele maag-darmstelsel tot expressie worden gebracht. Er 
werd al eerder waargenomen dat duodenale infusie van een combinatie van zoet, 
bitter en umami de voedselinname significant verminderde en de verzadiging deed 
toenemen. In Hoofdstuk 6 hebben we onderzocht of de eerdergenoemde proximale-
naar-distale gradiënt gevonden voor de ‘intestinal brake’ activering (Hoofdstuk 2) ook 
toepasbaar is voor activatie van smaakreceptoren. We hebben een single-blind, 
gerandomiseerde, cross-over studie uitgevoerd waarbij bij 14 deelnemers een naso-
duodenale-ileale katheter werd ingebracht. Ze kregen allemaal vier infusie regimes: 
duodenum en ileum placebo, duodenum smaakstoffen en ileum placebo, duodenum 
placebo ileum smaakstoffen, duodenum smaakstoffen en ileum smaakstoffen. We 
zagen geen verschil in voedselinname of verzadiging tussen de verschillende infusie 
regimes. Een mogelijke verklaring voor het niet kunnen repliceren van de resultaten 
van de eerder genoemde studie is dat alle deelnemers vier opeenvolgende dagen 
een katheter hadden, wat mogelijk een invloed had op het eetgedrag. 
 
De fysiologische rol van het maag-darmstelsel is het detecteren van voedingsstoffen 
en het activeren en toepassen van effectormechanismen. Een andere belangrijke rol 
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van het lumen van de darm is het detecteren en elimineren van potentieel 
schadelijke stoffen en het initiëren van verschillende beschermende reacties. In 
Hoofdstuk 7 hebben we onderzocht of er een mogelijke beschermende reactie 
optreedt na perfusie van een potentieel schadelijke stof in de slokdarm. Capsaïcine 
staat bekend om zijn vermogen om pijn te veroorzaken via het Transient Receptor 
Potential Vanilloid 1 (TRPV-1) kanaal. Deze receptor speelt een belangrijke rol bij de 
nociceptieve signalering van somatische en viscerale pijn. In deze studie hebben we 
onderzocht of oesofagiale TRPV1-activering door perfusie van capsaïcine in de 
slokdarm pijn veroorzaakt en de integriteit van de mucosale barrière beïnvloedt. De 
integriteit van de mucosale barrière werd geëvalueerd door middel van intraluminale 
impedantiemetingen en evaluatie van de intercellulaire afstand door transmissie-
elektronenmicroscopie (TEM). We hebben geobserveerd dat capsaïcine perfusie 
resulteerde in TRPV1-activering en meer pijn veroorzaakte in vergelijking met 
perfusie van de zout oplossing. Dit wordt waarschijnlijk verklaard door een 
verminderde mucosale barrière en een onvermogen tot herstel hiervan in de 
slokdarm. Een verstoorde mucosale barrière in de slokdarm resulteert in meer 
TRPV1-activering door het fenomeen dat de sensorische zenuwafferenten, die de 
TRPV1-receptor tot expressie brengen, meer worden blootgesteld aan capsaïcine. 
Het detectiemechanisme van capsaïcine in het lumen van de slokdarm en de 
signalen die voortkomen uit deze pijnsensatie geven onderbouwing voor 
bescherming van de slokdarmbarrière als een therapeutische modaliteit. 
 
In Hoofdstuk 8 hebben we twee verschillende methoden vergeleken om de 
intercellulaire afstand in slokdarmbiopten te evalueren. In deze studie vergeleken we 
de klassieke evaluatie van de intercellulaire afstand (ISDc) met een alternatieve 
methode; relatieve intercellulaire afstand (ISA). Het belangrijkste verschil tussen deze 
twee methoden is het aantal transmissie-elektronen microscopiefoto's dat nodig is 
voor analyse (10 versus 3). Een ander belangrijk gegeven is dat ISDc niet volledig 
rekening houdt met de onregelmatigheid van de afbakening van de intercellulaire 
ruimte. De resultaten toonden aan dat evaluatie van de intercellulaire ruimte met 
behulp van de alternatieve ISA-methode een sterke correlatie vertoonde met de 
waarden verkregen met ISDc. De alternatieve methode (ISA) is representatiever en 
minder tijdrovend. ISA liet ook een hoge intra- en interobserver overeenkomst zien. 
Deze meer representatieve en minder tijdrovende benadering kan in toekomstige 
studies worden gebruikt om de intercellulaure afstand bij patiënten met gastro-
oesofageale refluxziekte (GERD) of niet-erosieve gastro-oesofageale refluxziekte 




In Hoofdstuk 9 vatten we de belangrijkste bevindingen van de onderzoeken in dit 
proefschrift samen. Nieuwe bevindingen en de relatie tot de resultaten in eerder 
beschreven studies met betrekking tot de detectie- en signaleringsfunctie van het 








With the studies presented in this thesis, we aimed to understand the role of the 
gastrointestinal (GI) tract in preserving GI physiology by sensing the content of the gut 
lumen. The GI tract is a sensory organ that responds to a wide variety of signals from 
the GI lumen. At first, the GI tracts detects, senses and absorbs nutrients from the 
lumen. Second, the GI tracts senses potential noxious or toxic materials which can 
enter the systemic compartment via the epithelial barrier. This ‘sensing and signalling’ 
mechanism via the mucosal receptors and the intestinal network is crucial for 
maintaining GI homeostasis.  
 
In the first part of this thesis we focus on the function of the GI tract and its ability to 
influence food intake and satiety by the detection, digestion and absorption of 
nutrients. The GI tract is seen as an interesting target to influence food intake and 
satiety. The worldwide prevalence of overweight and obesity has nearly tripled the 
last 40 years, which comes with increased comorbidities, such as cardiovascular 
diseases. Moreover, this increasing prevalence also has significant economic and 
social impact. Bariatric procedures are successful in inducing weight loss on the long 
term in morbidly obese patients. However, patients with overweight are not eligible 
for these procedures. Therefore, non-invasive novel strategies are needed in the 
battle against the obesity epidemic. This thesis provides two studies in which 
macronutrients (lipid, carbohydrates and protein) were encapsulated and ingestion of 
these products resulted in a decrease in food intake. Future studies should focus on 
whether this effect is also observed after repetitive or chronic ingestion of these 
products. However, these studies provide a first step towards the development of 
novel functional foods. Encapsulated nutrients targeting the distal small intestine can 
be added in a dairy product in order to increase satiety and reduce food intake. This 
strategy could be of benefit in overweight patients or to prevent overweight to occur 
in normal weight patients.  
 
Both the stomach and the small intestine have an important role in controlling food 
intake and satiety, but underlying mechanisms differ from each other. The satiating 
effect from the stomach mainly occurs via stretching and tension mechanoreceptors 
after ingestion of a meal. In this thesis, we investigated whether this effect could be 
influenced by the infusion of lidocaine, a local anaesthic, in the stomach via a 
nasogastric catheter. We observed that infusion of lidocaine resulted in a small, but 
non-significant increase in food intake. However, we cannot exclude that the 
intubation may have influenced the results observed in our study. Future studies 
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need to consider other methods of administration of the lidocaine into the stomach, 
for example encapsulation, in order to further investigate the effect of lidocaine on 
the mechanoreceptors in the stomach wall. Moreover, strategies to target the entire 
stomach wall should also be considered. 
 
Besides nutrients, other food components are sensed by the GI lumen. This thesis 
investigated the potential role of the non-caloric bitter substance in decreasing food 
intake and increasing satiety. Tastants can serve as an important nutritional target in 
the treatment of overweight and obesity. However, the decrease in food intake 
observed was rather small. The impact of this study is in line with the studies in which 
macronutrients were encapsulated; a rather modest effect on food intake. However, 
ingestion of a certain amount of capsules with the bitter substance could lead to a 
reduction in food intake and subsequently in a reduction in body weight. Future, long-
term studies are needed to investigate whether this strategy can be preventive in the 
battle against overweight and obesity.  
 
In the second part of this thesis focused on the responses of the upper GI tract and 
the role of TRPV1 against potential noxious substances. We observed that infusion of 
capsaicin, the pungent substance of chilli peppers, into the distal esophagus resulted 
in pain and a decrease in impedance of the esophagus wall.  This was also related to 
the intercellular space area in the distal esophagus. This suggests that an impaired 
mucosal barrier plays a major role in pain symptom generation in patients with non-
erosive reflux disease (NERD). This study provides additional insight into esophageal 
pain symptom generation which has clinical relevance for treatment of heartburn and 
related symptoms, providing additional rationale for esophageal barrier protection as 
a therapeutic modality. The findings in this study can open the scientific discussion in 
order to establish the position of mucoprotective agents in the management of reflux 
symptoms. Future studies should focus on which structural aspects of these 
mucoprotective compounds are responsible for the beneficial effect. 
 
In summary, the research presented in this thesis shows that the upper GI tract has an 
important role in maintaining gut-health and that it can be considered as an 
interesting target to influence GI psychology in a beneficial way. Sensing of nutrients 
and food components in the upper GI tract can be seen as an interesting target to 
influence food intake and satiety. Moreover, the epithelial barrier in the upper GI tract 
is considered to play a major role in the protection against potential noxious 
substances. Taken together, this thesis provides relevant information regarding the 
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sensing and signalling function of the upper GI tract in order to activate several 








Ieder proefschrift bevat een dankwoord, het meest gelezen hoofdstuk van het 
boekje. Het schrijven van dit dankwoord voelt dan ook als een trotse afsluiting van 
mijn PhD. Allereerst wil ik beginnen om alle proefpersonen te bedanken die hebben 
deelgenomen aan de wetenschappelijke onderzoeken die in dit proefschrift 
beschreven staan. Zonder de hulp en bereidwilligheid van de proefpersonen konden 
de resultaten niet tot stand komen. Daarnaast wil ik een aantal personen in het 
bijzonder bedanken die hebben bijgedragen aan de totstandkoming van dit 
proefschrift. 
 
Prof. dr. Masclee, beste Ad, ik weet nog goed dat ik net mijn opleiding geneeskunde 
in Rotterdam had afgerond en graag terug wilde naar mijn ‘roots’. Ik kwam met u in 
contact en onze band voelde direct warm en vertrouwd. U adviseerde mij om mijn 
‘oudste’ coschap in deze regio te doen en daarna bood u mij een PhD plek aan in 
Maastricht. Alternatief: U heeft gedurende onze samenwerking, naast de interesse in 
mijn werk, ook altijd interesse getoond in mij als persoon. Ik heb veel bewondering 
voor uw passie voor het wetenschappelijk onderzoek en dit heeft mij gestimuleerd 
als onderzoeker. Ondanks uw drukke agenda kon ik altijd bij u binnenlopen voor 
overleg of een babbel. U heeft regelmatig uw vertrouwen in mij uitgesproken en 
daarvoor wil ik u bedanken. Ik zal u gaan missen als u met uw welverdiende pensioen 
gaat.  
 
Dr. Keszthelyi, beste Daniel, dank voor je hulp bij de verschillende studies 
beschreven in dit proefschrift. Ik bewonder je passie en drive voor wetenschappelijk 
onderzoek. Ik heb veel van je geleerd. Je bent een voorbeeld als arts en onderzoeker 
voor mij. Het oneindig herschrijven van onze artikelen dreef mij af en toe tot wanhoop, 
echter heeft het wel dit proefschrift naar een hoger niveau getild. Ook met privézaken 
kon ik bij je terecht, waarvoor heel veel dank.  
 
Dr. Troost, beste Freddy, in het begin van mijn promotietraject hebben we 
samengewerkt. Je maakte mij wegwijs binnen de onderzoekswereld. Samen met Tim 
hebben we de stoma studie succesvol volbracht. Onze tripjes naar Parijs waren ook 
altijd genieten. Dank voor de prettige samenwerking.  
 
Dr. Bakker, beste Minke, toen ik in Rotterdam mijn interesse voor de MDL kenbaar 
maakte, werd ik door de opleider aldaar naar jou verwezen. Mijn oudste coschap heb 
ik onder jouw supervisie met veel plezier in Heerlen gedaan. Ondanks dat een 
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volledig coschap bij de MDL in het toenmalige Atrium MC nog nooit in die vorm had 
plaatsgevonden, had je een mooi programma voor mij samengesteld. Je was mijn 
referentie voor de sollicitatie naar een opleidingsplek, waarvoor ik je wil bedanken. 
Toen ik hoorde dat je in het MUMC+ ging werken was ik heel enthousiast. Als mijn 
mentor, opleider en collega hoop ik dat deze samenwerking nog lang mag bestaan!   
 
Prof. dr. Bouvy, beste Nicole, wat was ik blij verrast toen ik hoorde dat jij tot voorzitter 
van mijn beoordelingscommissie werd benoemd. We hebben samen een aantal 
studies uitgevoerd en ik vond het altijd heel prettig samenwerken met jou. Het 
cadeau dat ik van u kreeg voor de geboorte van mijn eerste zoon is nog altijd een 
groot succes!  
Prof. dr. Tack, prof. dr. Witteman, dr. Lenaerts en dr. Adam, bedankt voor het kritisch 
evalueren van mijn proefschrift en het deel uitmaken van mijn beoordelings-
commissie.   
 
Als vreemdeling uit Rotterdam kwam ik snel in een warm bad terecht. Mede dankzij 
het mooie MDL-onderzoeksteam heb ik mijn promotietijd als geweldig ervaren. Ik kon 
bij jullie terecht voor alle vragen met betrekking tot onderzoek en privékwesties. 
Onze lunchmomenten, congresbezoeken, borrels en feestjes waren fantastisch en 
onvergetelijk. Daisy, Martine, Ankie, Fedde, Bouke, Chantal, Steven, Kirsten, 
Montserrat, Elhaseen, Roel, Pauline, Corinne, Roel, Zsa Zsa, Lisa, Roy, Yala, Selwyn, 
Hao Ran, Fabienne, Dion, Tim H., Pan, Lonne, Gonny, Bram, Heike, Toon, Wenke, 
Anke, Quirine, Laura en Merlijne, allemaal heel veel dank voor de mooie momenten, 
samenwerking, adviezen, roddels, grappen, warmte en gezelligheid.  
 
Een paar collega’s wil ik apart benoemen. Mark, bedankt voor je hulp bij de 
introductie binnen de groep en de start van mijn PhD traject. Jouw hulp maakte dit 
alles een stuk gemakkelijker. Ik kon een gedeelte van jouw onderzoeken voortzetten. 
Je hebt me veel geleerd over het opzetten van een onderzoek en het schrijven van 
artikelen. Je maakte altijd tijd voor het beantwoorden van mijn vragen. Tim, wat 
hebben wij veel uren samen doorgebracht in ons mooie lab. De stoma studie die we 
in de avonduren en weekenden samen hebben uitgevoerd heeft ons veel tijd en 
moeite gekost, maar samen hebben we er ons met veel lol, grappen en af en toe een 
beklag doorheen geslagen. Ik had dit met niemand anders willen doen. Onze tripjes 
naar Parijs samen waren ook onvergetelijk. Dank voor het overnemen van mijn 
onderzoeken tijdens mijn zwangerschapsverlof. Je bent een fijne collega en ik hoop 




Bas, Dion en Eveline, bedankt voor de fijne tijd als kamergenoten. Marin, Ellen en 
Wiesje, wat was het een onvergetelijke trip naar de DDW in Chicago!  
 
Ik wil graag de MDL-collega’s in de kliniek van het MUMC+ bedanken voor de fijne 
samenwerking gedurende mijn PhD tijd. Ton, de endoscopie dames en in het 
bijzonder de dames van de functiekamer Anja, Nicole en Rachelle, dank voor jullie 
hulp bij de praktische zaken in mijn studies. Daarnaast wil ik de dames van het 
secretariaat bedanken. Elly, Mietsie, Nienke en Tiny, jullie waren altijd zeer vriendelijk 
en behulpzaam.  
 
Ik wil ook mijn collega’s bedanken tijdens mijn vooropleiding Interne Geneeskunde in 
het MUMC+. In het bijzonder, Prof. Koopmans, Richard dank voor je ondersteuning, 
begeleiding en luisterend oor tijdens de vooropleiding. Dr. Magdelijns, Fabienne, als 
mentor en supervisor heb je veel voor mij betekend. Dank dat je altijd bereid was om 
naar mijn verhalen te luisteren.  
  
Lieve Gaby, sinds de middelbareschooltijd zijn we onafscheidelijk. Wat hebben wij 
mooie momenten gehad samen! Ondanks dat onze wegen een andere kant op zijn 
gegaan, is onze vriendschap altijd blijven bestaan. De positieve instelling en 
gedrevenheid is iets wat ik in jou bewonder. Ik vind het bijzonder om te zien hoe jouw 
politieke carrière je past. Ook in moeilijke tijden was je er altijd daar voor mij. Ik weet 
zeker dat al je dromen werkelijkheid worden. Ik ben trots op zo’n vriendin aan mijn 
zijde! 
 
Lieve Roos, Odette en Sophie, ‘bende van ellende’. We leerden elkaar kennen in 
onze studententijd bij de RVSV in Rotterdam. In de loop van de jaren groeiden we 
naar elkaar toe en werden we steeds hechter. Dit resulteerde erin dat we na onze tijd 
in onze RVSV-huizen samen op de Burgemeester Meineszlaan gingen wonen. Wat 
hebben wij hier een geweldige tijd gehad en mooie herinneringen gemaakt. Onze 
gezamenlijke reisjes hebben ook de nodige hilariteit opgeleverd; ik zal de momenten 
tijdens onze reis in Marokko nooit vergeten. Wat zijn wij een heerlijke chaos samen. 
Dank voor jullie steun, adviezen en interesse. Ik hoop dat we elkaar in de toekomst 
vaker kunnen zien! 
 
Lieve Diede, Diederik, oud-huisgenoot, jaarclubgenoot en lieve vriendin. Letterlijk 
sinds onze aankomst in Rotterdam zijn wij onafscheidelijk. Ik heb nog nooit 
meegemaakt je zo snel een klik voelt met een persoon. We hebben in de loop van de 
jaren een hele bijzondere band ontwikkeld. Dankzij het lobbyen van jou ben ik in 
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Jaarclub Leeuw terecht gekomen. Onze tijd in Villa Ravage was fantastisch; ik 
herinner onze tv-momenten (Lingo) op de bank, onze tripjes naar ‘Eetgoed’, onze 
dansjes op de sociëteit en een geweldig huwelijk in Toscane. Ik vind jou een prachtig 
persoon en je bent een hele bijzondere vriendin voor mij. Ik zal er altijd voor je zijn. 
Heel veel knuffels! 
 
Lieve Anne, wij zijn elkaar als vriendinnen gelukkig nooit uit het oog verloren en daar 
ben ik heel blij mee. Je bent altijd heel geïnteresseerd geweest in mijn 
promotietraject en opleiding. Ik wil je bedanken voor de hardloopmomenten, 
bootcamp, lunches, wandelingen en je onvoorwaardelijke steun. Je bent een schatje! 
 
Ik wil de rest van Jaarclub Leeuw, huisgenoten van Villa Ravage en de Eurekaweek 
commissie bedanken voor alle momenten van plezier en ontspanning. 
 
En dan mijn paranimfen Luc en Annique.  
 
Luc, lieve grote broer. Ik keek als kind al erg tegen je op. Je kon af en toe erg wild met 
mij stoeien, maar je ging altijd voor mij door het vuur. Ik hoefde niet lang na te denken 
wie ik voor de rol als paranimf moest vragen. De afgelopen tijd ben je een enorme 
steun voor mij geweest en was je er daar voor mij als broer. Ik kan altijd op je 
terugvallen en je bekommert je oprecht om mij. Ik vind het mooi om te zien hoe je 
geniet van je gezin en hoeveel liefde je voor je kinderen hebt. Je bent een bijzondere 
broer en papa.  
 
Daarnaast wil ik je vriendin, Kimberley, ook bedanken. Ik kan altijd fijn met je praten 
als collega dokter over het werk. Je hebt een verfrissende en nuchtere kijk op zaken, 
wat voor mij goed werkt. Ik wil je bedanken voor je steun. Ik vind het heel mooi om te 
zien dat jullie samen als gezin gelukkig zijn. 
 
Annique, je bent de vriendin die het langst in mijn leven is. We leerden elkaar kennen 
in de buurt op straat waar wij veel samen speelden. Daarna gingen we naar dezelfde 
middelbare school en samen op hockey. Wat hebben wij veel bijzondere momenten 
samen meegemaakt. Onze band is in de loop van de jaren steeds hechter geworden. 
Jouw positieve instelling weet mij altijd te raken en werkt gewoon aanstekelijk. Ik 
weet nog dat jij mij elke ochtend een ‘positieve spreuk’ stuurde. Ik kan altijd terecht in 
jouw warme nestje op de Caumerbeeklaan bij jouw fijne familie en dat voelt zo goed 
aan. Je was er daar voor me toen ik je nodig had en dat waardeer ik ontzettend. Ik ben 
benieuwd wat de toekomst voor jou in petto heeft. Ik weet zeker heel veel goeds. Ik 
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ben heel blij om te zien dat je gelukkig bent met Pepijn en Alba. Je verdient alle het 
geluk van de wereld! Je bent voor mij een bijzondere, unieke en lieve vriendin en een 
prachtig mooi persoon. Onze vriendschap is mij zoveel waard! 
 
Lieve Toine, lief broertje. Mensen zeggen vaak dat wij veel op elkaar lijken en volgens 
mij klopt dat ook. Ondanks je lengte blijf je altijd mijn kleine broertje en zal ik er altijd 
daar voor je zijn. Ik vind het mooi om te zien hoe je nu je vaderlijke rol vervult. Ik wil je 
bedanken voor je onvoorwaardelijke steun.  
 
Lieve Mama, altijd ben je trots geweest op mij als dochter. Door jouw kwaliteit om 
alles tot in de puntjes voor ons te regelen heb ik een zorgeloze jeugd gehad en alle 
kansen die op mijn pad kwamen kunnen benutten. Jij bent de drijvende kracht achter 
de keuze voor de studie Geneeskunde. Tijdens mijn promotietraject en de opleiding 
daarna zijn wij dichter tot elkaar gegroeid. Je hebt altijd veel interesse in mijn 
onderzoek en opleiding getoond. Dank voor je luisterend oor en je adviezen. Ik hou 
van je! 
 
Lieve Papa, wat ben jij toch een belangrijk persoon in mijn leven. Ik begreep dat toen 
ik nog een baby was, ik constant op jouw schoot zat. Dit is nooit meer veranderd. De 
band die wij hebben is bijzonder en uniek. Je vertelde mij ooit; als twee bijzondere 
personen elkaar ontmoeten dan kan er iets heel moois ontstaan. Dat is wat onze band 
typeert. Bedankt voor je luisterend oor, adviezen en er gewoon daar als vader voor 
mij te zijn. In mindere tijden was je daar voor mij als vader, zonder oordeel of kritiek. 
Jouw knuffels geven mij zoveel warmte en liefde. Zonder jou had ik dit proefschrift 
nooit kunnen afronden. Ik hou ontzettend veel van jou, lieve papa.  
 
Lieve Fedde en Sef, mijn jongens, mijn boeven, mijn zoontjes, mijn alles. Dat jullie 
gelukkig zijn, is het allerbelangrijkste in mijn leven. Jullie verrijken mijn leven. Ik hou zo 
ontzettend veel van jullie en jullie maken mij zo ontzettend trots en gelukkig. Heel 
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